

© The Kirby Institute
for infection and immunity in society

ISSN 1448-5915

This publication is available at: <http://www.kirby.unsw.edu.au>

The Kirby Institute
for infection and immunity in society
UNSW Australia
Sydney NSW 2052
Australia

Telephone: **02 9385 0900** Facsimile: **02 9385 0920** International prefix: **612** Email: recpt@kirby.unsw.edu.au

Suggested citation: Memedovic S, Iversen J, Geddes L, and Maher L. Australian Needle Syringe Program Survey National Data Report 2011-2015: Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. Sydney: Kirby Institute, UNSW Australia; 2016. ISSN: 1448-5915.

AUSTRALIAN NSP SURVEY

Prevalence of HIV, HCV and injecting and
sexual behaviour among NSP attendees

NATIONAL DATA REPORT

2011 - 2015

Report prepared by

Sonja Memedovic, Jenny Iversen, Louise Geddes and Lisa Maher

The Kirby Institute

for infection and immunity in society

UNSW Australia

Sydney NSW 2052

Australia

June 2016

The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health. The Kirby Institute is affiliated with the Faculty of Medicine, UNSW Australia.

ACKNOWLEDGEMENTS

We would like to acknowledge the many people who assist in the development and conduct of the Australian NSP Survey, particularly the clients, staff and managers at participating NSP services. We also appreciate the dedication and vision of the founding members of the project and the late Dr Margaret MacDonald who was responsible for the development and conduct of the ANSPS until 2003.

Special thanks also go to Mr Philip Cunningham, Senior Scientist and Operations Manager and Ms Beth Catlett, DBS Coordinator from the NSW State Reference Laboratory for HIV at St Vincent's Hospital and St Vincent's Centre for Applied Medical Research (AMR). Thanks are also due to Ms Rachel McCleave and Ms Sue Linsen from the Kirby Institute and to Mr Greg Smith and Ashwin Prekesh from Educational Assessment Australia, UNSW Global Pty Limited.

In 2015, the project received support and input from the following members of the Australian NSP Survey National Advisory Group: Ms Tammy Waters and Helene Delaney (ACT); Ms Rose Mason (NSW); Mr Shayne Kilford and Katherine Moriarty (NT); Mr Stephen Lymb and Mr Rob Gerrie (SA); Ms Francine Smith (TAS); Ms Anna Keato and Ms Cath Williams (VIC); Ms Jude Bevan (WA); Ms Annie Madden (Australian Injecting and Illicit Drug Users League); Mr John Ryan (Pennington Institute); and Ms Sonja Memedovic, Dr Jenny Iversen, Professor John Kaldor and Professor Lisa Maher (Kirby Institute). We would particularly like to thank Mr Robert Kemp (QLD) for chairing the National Advisory Group.

Ethical approvals were obtained from Institutional Ethics Committees associated with the investigators and participating NSP sites. The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health and Ageing. The Kirby Institute is affiliated with the Faculty of Medicine, UNSW Australia.

TABLE OF CONTENTS

Summary

Key Points	i
Introduction	1
Demographic characteristics.....	1
Injecting behaviour.....	2
Sexual behaviour	4
Drug treatment	4
HIV antibody prevalence	5
HCV antibody prevalence	6
HIV and HCV testing	8
HCV treatment uptake.....	8

Tables

1. National	9
2. Australian Capital Territory	30
3. New South Wales	43
4. Northern Territory.....	64
5. Queensland	77
6. South Australia	98
7. Tasmania	119
8. Victoria	132
9. Western Australia	153

Appendix

A. Participating NSP services	174
B. Methodological notes	176
C. List of tables	177

KEY POINTS

- The Australian NSP Survey (ANSPS) functions as a strategic early-warning system designed to monitor blood borne viral infections and associated risk behaviour among people who inject drugs.
- In 2015, 47 NSP services throughout Australia participated in the ANSPS and 2,304 NSP attendees completed the survey. The response rate was 41%.

Demographic characteristics:

- Over the period 2011 to 2015, the median age of survey respondents increased from 37 years to 40 years, with a concurrent decrease in the proportion of young injectors (aged <25 years) from 8% in 2011 to 5% in 2015.
- The median time since first injection increased from 17 years in 2011 to 20 years in 2015, although the proportion of new initiates (those injecting for less than three years) remained stable, ranging from 6% to 7% over the same period.

HIV and HCV antibody prevalence:

- HIV antibody prevalence remained low and stable nationally, ranging from 1.2% in 2011 to 2.1% in 2013, however the proportion of men testing HIV antibody positive increased from 1.4% in 2011 to 2.2% in 2015.
- Across all years 2011 to 2015, HIV antibody prevalence was higher among homosexual men than among bisexual or heterosexual men and women. From 2013 to 2015, HIV prevalence was also higher among men who reported sex work in the last month compared to men who did not, and among men who reported methamphetamine as the last drug injected.
- Hepatitis C virus (HCV) antibody prevalence was stable over the period 2011 to 2015, ranging from 53% to 57%.
- Prevalence of HCV antibody was higher among older participants, those with longer injection histories and respondents who reported injecting daily or more frequently.

Injecting behaviour:

- Over the period 2011 to 2015, approximately half of respondents reported daily or more frequent injecting in the month prior to the survey.
- The proportion of respondents reporting methamphetamine as the last drug injected increased from 27% in 2011 to 36% in 2015. In 2014 methamphetamine surpassed heroin as the most commonly reported drug last injected nationally.
- Heroin was reported as the last drug injected by approximately one third of respondents in all years 2011 to 2015.
- Pharmaceutical opioids were the third most commonly reported class of drugs last injected in all years 2011 to 2015; however, prevalence declined from 15% to 10% over this period.
- Nationally, 5% to 7% of respondents reported last injecting performance and image enhancing drugs (PIEDs) over the period 2011 to 2015. Among new initiates to injecting (those injecting for less than 3 years) in 2015, 38% reported last injecting PIEDs.
- Over the period 2011 to 2015, the proportion of respondents reporting reuse of needles and syringes (including reuse of one's own syringes) was stable, ranging from 21% to 25%.
- The proportion of respondents reporting receptive sharing of needles and syringes was also stable, ranging from 15% to 16% over the period 2011 to 2015. Receptive sharing of drug preparation equipment was also stable over the same period ranging from 28% to 31%.

INTRODUCTION

The Australian Needle and Syringe Program Survey (ANSPS) provides serial point prevalence estimates of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antibodies and sexual and injecting risk behaviour among people who inject drugs (PWID) in Australia. Conducted annually over a one-two week period in October, all clients attending participating Needle and Syringe Program (NSP) services are invited to complete a brief, anonymous questionnaire and to provide a capillary blood sample for HIV and HCV antibody testing (see methodological notes [Appendix B] for further details on the ANSPS design and implementation). This report presents national and state/territory data for the period 2011 to 2015.

In 2015, 47 NSP services participated in the ANSPS. Over the period 2011 to 2015, the number of ANSPS respondents ranged from 2,304 to 2,407 and the annual response rate ranged from 41% to 48% (Table 1.1.1). Of the 2,304 ANSPS respondents in 2015, the vast majority (93%) were recruited from the 42 NSP services that participated in the ANSPS in all years 2011 to 2015. A list of participating NSP services is provided at Appendix A.

Demographic Characteristics

Approximately two thirds of survey respondents were male and less than one percent identified as transgender across all five survey years 2011 to 2015. The majority of participants identified as heterosexual, while 8% identified as bisexual and 4% as homosexual in 2015 (Table 1.1.1).

The proportion of respondents from an Indigenous Australian background increased significantly from 12% to 15% over the period 2011 to 2015 (χ^2 trend $p=0.004$). The majority of respondents were born in Australia (ranging between 85% and 87%), with the United Kingdom and Ireland (5%) and New Zealand (3%) the predominant countries of birth outside Australia in 2015. Most respondents also reported that their parents spoke English at home (range 92% to 94% over the period 2011-2015).


The median age at survey completion increased from 37 years in 2011 to 40 years in 2015 and there was a concurrent significant decrease in the proportion of young injectors (aged <25 years) from 8% to 5% over the period 2011 to 2015 (χ^2 trend $p<0.001$). The median time since first injection increased from 17 years in 2011 to 20 years in 2015, however the proportion of new initiates (those injecting for less than 3 years) remained stable at 6% to 7% in all of the past five years, 2011 to 2015 (χ^2 trend $p=0.356$). The median age at first drug injection also remained stable in all years 2011 to 2015, ranging from 18 to 19 years of age (Table 1.1.1).

The proportion of participants reporting incarceration in the 12 months prior to survey completion was stable over the five year period, ranging from 10% to 11% (χ^2 trend $p=0.989$). Among those reporting recent incarceration, approximately one in three reported injecting in prison in all years 2011 to 2015 (Table 1.1.1).

Injecting behaviour

Methamphetamine was the most commonly reported drug last injected nationally since 2014, when it overtook heroin, which had been the most commonly injected drug in previous years (Table 1.1.2). Reports of methamphetamine injection increased significantly from 27% in 2011 to 36% in 2015 (χ^2 trend $p < 0.001$, Figure 1). In 2015, methamphetamine was the most commonly injected drug in the majority of jurisdictions, including New South Wales (32%), Queensland (34%), South Australia (53%), Tasmania (42%), and Western Australia (45%). Heroin was the second most commonly reported drug last injected nationally (31%), and the most commonly reported drug last injected in the Australian Capital Territory (45%) and Victoria (52%). Reports of heroin injection were stable over the five-year period, with around a third of respondents last injecting heroin between 2011 and 2015 (χ^2 trend $p = 0.107$).

Figure 1. Proportion of respondents (%) reporting last injecting heroin, methamphetamine and all other drugs, 2011–2015




The third most commonly reported class of drug last injected nationally was pharmaceutical opioids (including morphine and oxycodone) although prevalence declined from 15% to 10% over the period 2011 to 2015 (χ^2 trend $p < 0.001$, Figure 2). As in previous years, pharmaceutical opioids were the drug most commonly injected in the Northern Territory in 2015 (42%) and the second most commonly reported drug last injected in Tasmania (31%).

Methadone was reported as the last drug injected by less than ten percent of the ANSPS sample in all years 2011 to 2015 and prevalence remained stable over this period (χ^2 trend $p = 0.063$). Buprenorphine and buprenorphine-naloxone injection were reported by a minority of survey respondents. While the prevalence of buprenorphine-naloxone injection remained stable at between 1% and 2% (χ^2 trend $p = 0.087$) over the period 2011 to 2015, the prevalence of buprenorphine injection declined from 4% to 2% (χ^2 trend $p = 0.001$).

A minority of survey respondents ($\leq 1\%$ across all survey years) reported cocaine as the last drug injected. A significant increase in the prevalence of performance and image enhancing drugs (PIEDs) as the last drug injected occurred nationally over the period 2011 to 2015 (χ^2 trend $p=0.032$, Figure 2), although this increase was driven by QLD where prevalence increased from 7% in 2011 to 12% in 2015 (χ^2 trend $p=0.016$, Table 5.1.2). Prevalence of PIEDs injection in NSW remained stable at between 9% and 12% (χ^2 trend $p=0.387$) and less than 3% in all other jurisdictions. In 2015, 38% of new initiates (less than 3 years since first injection) reported last injecting PIEDs. In New South Wales and Queensland, the proportion of males who were new initiates to injecting who reported last injecting PIEDs was higher, 51% and 60% respectively.


Figure 2. Proportion of respondents (%) reporting last injecting pharmaceutical opioids, methadone and performance and image enhancing drugs, 2011–2015



Daily or more frequent injecting was reported by approximately half the respondents in all of the past five years (Table 1.1.2). Prevalence of at least one public injection (injection in a car, beach, park, street or squat) in the month prior to survey completion declined from 42% in 2011 to 37% in 2015 (χ^2 trend $p=0.021$, Table 1.1.3).

The proportion of respondents reporting reuse of needles and syringes (including one's own) in the month preceding the survey was stable over the period 2011 to 2015 (range 21% to 25%, χ^2 trend 0.064, Figure 3). Prevalence of receptive sharing of needles and syringes in the month prior to survey completion was also stable (range 15% to 16%, χ^2 trend $p=0.684$), as was receptive sharing of ancillary equipment (range 28% to 31%, χ^2 trend $p=0.538$). As in previous years, spoons and water were the most commonly identified receptively shared ancillary items in 2015 (Table 1.1.3).

Figure 3. Proportion of respondents (%) reporting reuse and receptive sharing of needles and syringes and receptive sharing of ancillary equipment in the last month, 2011–2015



Sexual behaviour

In each of the past five years, around half of respondents reported sex with a regular sex partner in the month prior to survey completion (range 46% to 49%, Table 1.1.6). Of these, a majority (70% to 77%) reported that they did not use condoms with their regular sex partner. A smaller proportion of respondents (14% to 15%) reported sex with other sex partners in the month preceding survey participation, although condom use was higher among this group, with approximately two thirds reporting use of condoms. The proportion of respondents reporting sex work in the month prior to the survey remained low and stable at 4% to 6% over the last five years (χ^2 trend $p=0.707$), while use of condoms at last paid sex was relatively high at between 62% and 82% in all years between 2011 and 2015 (Table 1.1.6). Among respondents who reported sex work in the previous month in 2015 ($n=96$), 56% were women, 38% were men and 6% identified as transgender.

Drug treatment


Respondents reported high rates of engagement with drug treatment services (Table 1.1.4), with nearly three quarters (73%) of 2015 respondents reporting current or previous drug treatment. The proportion of respondents reporting current opioid substitution therapy (OST; methadone, buprenorphine or buprenorphine-naloxone treatment) declined significantly from 42% in 2011 to 36% in 2015 (χ^2 trend $p<0.001$). Among respondents who reported last injecting opioids, current OST was stable over the period 2011 to 2015 (range 48% to 52%, χ^2 trend $p=0.776$). In 2015, current methadone maintenance treatment was reported by 26% of respondents, with current buprenorphine (8%) and buprenorphine-naloxone treatment (8%) reported by a further 16% of survey respondents.

HIV antibody prevalence

HIV antibody prevalence remained low and stable nationally over the period 2011 to 2015 (range 1.2% to 2.1%, χ^2 trend $p=0.086$, Table 1.2.1). The proportion of men testing HIV antibody positive increased significantly over the period 2011 to 2015 (χ^2 trend $p=0.017$, Figure 5). At the jurisdictional level (Figure 4), there was a significant increase in the overall proportion of HIV antibody positive respondents in New South Wales (from 1.0% in 2011 to 3.1% in 2015, χ^2 trend $p=0.002$) and Victoria (from 0.8% in 2011 to 2.2% in 2015, χ^2 trend $p=0.012$). These two jurisdictional increases were driven by significant increases in HIV antibody prevalence among men (Table 3.2.1 and Table 8.2.1). Conversely, in South Australia, there was a significant decrease in the overall proportion of HIV antibody positive respondents (from 2.4% in 2011 to 0.0% in 2015, χ^2 trend $p=0.020$), with a significant decline in HIV antibody prevalence among women, from 4% in 2011 to 0% in 2015 (χ^2 trend $p=0.018$, Table 6.2.1).


No respondents in Tasmania or the Australian Capital Territory tested positive to HIV antibodies in any of the previous five years.

Figure 4. HIV antibody prevalence (%) by jurisdiction, 2011–2015



Nationally, across all survey years, HIV antibody prevalence was consistently higher among homosexual male respondents than among bisexual and heterosexual male respondents or female respondents (Table 1.2.2 and Figure 5). In the last three years (2013 to 2015), HIV prevalence was also higher among male respondents who engaged in recent sex work compared to men who did not (Table 1.2.10) and among respondents reporting methamphetamine as the last drug injected (Table 1.2.4).

Figure 5. HIV antibody prevalence (%) by gender and sexual identity, 2011–2015



In 2015, the median age of HIV antibody positive respondents was 44 years (range 24-65 years) and respondents first injected a median of 12 years prior to survey participation (range 0-31 years). In 2015, there was no difference between the median age of HIV positive and negative respondents ($p=0.483$), however, the median time since first injection was significantly lower among HIV positive respondents compared to HIV negative respondents (12 years vs 20 years respectively, $p<0.001$).

HCV antibody prevalence

HCV antibody prevalence remained stable both nationally (χ^2 trend $p=0.139$, Table 1.3.1) and by jurisdiction (Figure 6) over the period 2011 to 2015. However, the prevalence of HCV was higher among certain subgroups. Across all five years of the survey, HCV antibody prevalence was significantly higher among older participants, those with longer injection histories and respondents who reported injecting daily or more frequently (Table 1.3.3, 1.3.5 and 1.3.7). Figure 7 illustrates the correlation between exposure to HCV and time since first injection among participants in 2015.

Figure 6. HCV antibody prevalence (%) by jurisdiction, 2011–2015





Figure 7. HCV antibody prevalence (%) by time since first injection, 2015



In all survey years, prevalence of HCV was also higher among respondents reporting heroin or other opioids as the last drug injected compared to respondents who last injected methamphetamine (Figure 8). HCV antibody prevalence was also consistently higher among respondents reporting imprisonment in the year preceding survey completion than among those not reporting recent imprisonment. Further, receptive syringe sharing in the last month was associated with a higher prevalence of HCV in the majority of the survey years.

Figure 8. HCV antibody prevalence (%) by drug last injected and gender, 2011–2015



HIV and HCV testing


ANSPS respondents reported high rates of lifetime HIV diagnostic screening (Table 1.1.5) over the period 2011 to 2015, with 82% to 85% of respondents reporting ever testing for HIV and in 2015, 50% of respondents reported having had an HIV test in the previous 12 months. Among the 38 respondents who tested HIV antibody positive, the majority (89%) were aware of their HIV positive status, 5% (n=2) reported their status as HIV negative and 5% (n=2) did not report their HIV status.

Respondents also reported high rates of lifetime HCV diagnostic screening (range 83% to 88%). In 2015, just over half (54%) of respondents reported having had an HCV test in the previous 12 months. Among respondents who tested HCV antibody positive, just over one in three (38%) reported a lifetime history of HCV RNA testing to distinguish between chronic and cleared HCV infection, with most of these respondents (24%) reporting RNA testing in the previous 12 months.

HCV treatment uptake

Among respondents who tested HCV antibody positive and who did not self-report spontaneous HCV clearance, the proportion who reported a lifetime history of HCV antiviral treatment increased significantly from 9% in 2011 to 12% in 2015 (χ^2 trend $p=0.014$, Figure 9). Among respondents who tested HCV antibody positive and who self-reported chronic infection (excluding respondents who self-reported spontaneous or treatment induced HCV clearance) the proportion who reported HCV treatment in the 12 months prior to survey participation was low and stable at between 1% and 3% in all survey years, 2011 to 2015 (χ^2 trend $p=0.410$).

Figure 9. Proportion of respondents (%) reporting lifetime and current antiviral treatment among HCV antibody positive respondents, 2011–2015



National

Table 1.1.1 Number (percentage) of respondents by demographic characteristics and survey year

National	2011	2012	2013	2014	2015
Number of sites	52	52	50	50	47
N° surveyed	N=2395	N=2391	N=2407	N=2378	N=2304
Response rate (%)	41%	46%	44%	48%	41%
Gender (%)					
Male	1602 (67)	1623 (68)	1636 (68)	1635 (69)	1568 (68)
Female	780 (33)	753 (31)	754 (31)	725 (30)	716 (31)
Transgender	10 (<1)	11 (<1)	13 (<1)	16 (<1)	18 (1)
Not reported	3 (<1)	4 (<1)	4 (<1)	2 (<1)	2 (<1)
Sexual identity (%)					
Heterosexual	1982 (83)	1949 (82)	1934 (80)	1914 (80)	1900 (82)
Bisexual	208 (9)	210 (9)	180 (7)	209 (9)	192 (8)
Homosexual	96 (4)	82 (3)	108 (4)	92 (4)	95 (4)
Not reported	109 (5)	150 (6)	185 (8)	163 (7)	117 (5)
Aboriginal and Torres Strait Islander origin (%)					
No	2065 (86)	2056 (86)	2003 (83)	2010 (85)	1930 (84)
Yes	276 (12)	294 (12)	324 (13)	321 (14)	334 (15)
Not reported	54 (2)	41 (2)	80 (3)	47 (2)	40 (2)
Region/country of birth (%)					
Australia	2046 (85)	2070 (87)	2070 (86)	2021 (85)	1961 (85)
Other Oceania	80 (3)	86 (4)	74 (3)	89 (4)	83 (4)
Asia	31 (1)	26 (1)	35 (1)	40 (2)	42 (2)
UK & Ireland	111 (5)	105 (4)	108 (4)	100 (4)	107 (5)
Other	101 (4)	85 (4)	109 (5)	107 (5)	73 (3)
Not reported	26 (1)	19 (<1)	11 (<1)	21 (<1)	38 (2)
Main language spoken at home by parents (%)					
English	2237 (93)	2252 (94)	2239 (93)	2195 (92)	2158 (94)
Non-English	134 (6)	129 (5)	159 (7)	165 (7)	117 (5)
Not reported	24 (1)	10 (<1)	9 (<1)	18 (<1)	29 (1)
Age and time since first injection (years)					
<i>Median age</i>	37	38	39	39	40
<i>Age range</i>	16-65	16-71	15-67	14-68	15-70
Age group (%)					
<25 years	182 (8)	176 (7)	181 (8)	143 (6)	108 (5)
25+ years	2205 (92)	2212 (93)	2217 (92)	2226 (94)	2191 (95)
Not reported	8 (<1)	3 (<1)	9 (<1)	9 (<1)	5 (<1)
Median age first injection					
<i>Median age first injection</i>	18	18	19	18	19
<i>Age range</i>	10-56	10-70	10-61	14-68	10-63
<i>N° not reported</i>	62	67	91	67	62
Median yrs since first injection					
<i>Median yrs since first injection</i>	17	17	18	19	20
<i>Range</i>	<1-41	<1-53	<1-51	<1-49	<1-52
Years since first injection					
<3 years	168 (7)	173 (7)	177 (7)	165 (7)	147 (6)
3+ years	2162 (90)	2150 (90)	2139 (89)	2140 (90)	2093 (91)
Not reported	65 (3)	68 (3)	91 (4)	73 (3)	64 (3)
Imprisonment last year (%)					
No	2049 (86)	2037 (85)	1990 (83)	1947 (82)	1958 (85)
Yes	238 (10)	261 (11)	252 (10)	254 (11)	231 (10)
Not reported	108 (5)	93 (4)	165 (7)	177 (7)	115 (5)
N° in prison					
<i>N° in prison</i>	N=238	N=261	N=252	N=254	N=231
Injected in prison	75 (32)	90 (34)	74 (29)	91 (36)	80 (35)

Table 1.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

National N° surveyed	2011 N=2395	2012 N=2391	2013 N=2407	2014 N=2378	2015 N=2304
Drug last injected (%)					
Cocaine	23 (1)	21 (1)	31 (1)	29 (1)	20 (1)
Methamphetamine	649 (27)	621 (26)	703 (29)	779 (33)	838 (36)
Heroin	802 (33)	799 (33)	709 (29)	727 (31)	725 (31)
Pharm. opioids	358 (15)	341 (14)	332 (14)	252 (11)	226 (10)
Methadone	173 (7)	159 (7)	163 (7)	139 (6)	139 (6)
Buprenorphine	94 (4)	84 (4)	78 (3)	53 (2)	62 (3)
Buprenorphine/naloxone	43 (2)	46 (2)	46 (2)	42 (2)	26 (1)
PIEDs	109 (5)	162 (7)	157 (7)	156 (7)	148 (6)
More than one	106 (4)	121 (5)	156 (6)	128 (5)	92 (4)
Other	33 (1)	22 (1)	19 (1)	62 (3)	28 (1)
Not reported	5 (<1)	15 (1)	13 (1)	11 (<1)	0 (0)
Frequency of injection last month (%)					
Not last month	250 (10)	235 (10)	223 (9)	206 (9)	200 (9)
Less than weekly	387 (16)	444 (19)	451 (19)	364 (15)	377 (16)
Weekly not daily	563 (24)	554 (23)	590 (25)	617 (26)	605 (26)
Daily or more	1159 (48)	1130 (47)	1070 (44)	1160 (49)	1089 (47)
Not reported	36 (2)	28 (1)	73 (3)	31 (1)	33 (1)
Present when someone injected for the first time in the last 12 months (%)					
Yes	--	353 (15)	311 (13)	403 (17)	367 (16)
No		1796 (75)	1730 (72)	1902 (80)	1881 (82)
Not reported		242 (10)	366 (15)	73 (3)	56 (2)
Overdosed in last 12 months					
Yes	--	--	279 (12)	367 (15)	328 (14)
No	--	--	2055 (83)	1935 (81)	1922 (83)
Not reported	--	--	73 (3)	76 (3)	54 (2)

Table 1.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

National N° injected last month	2011 N=2109	2012 N=2128	2013 N=2111	2014 N=2141	2015 N=2071
Places injected last month (%)					
Any public	882 (42)	836 (39)	828 (39)	781 (36)	774 (37)
All private	1154 (55)	1222 (57)	1262 (60)	1346 (63)	1287 (62)
Not reported	73 (3)	70 (3)	21 (1)	14 (<1)	10 (<1)
Use of new and sterile needles and syringes last month (%)					
All injections	1569 (74)	1593 (75)	1586 (75)	1657 (77)	1537 (74)
Most of the time	383 (18)	366 (17)	420 (20)	381 (18)	426 (21)
Half of the time	41 (2)	36 (2)	34 (2)	33 (2)	55 (3)
Some of the time	26 (1)	21 (1)	31 (1)	20 (1)	23 (1)
Not last month	4 (<1)	15 (<1)	9 (<1)	8 (<1)	11 (1)
Not reported	86 (4)	97 (5)	31 (1)	42 (2)	19 (1)
Re-used someone else's used needle & syringe last month (%)					
None	1663 (79)	1713 (81)	1770 (84)	1772 (83)	1728 (83)
Once	104 (5)	148 (7)	105 (5)	129 (6)	104 (5)
Twice	80 (4)	60 (3)	79 (4)	84 (4)	85 (4)
3-5 times	74 (4)	61 (3)	63 (3)	71 (3)	85 (4)
>5 times	58 (3)	67 (3)	67 (3)	48 (2)	58 (3)
Not reported	130 (6)	79 (4)	27 (1)	37 (2)	11 (1)
Number of people needle & syringe was re-used after last month (%)					
None	1663 (79)	1713 (81)	1770 (84)	1772 (83)	1728 (83)
One	166 (8)	158 (7)	139 (7)	136 (6)	142 (7)
Two	23 (1)	23 (1)	31 (1)	27 (1)	36 (2)
Three to five	14 (<1)	11 (<1)	13 (1)	12 (<1)	19 (1)
More than five	14 (<1)	22 (1)	19 (1)	18 (1)	11 (1)
Don't know	64 (3)	48 (2)	69 (3)	60 (3)	72 (3)
Not reported	165 (8)	153 (7)	70 (3)	116 (5)	63 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	196 (9)	113 (5)	131 (6)	132 (6)	117 (6)
Casual sex partner	9 (<1)	8 (<1)	19 (1)	10 (<1)	17 (1)
Close friend	125 (6)	96 (5)	88 (4)	62 (3)	94 (5)
Acquaintance	59 (3)	44 (2)	54 (3)	36 (2)	38 (2)
Other	48 (2)	21 (1)	32 (2)	26 (1)	32 (2)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	481 (22)	450 (21)	511 (24)	460 (21)	461 (22)
Water	310 (15)	311 (15)	373 (18)	362 (17)	358 (17)
Filter	222 (11)	226 (11)	241 (11)	223 (10)	228 (11)
Drug mix	174 (8)	190 (9)	189 (9)	177 (8)	221 (11)
None	1387 (66)	1421 (67)	1436 (68)	1477 (69)	1415 (68)
Injected by someone after that person injected themselves or others last month (%)					
No	1731 (82)	1745 (82)	1754 (83)	1740 (81)	1761 (85)
Yes	283 (13)	284 (13)	278 (13)	316 (15)	288 (14)
Not reported	95 (5)	99 (5)	79 (4)	85 (4)	22 (1)
Source of needle acquisition					
Needle Syringe Program	1917 (91)	1888 (89)	1952 (92)	1916 (89)	1865 (90)
Chemist/Pharmacy	415 (20)	503 (24)	436 (21)	456 (21)	465 (22)
Personal sources	184 (9)	248 (12)	197 (9)	230 (11)	255 (12)
Dispensing/Vending Machine	205 (10)	255 (12)	240 (11)	279 (13)	280 (14)
Other sources	35 (2)	18 (1)	42 (2)	37 (2)	52 (3)

Table 1.1.4 Number (percentage) of respondents by treatment for drug use and survey year

National N° surveyed	2011 N=2395	2012 N=2391	2013 N=2407	2014 N=2378	2015 N=2304
Ever any treatment/therapy for drug use (%)					
No	489 (20)	539 (23)	575 (24)	582 (24)	590 (26)
Yes	1842 (77)	1826 (76)	1800 (75)	1750 (74)	1672 (73)
Not reported	64 (3)	26 (1)	32 (1)	46 (2)	42 (2)
History of methadone maintenance treatment (%)					
Currently	693 (29)	712 (30)	718 (29)	641 (27)	600 (26)
Previously	586 (24)	622 (26)	559 (23)	565 (24)	550 (24)
Never	1006 (42)	1041 (44)	1112 (46)	1123 (47)	1105 (48)
Not reported	110 (5)	16 (1)	18 (1)	49 (2)	49 (2)
History of buprenorphine (Subutex®) treatment (%)					
Currently	231 (10)	241 (10)	193 (8)	197 (8)	177 (8)
Previously	641 (27)	665 (28)	694 (29)	653 (27)	655 (28)
Never	1426 (60)	1456 (61)	1475 (61)	1472 (62)	1422 (62)
Not reported	97 (4)	29 (1)	45 (2)	56 (2)	50 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	224 (9)	245 (10)	219 (9)	196 (8)	187 (8)
Previously	438 (18)	469 (20)	529 (22)	526 (22)	533 (23)
Never	1640 (68)	1639 (69)	1602 (67)	1597 (67)	1530 (66)
Not reported	93 (4)	38 (2)	57 (2)	59 (2)	54 (2)

Table 1.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

National N° surveyed	2011 N=2395	2012 N=2391	2013 N=2407	2014 N=2378	2015 N=2304
Previous HIV test (%)					
Yes, ever	2021 (84)	1997 (83)	2017 (84)	1951 (82)	1950 (85)
Yes, last year	1172 (49)	1157 (48)	1205 (50)	1170 (49)	1151 (50)
>1 year ago	849 (35)	840 (35)	812 (34)	781 (33)	799 (35)
Never tested	287 (12)	299 (13)	320 (13)	332 (14)	297 (13)
Not reported	87 (4)	95 (4)	70 (3)	95 (4)	57 (2)
Previous HCV test (%)					
Yes, ever	2083 (87)	2086 (88)	2013 (83)	2047 (86)	2016 (88)
Yes, last year	1289 (54)	1305 (55)	1235 (51)	1276 (54)	1244 (54)
>1 year ago	794 (33)	781 (33)	778 (32)	771 (32)	772 (34)
Never tested	169 (7)	181 (8)	196 (8)	214 (9)	187 (8)
Not reported	143 (6)	124 (5)	198 (8)	117 (5)	101 (4)
Lifetime treatment for HCV (%)					
N° self-reported chronic HCV[#]*	N=637	N=653	N=646	N=588	N=496
Antiviral treatment	55 (9)	61 (9)	70 (11)	76 (13)	61 (12)
No antiviral treatment	564 (89)	582 (89)	557 (86)	497 (85)	409 (82)
Not reported	18 (3)	10 (2)	19 (3)	15 (3)	26 (5)
Treatment for HCV in past 12 months (%)					
N° self-reported chronic HCV[#]	N=606	N=622	N=608	N=533	N=451
Antiviral treatment	15 (2)	14 (2)	19 (3)	4 (1)	11 (2)
No antiviral treatment	583 (96)	604 (97)	560 (92)	501 (94)	428 (95)
Not reported	8 (1)	4 (1)	29 (5)	28 (5)	12 (3)

among people who tested HCV antibody positive

* includes people who reported treatment induced clearance

Table 1.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

National	2011	2012	2013	2014	2015
N° surveyed	N=2395	N=2391	N=2407	N=2378	N=2304
Sex with a regular partner last month (%)					
No	1105 (46)	1173 (49)	1176 (49)	1166 (49)	1116 (48)
Yes	1133 (47)	1152 (48)	1151 (48)	1114 (47)	1086 (47)
Not reported	157 (7)	66 (3)	80 (3)	98 (4)	102 (4)
Condom used with regular partner last month (%)					
N° surveyed	N=1133	N=1152	N=1151	N=1114	N=1086
Never	800 (71)	815 (71)	801 (70)	800 (72)	832 (77)
Sometimes	133 (12)	147 (13)	166 (14)	145 (13)	106 (10)
Every time	141 (12)	127 (11)	113 (10)	110 (10)	113 (10)
Not reported	59 (5)	63 (5)	71 (6)	59 (5)	35 (3)
Sex with other partner(s) last month (%)					
No	1966 (82)	1953 (82)	1929 (80)	1895 (80)	1901 (83)
Yes	330 (14)	336 (14)	364 (15)	357 (15)	319 (14)
Not reported	99 (4)	102 (4)	114 (5)	126 (5)	84 (4)
Condom used with other partner(s) last month (%)					
N° surveyed	N=330	N=336	N=364	N=357	N=319
Never	108 (33)	115 (34)	117 (32)	118 (33)	112 (35)
Sometimes	80 (24)	92 (27)	103 (28)	98 (27)	99 (31)
Every time	127 (38)	109 (32)	128 (35)	101 (28)	95 (30)
Not reported	15 (5)	20 (6)	16 (4)	40 (11)	13 (4)
Sex work last month (%)					
No	2169 (91)	2195 (92)	2141 (89)	2050 (86)	2137 (93)
Yes	114 (5)	119 (5)	98 (4)	133 (6)	96 (4)
Not reported	112 (5)	77 (3)	168 (7)	195 (8)	71 (3)
Condom used at last sex work (%)					
Yes	88 (77)	98 (82)	72 (73)	83 (62)	66 (69)

HIV antibody prevalence

Table 1.2.1 HIV antibody prevalence by gender and survey year

National Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011	1560	21 (1.4)	764	7 (0.9)	2337	29 (1.2)
2012	1546	18 (1.2)	718	9 (1.3)	2279	28 (1.2)
2013	1563	41 (2.6)	727	6 (0.8)	2307	48 (2.1)
2014	1558	33 (2.1)	702	3 (0.4)	2273	39 (1.7)
2015	1502	33 (2.2)	696	3 (0.4)	2217	38 (1.7)
X ² p trend p value		0.017		0.089		0.086

Table 1.2.2 HIV antibody prevalence by sexual identity, gender and survey year

National Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Heterosexual	1393	6 (0.4)	547	5 (0.9)	1943	11 (0.6)
Bisexual	57	3 (5.3)	141	2 (1.4)	203	6 (3.0)
Homosexual	51	12 (23.5)	38	0 (0.0)	91	12 (13.2)
p value		<0.001		0.751		<0.001
2012						
Heterosexual	1350	4 (0.3)	506	8 (1.6)	1859	12 (0.7)
Bisexual	69	2 (2.9)	127	0 (0.0)	200	3 (1.5)
Homosexual	42	9 (21.4)	31	0 (0.0)	77	9 (11.7)
p value		<0.001		0.570		<0.001
2013						
Heterosexual	1322	9 (0.7)	519	6 (1.2)	1848	15 (0.8)
Bisexual	59	6 (10.2)	114	0 (0.0)	175	7 (4.0)
Homosexual	73	24 (32.9)	26	0 (0.0)	105	24 (22.9)
p value		<0.001		0.684		<0.001
2014						
Heterosexual	1332	8 (0.6)	497	3 (0.6)	1832	11 (0.6)
Bisexual	58	5 (8.6)	134	0 (0.0)	199	8 (4.0)
Homosexual	64	19 (29.7)	23	0 (0.0)	88	19 (21.6)
p value		<0.001		1.000		<0.001
2015						
Heterosexual	1315	7 (0.5)	514	2 (0.4)	1835	9 (0.5)
Bisexual	69	4 (5.8)	110	1 (0.9)	185	6 (3.2)
Homosexual	53	21 (39.6)	28	0 (0.0)	84	21 (25.0)
p value		<0.001		0.511		<0.001

Table 1.2.3 HIV antibody prevalence by age group, gender and survey year

National Age group	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
<25 years	118	1 (0.9)	56	2 (3.6)	176	3 (1.7)
25-34 years	457	1 (0.2)	287	1 (0.4)	748	2 (0.3)
35-44 years	569	9 (1.6)	250	1 (0.4)	824	11 (1.3)
45+ years	410	10 (2.4)	169	3 (1.8)	580	13 (2.2)
p value		0.022		0.053		0.005
2012						
<25 years	130	0 (0.0)	38	0 (0.0)	169	0 (0.0)
25-34 years	412	2 (0.5)	241	3 (1.2)	657	5 (0.8)
35-44 years	580	5 (0.9)	266	1 (0.4)	856	7 (0.8)
45+ years	418	11 (2.6)	172	5 (2.9)	595	16 (2.7)
p value		0.022		0.135		0.005
2013						
<25 years	110	2 (1.8)	60	0 (0.0)	170	2 (1.2)
25-34 years	394	6 (1.5)	215	2 (0.9)	616	9 (1.5)
35-44 years	569	15 (2.6)	256	0 (0.0)	828	15 (1.8)
45+ years	483	18 (3.7)	195	4 (2.1)	684	22 (3.2)
p value		0.239		0.097		0.127
2014						
<25 years	98	1 (1.0)	33	0 (0.0)	133	1 (0.8)
25-34 years	363	7 (1.9)	204	0 (0.0)	570	8 (1.4)
35-44 years	596	8 (1.3)	273	2 (0.7)	874	12 (1.4)
45+ years	495	17 (3.4)	190	1 (0.5)	688	18 (2.6)
p value		0.114		0.681		0.224
2015						
<25 years	67	0 (0.0)	32	1 (3.1)	101	1 (1.0)
25-34 years	347	10 (2.9)	187	1 (0.5)	540	13 (2.4)
35-44 years	545	6 (1.1)	248	0 (0.0)	796	6 (0.8)
45+ years	539	17 (3.2)	229	1 (0.4)	776	18 (2.3)
p value		0.055		0.092		0.033

Table 1.2.4 HIV antibody prevalence by last drug injected, gender and survey year

National Last drug injected	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
Heroin	513	2 (0.4)	267	4 (1.5)	783	7 (0.9)
Methamphetamine	382	12 (3.1)	247	1 (0.4)	632	13 (2.1)
Other opioids	448	6 (1.3)	202	2 (1.0)	655	8 (1.2)
PIEDs	101	0 (0.0)	5	0 (0.0)	106	0 (0.0)
Other drugs	113	1 (0.9)	41	0 (0.0)	156	1 (0.6)
p value		0.011		0.647		0.292
2012						
Heroin	507	2 (0.4)	262	6 (2.3)	773	9 (1.2)
Methamphetamine	355	8 (2.3)	216	2 (0.9)	577	10 (1.7)
Other opioids	416	7 (1.7)	187	1 (0.5)	605	8 (1.3)
PIEDs	146	1 (0.7)	4	0 (0.0)	152	1 (0.7)
Other drugs	111	0 (0.0)	45	0 (0.0)	157	0 (0.0)
p value		0.069		0.423		0.551
2013						
Heroin	449	5 (1.1)	230	4 (1.7)	683	9 (1.3)
Methamphetamine	413	24 (5.8)	249	2 (0.8)	668	26 (3.9)
Other opioids	423	8 (1.9)	177	0 (0.0)	601	8 (1.3)
PIEDs	136	1 (0.7)	3	0 (0.0)	141	1 (0.7)
Other drugs	133	3 (2.3)	65	0 (0.0)	201	4 (2.0)
p value		<0.001		0.340		0.007
2014						
Heroin	460	6 (1.3)	233	1 (0.4)	696	8 (1.2)
Methamphetamine	472	20 (4.2)	265	1 (0.4)	741	21 (2.8)
Other opioids	326	3 (0.9)	145	0 (0.0)	474	3 (0.6)
PIEDs	144	2 (1.4)	5	0 (0.0)	150	2 (1.3)
Other drugs	149	2 (1.3)	52	1 (1.9)	203	5 (2.5)
p value		0.011		0.416		0.024
2015						
Heroin	468	9 (1.9)	230	1 (0.4)	704	11 (1.6)
Methamphetamine	516	21 (4.1)	271	2 (0.7)	798	24 (3.0)
Other opioids	300	2 (0.7)	142	0 (0.0)	444	2 (0.5)
PIEDs	140	1 (0.7)	6	0 (0.0)	146	1 (0.7)
Other drugs	78	0 (0.0)	47	0 (0.0)	125	0 (0.0)
p value		0.008		0.842		0.005

Table 1.2.5 HIV antibody prevalence by years of injection, gender and survey year

National Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
<3 years	114	2 (1.8)	48	0 (0.0)	163	2 (1.2)
3 to 10 years	251	4 (1.6)	152	2 (1.3)	404	6 (1.5)
11 + years	1148	15 (1.3)	549	5 (0.9)	1707	21 (1.2)
p value		0.731		0.780		0.845
2012						
<3 years	126	1 (0.8)	35	0 (0.0)	162	1 (0.6)
3 to 10 years	242	3 (1.2)	129	3 (2.3)	373	6 (1.6)
11 + years	1134	14 (1.2)	535	6 (1.1)	1680	21 (1.3)
p value		1.000		0.615		0.701
2013						
<3 years	120	5 (4.2)	38	0 (0.0)	160	5 (3.1)
3 to 10 years	228	10 (4.4)	140	0 (0.0)	369	10 (2.7)
11 + years	1150	25 (2.2)	527	6 (1.1)	1689	32 (1.9)
p value		0.079		0.536		0.323
2014						
<3 years	116	3 (2.6)	41	0 (0.0)	158	3 (1.9)
3 to 10 years	215	10 (4.7)	119	0 (0.0)	335	10 (3.0)
11 + years	1176	19 (1.6)	526	3 (0.6)	1712	24 (1.4)
p value		0.020		1.000		0.097
2015						
<3 years	110	4 (3.6)	32	0 (0.0)	143	4 (2.8)
3 to 10 years	222	10 (4.5)	108	1 (0.9)	337	11 (3.3)
11 + years	1130	18 (1.6)	537	2 (0.4)	1678	22 (1.3)
p value		0.013		0.502		0.020

Table 1.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

National Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No receptive sharing	1093	15 (1.4)	529	7 (1.3)	1627	22 (1.4)
Receptive sharing	198	1 (0.5)	105	0 (0.0)	306	1 (0.3)
p value		0.491		0.607		0.158
2012						
No receptive sharing	1117	12 (1.1)	506	9 (1.8)	1634	22 (1.4)
Receptive sharing	220	0 (0.0)	100	0 (0.0)	320	0 (0.0)
p value		0.234		0.368		0.037
2013						
No receptive sharing	1155	27 (2.3)	534	6 (1.1)	1701	33 (1.9)
Receptive sharing	207	4 (1.9)	98	0 (0.0)	306	5 (1.6)
p value		1.000		0.597		1.000
2014						
No receptive sharing	1163	22 (1.9)	520	2 (0.4)	1693	26 (1.5)
Receptive sharing	213	4 (1.9)	102	1 (1.0)	316	6 (1.9)
p value		1.000		0.416		0.636
2015						
No receptive sharing	1117	29 (2.6)	535	3 (0.6)	1665	34 (2.0)
Receptive sharing	217	3 (1.4)	96	0 (0.0)	315	3 (1.0)
p value		0.464		1.000		0.257

Table 1.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

National Frequency of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
Less than daily	619	11 (1.8)	306	3 (1.0)	929	15 (1.6)
Daily or more	752	5 (0.7)	369	4 (1.1)	1127	9 (0.8)
Not last month	161	4 (2.5)	83	0 (0.0)	246	4 (1.6)
p value		0.047		1.000		0.179
2012						
Less than daily	632	8 (1.3)	312	6 (1.9)	953	15 (1.6)
Daily or more	748	6 (0.8)	324	3 (0.9)	1076	9 (0.8)
Not last month	146	4 (2.7)	78	0 (0.0)	225	4 (1.8)
p value		0.111		0.483		0.209
2013						
Less than daily	662	20 (3.0)	334	5 (1.5)	1001	25 (2.5)
Daily or more	713	13 (1.8)	310	1 (0.3)	1031	15 (1.5)
Not last month	146	6 (4.1)	61	0 (0.0)	208	6 (2.9)
p value		0.172		0.339		0.171
2014						
Less than daily	641	11 (1.7)	301	0 (0.0)	946	11 (1.2)
Daily or more	753	16 (2.1)	336	3 (0.9)	1096	22 (2.0)
Not last month	144	6 (4.2)	55	0 (0.0)	201	6 (3.0)
p value		0.186		0.416		0.127
2015						
Less than daily	652	18 (2.8)	276	2 (0.7)	937	21 (2.2)
Daily or more	690	14 (2.0)	357	1 (0.3)	1053	16 (1.5)
Not last month	136	1 (0.7)	54	0 (0.0)	194	1 (0.5)
p value		0.339		0.674		0.215

Table 1.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

National Imprisonment last year	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No imprisonment	1303	21 (1.6)	683	6 (0.9)	1997	28 (1.4)
Imprisonment	176	0 (0.0)	56	1 (1.8)	233	1 (0.4)
p value		0.163		0.425		0.356
2012						
No imprisonment	1289	17 (1.3)	639	9 (1.4)	1942	27 (1.4)
Imprisonment	199	1 (0.5)	47	0 (0.0)	247	1 (0.4)
p value		0.496		1.000		0.360
2013						
No imprisonment	1266	36 (2.8)	634	6 (1.0)	1912	43 (2.3)
Imprisonment	189	4 (2.1)	50	0 (0.0)	241	4 (1.7)
p value		0.811		1.000		0.814
2014						
No imprisonment	1260	26 (2.1)	609	3 (0.5)	1874	29 (1.6)
Imprisonment	180	0 (0.0)	51	0 (0.0)	236	3 (1.3)
p value		0.065		1.000		1.000
2015						
No imprisonment	1249	29 (2.3)	625	2 (0.3)	1890	33 (1.8)
Imprisonment	168	1 (0.6)	48	0 (0.0)	219	1 (0.5)
p value		0.247		1.000		0.250

Table 1.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

National Condom use at last sex	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No condom use	475	6 (1.3)	308	3 (1.0)	784	9 (1.2)
Condom use	179	4 (2.2)	82	1 (1.2)	263	5 (1.9)
p value		0.473		1.000		0.359
2012						
No condom use	475	2 (0.4)	287	2 (0.7)	767	4 (0.5)
Condom use	173	7 (4.1)	90	2 (2.2)	263	9 (3.4)
p value		0.002		0.242		0.001
2013						
No condom use	448	6 (1.3)	319	1 (0.3)	770	7 (0.9)
Condom use	187	8 (4.3)	76	2 (2.6)	268	11 (4.1)
p value		0.022		0.096		0.001
2014						
No condom use	468	7 (1.5)	302	1 (0.3)	771	8 (1.0)
Condom use	177	5 (2.8)	66	0 (0.0)	246	7 (2.9)
p value		0.265		1.000		0.041
2015						
No condom use	495	9 (1.8)	303	0 (0.0)	802	11 (1.4)
Condom use	139	2 (1.4)	66	1 (1.5)	208	3 (1.4)
p value		1.000		0.179		1.000

Table 1.2.10 HIV antibody prevalence by sex work last month, gender and survey year

National Sex work last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No sex work	1452	19 (1.3)	666	6 (0.9)	2125	25 (1.2)
Sex work	29	0 (0.0)	75	1 (1.3)	108	2 (1.9)
p value		1.000		0.528		0.378
2012						
No sex work	1451	17 (1.2)	629	8 (1.3)	2090	25 (1.2)
Sex work	37	1 (2.7)	72	1 (1.4)	114	3 (2.6)
p value		0.366		1.000		0.174
2013						
No sex work	1415	35 (2.5)	624	6 (1.0)	2052	41 (2.0)
Sex work	36	4 (11.1)	56	0 (0.0)	94	5 (5.3)
p value		0.014		1.000		0.048
2014						
No sex work	1364	21 (1.5)	599	3 (0.5)	1969	25 (1.3)
Sex work	58	5 (8.6)	60	0 (0.0)	124	7 (5.7)
p value		<0.001		1.000		<0.001
2015						
No sex work	1415	25 (1.8)	631	3 (0.5)	2059	29 (1.4)
Sex work	34	6 (17.7)	54	0 (0.0)	94	7 (7.5)
p value		<0.001		1.000		<0.001

Table 1.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Non Indigenous	1366	20 (1.5)	641	5 (0.8)	2016	25 (1.2)
Indigenous	158	1 (0.6)	111	2 (1.8)	271	4 (1.5)
p value		0.716		0.277		0.770
2012						
Non Indigenous	1349	18 (1.3)	598	8 (1.3)	1959	26 (1.3)
Indigenous	172	0 (0.0)	106	0 (0.0)	281	1 (0.4)
p value		0.251		0.614		0.242
2013						
Non Indigenous	1322	34 (2.6)	587	6 (1.0)	1920	41 (2.1)
Indigenous	184	4 (2.2)	124	0 (0.0)	312	4 (1.3)
p value		1.000		0.597		0.391
2014						
Non Indigenous	1352	26 (1.9)	558	2 (0.4)	1922	30 (1.6)
Indigenous	174	4 (2.3)	132	1 (0.8)	307	6 (2.0)
p value		0.769		0.472		0.612
2015						
Non Indigenous	1282	28 (2.2)	565	1 (0.2)	1864	31 (1.7)
Indigenous	197	5 (2.5)	122	2 (1.6)	319	7 (2.2)
p value		0.754		0.083		0.503

Table 1.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

National Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
English speaking	1444	20 (1.4)	731	7 (1.0)	2187	28 (1.3)
Non-English speaking	100	1 (1.0)	28	0 (0.0)	129	1 (0.8)
p value		1.000		1.000		1.000
2012						
English speaking	1446	15 (1.0)	685	9 (1.3)	2143	25 (1.2)
Non-English speaking	96	3 (3.1)	27	0 (0.0)	126	3 (2.4)
p value		0.097		1.000		0.201
2013						
English speaking	1441	37 (2.6)	689	6 (0.9)	2145	44 (2.1)
Non-English speaking	114	4 (3.5)	38	0 (0.0)	153	4 (2.6)
p value		0.537		1.000		0.557
2014						
English speaking	1426	29 (2.0)	659	2 (0.3)	2096	34 (1.6)
Non-English speaking	120	2 (1.7)	38	1 (2.6)	160	3 (1.9)
p value		1.000		0.155		0.744
2015						
English speaking	1390	31 (2.2)	666	3 (0.5)	2075	36 (1.7)
Non-English speaking	92	2 (2.2)	25	0 (0.0)	117	2 (1.7)
p value		1.000		1.000		1.000

Table 1.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

National Region/country of birth	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Australia	1322	20 (1.5)	665	7 (1.1)	1999	28 (1.4)
Other Oceania	46	0 (0.0)	34	0 (0.0)	80	0 (0.0)
Asia	24	1 (4.2)	7	0 (0.0)	31	1 (3.2)
UK & Ireland	73	0 (0.0)	34	0 (0.0)	108	0 (0.0)
Other	77	0 (0.0)	20	0 (0.0)	97	0 (0.0)
p value		0.448		1.000		0.362
2012						
Australia	1328	12 (0.9)	630	9 (1.4)	1972	22 (1.1)
Other Oceania	49	2 (4.1)	32	0 (0.0)	81	2 (2.5)
Asia	22	0 (0.0)	3	0 (0.0)	26	0 (0.0)
UK & Ireland	73	1 (1.4)	26	0 (0.0)	99	1 (1.0)
Other	58	3 (5.2)	24	0 (0.0)	82	3 (3.7)
p value		0.022		1.000		0.179
2013						
Australia	1329	32 (2.4)	642	6 (0.9)	1983	38 (1.9)
Other Oceania	50	2 (4.0)	20	0 (0.0)	71	3 (4.2)
Asia	30	3 (10.0)	5	0 (0.0)	35	3 (8.6)
UK & Ireland	70	1 (1.4)	31	0 (0.0)	102	1 (1.0)
Other	76	3 (4.0)	27	0 (0.0)	105	3 (2.9)
p value		0.088		1.000		0.048
2014						
Australia	1304	26 (2.0)	620	2 (0.3)	1934	29 (1.5)
Other Oceania	63	1 (1.6)	20	0 (0.0)	85	3 (3.5)
Asia	35	1 (2.9)	4	1 (25)	39	2 (5.1)
UK & Ireland	70	0 (0.0)	28	0 (0.0)	98	0 (0.0)
Other	72	3 (4.2)	26	0 (0.0)	99	3 (3.0)
p value		0.372		0.048		0.056
2015						
Australia	1266	29 (2.3)	606	3 (0.5)	1888	33 (1.8)
Other Oceania	61	1 (1.6)	18	0 (0.0)	80	2 (2.5)
Asia	32	1 (3.1)	9	0 (0.0)	42	1 (2.4)
UK & Ireland	63	1 (1.6)	40	0 (0.0)	104	1 (1.0)
Other	51	0 (0.0)	18	0 (0.0)	69	0 (0.0)
p value		0.878		1.000		0.699

HCV ANTIBODY PREVALENCE

Table 1.3.1 HCV antibody prevalence by gender and survey year

National Survey year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011	1530	826 (54)	748	386 (52)	2290	1216 (53)
2012	1524	794 (52)	713	384 (54)	2252	1184 (53)
2013	1554	831 (53)	726	396 (55)	2296	1235 (54)
2014	1506	802 (53)	684	380 (56)	2203	1188 (54)
2015	1382	790 (57)	654	375 (57)	2054	1173 (57)
X ² p trend value		0.341		0.229		0.139

Table 1.3.2 HCV antibody prevalence by sexual identity, gender and survey year

National Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Heterosexual	1369	750 (55)	531	273 (51)	1903	1024 (54)
Bisexual	55	24 (44)	140	71 (51)	200	96 (48)
Homosexual	51	20 (39)	37	15 (41)	90	36 (40)
p value		0.028		0.441		0.014
2012						
Heterosexual	1329	703 (53)	501	270 (54)	1833	974 (53)
Bisexual	70	33 (47)	127	71 (56)	201	105 (52)
Homosexual	41	12 (29)	31	14 (45)	76	27 (36)
p value		0.008		0.560		0.011
2013						
Heterosexual	1316	717 (54)	518	283 (55)	1841	1005 (55)
Bisexual	58	29 (50)	114	61 (54)	173	90 (52)
Homosexual	72	19 (26)	26	12 (46)	104	33 (32)
p value		<0.001		0.692		<0.001
2014						
Heterosexual	1286	692 (54)	481	266 (55)	1770	959 (54)
Bisexual	57	28 (49)	133	72 (54)	197	104 (53)
Homosexual	64	22 (34)	23	12 (52)	88	34 (39)
p value		0.008		0.936		0.017
2015						
Heterosexual	1214	698 (58)	481	273 (57)	1701	974 (57)
Bisexual	58	34 (59)	103	63 (61)	167	98 (59)
Homosexual	50	19 (38)	27	15 (56)	80	36 (45)
p value		0.023		0.699		0.085

Table 1.3.3 HCV antibody prevalence by age group, gender and survey year

National Age group	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
<25 years	118	18 (15)	56	16 (29)	176	34 (19)
25-34 years	447	206 (46)	279	136 (49)	730	343 (47)
35-44 years	561	329 (59)	244	139 (57)	809	470 (58)
45+ years	398	270 (68)	167	95 (57)	566	365 (64)
p value		<0.001		0.001		<0.001
2012						
<25 years	129	12 (9)	38	12 (32)	168	24 (14)
25-34 years	408	179 (44)	242	132 (55)	654	314 (48)
35-44 years	575	336 (58)	262	140 (53)	842	478 (57)
45+ years	411	266 (65)	170	99 (58)	586	366 (62)
p value		<0.001		0.030		<0.001
2013						
<25 years	109	11 (10)	60	15 (25)	169	26 (15)
25-34 years	392	155 (40)	215	105 (49)	613	263 (43)
35-44 years	565	346 (61)	255	148 (58)	823	494 (60)
45+ years	481	316 (66)	195	127 (65)	682	448 (66)
p value		<0.001		<0.001		<0.001
2014						
<25 years	98	12 (12)	33	8 (24)	133	20 (15)
25-34 years	355	136 (38)	198	109 (55)	556	247 (44)
35-44 years	572	336 (59)	266	144 (54)	843	482 (57)
45+ years	475	315 (66)	185	117 (63)	663	434 (65)
p value		<0.001		<0.001		<0.001
2015						
<25 years	60	11 (18)	29	5 (17)	91	16 (18)
25-34 years	325	127 (39)	176	102 (58)	507	232 (46)
35-44 years	507	302 (60)	232	120 (52)	742	423 (57)
45+ years	486	347 (71)	217	148 (68)	710	499 (70)
p value		<0.001		<0.001		<0.001

Table 1.3.4 HCV antibody prevalence by years since first injection, gender and survey year

National Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
<3 years	114	12 (11)	47	13 (28)	162	25 (15)
3 to 10 years	249	93 (37)	151	62 (41)	401	155 (39)
11+years	1120	703 (63)	536	305 (57)	1665	1011 (61)
p value		<0.001		<0.001		<0.001
2012						
<3 years	125	12 (10)	35	10 (29)	161	23 (14)
3 to 10 years	238	79 (33)	126	50 (40)	366	129 (35)
11+years	1118	681 (61)	533	313 (59)	1662	999 (60)
p value		<0.001		<0.001		<0.001
2013						
<3 years	120	5 (4)	38	9 (24)	160	15 (9)
3 to 10 years	224	58 (26)	140	62 (44)	365	120 (33)
11+years	1145	723 (63)	526	317 (60)	1682	1046 (62)
p value		<0.001		<0.001		<0.001
2014						
<3 years	116	7 (6)	41	5 (12)	158	12 (8)
3 to 10 years	212	67 (32)	119	54 (45)	332	121 (37)
11+years	1126	704 (63)	508	311 (61)	1644	1021 (62)
p value		<0.001		<0.001		<0.001
2015						
<3 years	101	14 (14)	27	6 (22)	128	20 (16)
3 to 10 years	206	67 (33)	101	40 (40)	314	108 (34)
11+years	1040	693 (67)	508	321 (63)	1559	1021 (65)
p value		<0.001		<0.001		<0.001

Table 1.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

National Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No receptive sharing	110	15 (14)	1449	811 (56)	1593	840 (53)
Receptive sharing	15	5 (33)	276	171 (62)	297	180 (61)
p value		0.051		0.066		0.012
2012						
No receptive sharing	107	19 (18)	1480	808 (55)	1620	843 (52)
Receptive sharing	10	2 (20)	292	192 (66)	315	205 (65)
p value		1.000		<0.001		<0.001
2013						
No receptive sharing	111	8 (7)	1538	869 (57)	1694	910 (54)
Receptive sharing	14	3 (21)	270	162 (60)	303	177 (58)
p value		0.108		0.284		0.131
2014						
No receptive sharing	113	10 (9)	1496	840 (56)	1647	869 (53)
Receptive sharing	9	1 (11)	282	195 (69)	302	205 (68)
p value		0.586		<0.001		<0.001
2015						
No receptive sharing	92	13 (14)	1428	862 (60)	1545	888 (57)
Receptive sharing	13	4 (31)	275	180 (65)	294	190 (65)
p value		0.218		0.113		0.023

Table 1.3.6 HCV antibody prevalence by last drug injected, years since first injection, and survey year

National Last drug injected	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Heroin	27	8 (30)	729	452 (62)	773	470 (61)
Methamphetamine	29	5 (17)	577	265 (46)	620	274 (44)
Other opioids	24	6 (25)	600	366 (61)	634	378 (60)
PIEDs	64	2 (3)	31	3 (10)	105	5 (5)
Other drugs	17	4 (24)	125	78 (62)	153	87 (57)
p value		0.007		<0.001		<0.001
2012						
Heroin	24	5 (21)	727	459 (63)	768	478 (62)
Methamphetamine	27	9 (33)	531	234 (44)	568	249 (44)
Other opioids	14	6 (43)	568	344 (61)	597	358 (60)
PIEDs	87	2 (2)	57	5 (9)	151	7 (5)
Other drugs	8	1 (13)	138	82 (59)	153	87 (57)
p value		<0.001		<0.001		<0.001
2013						
Heroin	13	4 (31)	651	438 (67)	681	453 (67)
Methamphetamine	43	7 (16)	596	281 (47)	662	305 (46)
Other opioids	15	2 (13)	565	338 (60)	599	354 (59)
PIEDs	75	1 (1)	63	1 (1)	141	2 (1)
Other drugs	11	1 (9)	169	105 (62)	200	116 (58)
p value		0.004		<0.001		<0.001
2014						
Heroin	17	4 (24)	639	429 (67)	674	444 (66)
Methamphetamine	46	4 (9)	568	336 (51)	717	347 (48)
Other opioids	11	3 (27)	437	272 (62)	456	279 (61)
PIEDs	68	0 (0)	72	1 (1)	149	2 (1)
Other drugs	15	1 (7)	168	102 (61)	198	113 (57)
p value		0.001		<0.001		<0.001
2015						
Heroin	10	2 (20)	646	475 (74)	663	483 (73)
Methamphetamine	51	10 (20)	665	321 (48)	729	340 (47)
Other opioids	9	3 (33)	388	263 (68)	402	271 (67)
PIEDs	49	1 (2)	69	2 (3)	127	3 (2)
Other drugs	7	3 (43)	90	59 (66)	104	64 (62)
p value		0.007		<0.001		<0.001

Table 1.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

National Frequency of injection last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Less than daily	74	9 (12)	823	431 (52)	912	442 (48)
Daily or more	59	13 (22)	1012	615 (61)	1100	645 (59)
Not last month	26	2 (8)	205	105 (51)	244	110 (45)
p value		0.148		<0.001		<0.001
2012						
Less than daily	67	12 (18)	856	478 (56)	939	501 (53)
Daily or more	52	9 (17)	985	557 (57)	1069	584 (55)
Not last month	40	2 (5)	168	83 (49)	219	88 (40)
p value		0.130		0.224		<0.001
2013						
Less than daily	89	5 (6)	872	489 (56)	996	515 (52)
Daily or more	38	7 (18)	955	554 (58)	1025	587 (57)
Not last month	30	3 (10)	165	84 (51)	208	90 (43)
p value		0.080		0.218		<0.001
2014						
Less than daily	63	3 (5)	840	464 (55)	926	480 (52)
Daily or more	61	8 (13)	966	589 (61)	1055	612 (58)
Not last month	33	1 (3)	147	75 (51)	194	79 (41)
p value		0.165		0.011		<0.001
2015						
Less than daily	65	7 (11)	792	467 (59)	875	483 (55)
Daily or more	41	10 (24)	919	578 (63)	973	598 (61)
Not last month	20	2 (10)	147	75 (51)	177	80 (45)
p value		0.181		0.015		<0.001

Table 1.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

National Imprisonment last year	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No imprisonment	149	20 (13)	1717	924 (54)	1914	964 (50)
Imprisonment	7	3 (43)	210	157 (75)	226	164 (72)
p value		0.066		<0.001		<0.001
2012						
No imprisonment	152	23 (15)	1719	913 (53)	1921	962 (50)
Imprisonment	6	0 (0)	228	156 (68)	243	161 (66)
p value		0.594		<0.001		<0.001
2013						
No imprisonment	146	14 (10)	1691	913 (54)	1905	965 (51)
Imprisonment	8	0 (0)	224	166 (74)	238	171 (72)
p value		1.000		<0.001		<0.001
2014						
No imprisonment	143	8 (6)	1618	908 (56)	1814	942 (52)
Imprisonment	7	2 (29)	215	144 (67)	228	149 (65)
p value		0.070		0.003		<0.001
2015						
No imprisonment	113	17 (15)	1590	914 (54)	1750	950 (54)
Imprisonment	7	3 (43)	188	152 (76)	200	152 (76)
p value		0.090		<0.001		<0.001

Table 1.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year

National Sex work last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
No sex work	150	24 (16)	1886	1055 (56)	2085	1098 (53)
Sex work	2	0 (0)	94	57 (61)	103	60 (58)
p value		1.000		0.370		0.267
2012						
No sex work	150	21 (14)	1857	1024 (55)	2061	1076 (52)
Sex work	6	1 (17)	103	63 (61)	115	65 (57)
p value		1.000		0.231		0.367
2013						
No sex work	142	10 (7)	1833	1030 (56)	2045	1083 (53)
Sex work	8	3 (38)	79	46 (58)	92	53 (58)
p value		0.022		0.721		0.382
2014						
No sex work	139	8 (6)	1712	982 (57)	1903	1016 (53)
Sex work	8	2 (25)	110	72 (65)	123	76 (62)
p value		0.094		0.096		0.070
2015						
No sex work	116	19 (16)	1741	1042 (60)	1905	1080 (57)
Sex work	6	1 (17)	78	56 (72)	87	60 (69)
p value		1.000		0.035		0.024

Table 1.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Non Indigenous	1341	712 (53)	629	321 (51)	1978	1035 (52)
Indigenous	153	90 (59)	108	58 (54)	263	149 (57)
p value		0.178		0.608		0.186
2012						
Non Indigenous	1330	679 (51)	594	321 (54)	1936	1005 (52)
Indigenous	169	101 (60)	105	54 (51)	277	156 (56)
p value		0.034		0.671		0.177
2013						
Non Indigenous	1314	689 (52)	586	305 (52)	1910	998 (52)
Indigenous	184	111 (60)	124	80 (65)	312	194 (62)
p value		0.044		0.011		0.001
2014						
Non Indigenous	1307	675 (52)	545	293 (54)	1864	974 (52)
Indigenous	169	112 (66)	127	79 (62)	297	191 (64)
p value		<0.001		0.085		<0.001
2015						
Non Indigenous	1190	654 (55)	529	298 (56)	1735	958 (55)
Indigenous	173	129 (75)	116	73 (63)	289	202 (70)
p value		<0.001		0.193		<0.001

Table 1.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

National	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
English speaking	1415	746 (53)	716	373 (52)	2142	1122 (52)
Non-English speaking	99	67 (68)	27	11 (41)	127	79 (62)
p value		0.004		0.246		0.031
2012						
English speaking	1425	738 (52)	680	365 (54)	2177	1108 (52)
Non-English speaking	95	55 (58)	27	14 (52)	125	70 (56)
p value		0.249		0.852		0.461
2013						
English speaking	1432	761 (53)	688	373 (54)	2134	1142 (54)
Non-English speaking	114	66 (58)	38	23 (61)	153	89 (58)
p value		0.328		0.447		0.265
2014						
English speaking	1381	732 (53)	641	355 (55)	2033	1092 (54)
Non-English speaking	114	65 (57)	38	21 (55)	154	87 (56)
p value		0.409		0.989		0.505
2015						
English speaking	1275	723 (57)	625	356 (57)	1918	1087 (57)
Non-English speaking	89	56 (63)	24	16 (67)	113	72 (64)
p value		0.252		0.345		0.142

Table 1.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

National Region/Country of birth	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Australia	1296	691 (53)	652	339 (52)	1959	1034 (53)
Other Oceania	44	22 (50)	33	19 (58)	77	41 (53)
Asia	24	16 (67)	7	1 (14)	31	17 (55)
UK & Ireland	73	42 (58)	32	16 (50)	106	58 (55)
Other	76	42 (55)	20	9 (45)	96	51 (53)
p value		0.654		0.309		0.995
2012						
Australia	1307	672 (51)	627	330 (53)	1948	1008 (52)
Other Oceania	48	21 (44)	31	20 (65)	79	41 (52)
Asia	22	19 (86)	2	2 (100)	25	21 (84)
UK & Ireland	72	41 (57)	26	17 (65)	98	58 (59)
Other	59	33 (56)	24	13 (54)	83	46 (55)
p value		0.011		0.332		0.011
2013						
Australia	1322	708 (54)	641	351 (55)	1975	1067 (54)
Other Oceania	50	24 (48)	20	12 (60)	70	36 (51)
Asia	29	21 (72)	5	4 (80)	34	25 (74)
UK & Ireland	70	37 (53)	31	16 (52)	102	53 (52)
Other	75	37 (49)	27	11 (41)	104	48 (46)
p value		0.257		0.466		0.088
2014						
Australia	1257	687 (55)	602	327 (54)	1869	1018 (54)
Other Oceania	63	26 (41)	19	10 (53)	84	37 (44)
Asia	35	22 (63)	4	3 (75)	39	25 (64)
UK & Ireland	68	35 (51)	29	21 (72)	97	56 (58)
Other	70	28 (40)	26	16 (62)	97	45 (46)
p value		0.027		0.318		0.095
2015						
Australia	1167	674 (58)	571	339 (59)	1753	1020 (58)
Other Oceania	54	26 (48)	15	6 (40)	70	33 (47)
Asia	32	16 (50)	8	3 (38)	41	19 (46)
UK & Ireland	55	31 (56)	37	17 (46)	93	48 (52)
Other	49	28 (57)	18	8 (44)	67	36 (54)
p value		0.619		0.117		0.132

Australian Capital Territory

Table 2.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Australian Capital Territory	2011	2012	2013	2014	2015
Number of sites	1	1	1	1	1
N° surveyed	N=100	N=78	N=100	N=99	N=110
Response rate (%)	56%	65%	80%	69%	71%
Gender (%)					
Male	68 (68)	53 (68)	67 (67)	76 (77)	77 (70)
Female	32 (32)	25 (32)	32 (32)	23 (23)	33 (30)
Transgender	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	83 (83)	71 (91)	85 (85)	81 (82)	98 (89)
Bisexual	5 (5)	5 (6)	4 (4)	9 (9)	7 (6)
Homosexual	5 (5)	0 (0)	1 (1)	2 (2)	2 (2)
Not reported	7 (7)	2 (3)	10 (10)	7 (7)	3 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	85 (85)	71 (91)	80 (80)	87 (88)	85 (77)
Yes	12 (12)	4 (5)	18 (18)	11 (11)	25 (23)
Not reported	3 (3)	3 (4)	2 (2)	1 (1)	0 (0)
Region/country of birth (%)					
Australia	90 (90)	71 (91)	88 (88)	88 (89)	95 (86)
Other Oceania	4 (4)	1 (1)	0 (0)	3 (3)	1 (1)
Asia	0 (0)	1 (1)	2 (2)	2 (2)	3 (3)
UK & Ireland	0 (0)	5 (6)	5 (5)	4 (4)	5 (5)
Other	6 (6)	0 (0)	4 (4)	1 (1)	4 (4)
Not reported	0 (0)	0 (0)	1 (1)	1 (1)	2 (2)
Main language spoken at home by parents (%)					
English	95 (95)	75 (96)	93 (93)	92 (93)	101 (92)
Non-English	5 (5)	3 (4)	7 (7)	6 (6)	8 (7)
Not reported	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)
Age and time since first injection (years)					
<i>Median age</i>	35	40	40	41	42
<i>Age range</i>	22-65	20-66	20-67	19-60	21-61
<i>Age group (%)</i>					
<25 years	4 (4)	4 (5)	4 (4)	6 (6)	3 (3)
25+ years	96 (96)	74 (95)	96 (96)	92 (93)	106 (96)
Not reported	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)
<i>Median age first injection</i>	18	18	17	17	18
<i>Age range</i>	10-55	12-41	10-51	12-55	11-45
<i>N° not reported</i>	2	0	6	1	2
<i>Median yrs since first injection</i>	18	20	20	22	22
<i>Range</i>	1-49	<1-51	<1-51	1-38	<1-47
<i>Years since first injection</i>					
<3 years	4 (4)	2 (3)	1(1)	5 (5)	3 (3)
3+ years	94 (94)	76 (97)	93 (93)	92 (93)	105 (95)
Not reported	2 (2)	0 (0)	6 (6)	2 (2)	2 (2)
Imprisonment last year (%)					
No	89 (89)	67 (86)	76 (76)	83 (84)	103 (94)
Yes	6 (6)	4 (5)	16 (16)	9 (9)	5 (5)
Not reported	5 (5)	7 (9)	8 (8)	7 (7)	2 (2)
N° in prison					
Injected in prison	2 (33)	3 (75)	4 (25)	3 (33)	2 (40)

Table 2.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Australian Capital Territory N° surveyed	2011 N=100	2012 N=78	2013 N=100	2014 N=99	2015 N=110
Drug last injected (%)					
Cocaine	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Methamphetamine	24 (24)	23 (29)	30 (30)	31 (31)	45 (41)
Heroin	44 (44)	30 (38)	56 (56)	44 (44)	50 (45)
Pharm. opioids	3 (3)	3 (4)	4 (4)	6 (6)	1 (1)
Methadone	12 (12)	9 (12)	6 (6)	6 (6)	7 (6)
Buprenorphine	7 (7)	3 (4)	0 (0)	2 (2)	2 (2)
Buprenorphine/naloxone	1 (1)	0 (0)	1 (1)	2 (2)	0 (0)
PIEDs	1 (1)	0 (0)	0 (0)	0 (0)	3 (3)
More than one	5 (5)	5 (6)	3 (3)	4 (4)	2 (2)
Other	3 (3)	3 (4)	0 (0)	4 (4)	0 (0)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Frequency of injection last month (%)					
Not last month	10 (10)	2 (3)	5 (5)	3 (3)	5 (5)
Less than weekly	16 (16)	10 (13)	17 (17)	13 (13)	11 (10)
Weekly not daily	22 (22)	22 (28)	28 (28)	40 (40)	47 (43)
Daily or more	50 (50)	44 (56)	47 (47)	43 (43)	46 (42)
Not reported	2 (2)	0 (0)	3 (3)	0 (0)	1 (1)
Present when someone injected for the first time in the last 12 months (%)					
Yes	--	10 (13)	12 (12)	14 (14)	17 (15)
No	--	65 (83)	76 (76)	82 (83)	92 (84)
Not reported	--	3 (4)	12 (12)	3 (3)	1 (1)
Overdosed in last 12 months					
Yes	--	--	10 (10)	18 (18)	13 (12)
No	--	--	86 (83)	78 (79)	94 (85)
Not reported	--	--	4 (4)	3 (3)	3 (3)

Table 2.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Australian Capital Territory N° injected last month	2011 N=88	2012 N=76	2013 N=92	2014 N=96	2015 N=104
Places injected last month (%)					
Any public	40 (45)	33 (43)	43 (47)	27 (28)	39 (38)
All private	47 (53)	42 (55)	49 (53)	69 (72)	65 (63)
Not reported	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	59 (67)	56 (74)	60 (65)	77 (80)	78 (75)
Most of the time	24 (27)	17 (22)	29 (32)	16 (17)	23 (22)
Half of the time	2 (2)	0 (0)	2 (2)	1 (1)	2 (2)
Some of the time	1 (1)	1 (1)	0 (0)	1 (1)	0 (0)
Not last month	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)
Not reported	2 (2)	1 (1)	1 (1)	1 (1)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	75 (85)	60 (79)	74 (80)	82 (85)	88 (85)
Once	4 (5)	6 (8)	9 (10)	6 (6)	4 (4)
Twice	0 (0)	1 (1)	1 (1)	3 (3)	3 (3)
3-5 times	2 (2)	1 (1)	4 (4)	3 (3)	8 (8)
>5 times	3 (3)	5 (7)	3 (3)	0 (0)	1 (1)
Not reported	4 (5)	3 (4)	1 (1)	2 (2)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	75 (85)	60 (79)	74 (80)	82 (85)	88 (85)
One	4 (5)	4 (5)	9 (10)	5 (5)	4 (4)
Two	0 (0)	0 (0)	1 (1)	3 (3)	1 (1)
Three to five	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)
More than five	2 (2)	3 (4)	1 (1)	0 (0)	0 (0)
Don't know	3 (3)	4 (5)	3 (3)	2 (2)	6 (6)
Not reported	4 (4)	5 (7)	3 (3)	4 (4)	4 (4)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	8 (9)	2 (3)	8 (9)	6 (6)	6 (6)
Casual sex partner	1 (1)	1 (1)	0 (0)	0 (0)	1 (1)
Close friend	3 (3)	3 (4)	8 (9)	1 (1)	3 (3)
Acquaintance	1 (1)	4 (5)	2 (2)	2 (2)	1 (1)
Other	2 (2)	0 (0)	0 (0)	1 (1)	2 (2)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	12 (14)	19 (25)	33 (36)	32 (33)	23 (22)
Water	14 (16)	13 (17)	16 (17)	10 (10)	10 (10)
Filter	11 (13)	6 (8)	14 (15)	9 (9)	5 (5)
Drug mix	9 (10)	5 (7)	12 (13)	11 (11)	8 (8)
None	64 (73)	51 (67)	53 (58)	57 (59)	71 (68)
Injected by someone after that person injected themselves or others last month (%)					
No	80 (91)	69 (91)	81 (88)	79 (82)	92 (88)
Yes	6 (7)	6 (8)	9 (10)	14 (15)	12 (12)
Not reported	2 (2)	1 (1)	2 (2)	3 (3)	0 (0)
Source of needle acquisition					
Needle Syringe Program	81 (92)	70 (92)	81 (81)	83 (86)	92 (88)
Chemist/Pharmacy	17 (19)	27 (36)	30 (30)	29 (30)	28 (27)
Personal sources	8 (9)	14 (18)	19 (19)	13 (14)	14 (13)
Dispensing/Vending Machine	14 (16)	22 (29)	24 (24)	23 (24)	20 (19)
Other sources	1 (1)	0 (0)	2 (2)	2 (2)	2 (2)

Table 2.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Australian Capital Territory N° surveyed	2011 N=100	2012 N=78	2013 N=100	2014 N=99	2015 N=110
Ever any treatment/therapy for drug use (%)					
No	14 (14)	9 (12)	5 (5)	9 (9)	23 (21)
Yes	86 (86)	69 (88)	94 (94)	90 (91)	87 (79)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	43 (43)	34 (44)	47 (47)	37 (38)	46 (42)
Previously	20 (20)	27 (35)	31 (31)	29 (29)	31 (28)
Never	33 (33)	17 (22)	21 (21)	32 (32)	31 (28)
Not reported	4 (4)	0 (0)	1 (1)	1 (1)	2 (2)
History of buprenorphine (Subutex®) treatment (%)					
Currently	7 (7)	7 (9)	10 (10)	11 (11)	10 (9)
Previously	34 (34)	20 (26)	35 (35)	27 (27)	27 (25)
Never	57 (57)	49 (63)	51 (51)	59 (60)	72 (65)
Not reported	2 (2)	2 (3)	4 (4)	2 (2)	1 (1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	10 (10)	5 (6)	8 (8)	10 (10)	7 (6)
Previously	21 (21)	13 (17)	27 (27)	25 (25)	18 (16)
Never	66 (66)	60 (77)	63 (63)	63 (64)	84 (76)
Not reported	3 (3)	0 (0)	2 (2)	1 (1)	1 (1)

Table 2.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Australian Capital Territory N° surveyed	2011 N=100	2012 N=78	2013 N=100	2014 N=99	2015 N=110
Previous HIV test (%)					
Yes, ever	83 (83)	72 (92)	88 (88)	82 (83)	91 (83)
Yes, last year	43 (43)	42 (54)	44 (44)	50 (51)	51 (46)
>1 year ago	40 (40)	30 (38)	44 (44)	32 (32)	40 (36)
Never tested	14 (14)	3 (4)	8 (8)	12 (12)	19 (17)
Not reported	3 (3)	3 (4)	4 (4)	5 (5)	0 (0)
Previous HCV test (%)					
Yes, ever	91 (91)	73 (94)	86 (86)	88 (89)	99 (90)
Yes, last year	53 (53)	44 (56)	41 (41)	53 (54)	53 (48)
>1 year ago	38 (38)	29 (37)	45 (45)	35 (35)	46 (42)
Never tested	5 (5)	2 (3)	5 (5)	7 (7)	4 (4)
Not reported	4 (4)	3 (4)	9 (9)	4 (4)	7 (6)
Lifetime treatment for HCV (%)					
N° self-reported chronic HCV#*					
Antiviral treatment	3 (10)	0 (0)	2 (6)	4 (11)	1 (3)
No antiviral treatment	26 (90)	29 (100)	33 (94)	30 (86)	31 (94)
Not reported	0 (0)	0 (0)	0 (0)	1 (3)	1 (3)
Treatment for HCV in past 12 months (%)					
N° self-reported chronic HCV#					
Antiviral treatment	0 (0)	0 (0)	1 (3)	0 (0)	1 (3)
No antiviral treatment	27 (100)	28 (100)	33 (97)	30 (91)	30 (97)
Not reported	0 (0)	0 (0)	0 (0)	3 (9)	0 (0)

among people who tested HCV antibody positive

* includes people who reported treatment induced clearance

Table 2.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Australian Capital Territory N° surveyed	2011 N=100	2012 N=78	2013 N=100	2014 N=99	2015 N=110
Sex with a regular partner last month (%)					
No	54 (54)	53 (68)	59 (59)	58 (59)	61 (55)
Yes	44 (44)	24 (31)	36 (36)	35 (35)	45 (41)
Not reported	2 (2)	1 (1)	5 (5)	6 (6)	4 (4)
Condom used with regular partner last month (%)					
N° surveyed	N=44	N=24	N=36	N=35	N=45
Never	31 (70)	13 (54)	24 (67)	27 (77)	36 (87)
Sometimes	9 (20)	9 (38)	5 (14)	5 (14)	3 (7)
Every time	3 (7)	2 (8)	2 (6)	2 (6)	4 (9)
Not reported	1 (2)	0 (0)	5 (14)	1 (3)	2 (4)
Sex with other partner(s) last month (%)					
No	91 (91)	63 (81)	86 (86)	86 (87)	92 (84)
Yes	6 (6)	11 (14)	11 (11)	8 (8)	14 (13)
Not reported	3 (3)	4 (5)	3 (3)	5 (5)	4 (4)
Condom used with other partner(s) last month (%)					
N° surveyed	N=6	N=11	N=11	N=8	N=14
Never	2 (33)	2 (18)	5 (45)	3 (38)	5 (36)
Sometimes	2 (33)	3 (27)	2 (18)	3 (38)	5 (36)
Every time	2 (33)	6 (55)	4 (36)	2 (25)	3 (21)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (7)
Sex work last month (%)					
No	91 (91)	72 (92)	92 (92)	89 (90)	106 (96)
Yes	2 (2)	3 (4)	2 (2)	4 (4)	3 (3)
Not reported	7 (7)	3 (4)	6 (6)	6 (6)	1 (1)
Condom used at last sex work (%)					
Yes	1 (50)	2 (67)	1 (50)	3 (75)	1 (33)

HIV antibody prevalence

Table 2.2.1 HIV antibody prevalence by gender and survey year

Aust. Capital Territory Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011	64	0 (0.0)	31	0 (0.0)	95	0 (0.0)
2012	53	0 (0.0)	25	0 (0.0)	78	0 (0.0)
2013	67	0 (0.0)	32	0 (0.0)	100	0 (0.0)
2014	73	0 (0.0)	23	0 (0.0)	96	0 (0.0)
2015	76	0 (0.0)	33	0 (0.0)	109	0 (0.0)
X ² p trend p value		--		--		--

HCV antibody prevalence

Table 2.3.1 HCV antibody prevalence by gender and survey year

Aust. Capital Territory Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011	62	44 (71)	31	12 (39)	93	56 (60)
2012	53	34 (64)	25	16 (64)	78	50 (64)
2013	67	49 (73)	32	18 (56)	100	67 (67)
2014	71	49 (69)	23	12 (52)	94	61 (65)
2015	70	54 (77)	29	21 (72)	99	75 (76)
X ² p trend value		0.702		0.274		0.348

Table 2.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Aust. Capital Territory Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Heterosexual	56	41 (73)	22	9 (41)	78	50 (64)
Bisexual	2	1 (50)	3	2 (67)	5	3 (60)
Homosexual	3	2 (67)	2	1 (50)	5	3 (60)
p value		0.585		0.777		1.000
2012						
Heterosexual	49	31 (63)	22	13 (59)	71	44 (62)
Bisexual	2	1 (50)	3	3 (100)	5	4 (80)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		0.280		0.646
2013						
Heterosexual	60	44 (73)	24	11 (46)	85	55 (65)
Bisexual	1	1 (100)	3	3 (100)	4	4 (100)
Homosexual	1	1 (100)	0	0 (0)	1	1 (100)
p value		1.000		0.222		0.395
2014						
Heterosexual	65	45 (69)	12	5 (42)	77	50 (65)
Bisexual	1	0 (0)	8	5 (63)	9	5 (56)
Homosexual	1	1 (100)	1	0 (0)	2	1 (50)
p value		0.532		0.513		0.755
2015						
Heterosexual	65	50 (77)	24	18 (75)	89	68 (76)
Bisexual	2	2 (100)	3	1 (33)	5	3 (60)
Homosexual	0	0 (0)	2	2 (100)	2	2 (100)
p value		1.000		0.237		0.765

Table 2.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
<25 years	1	1 (100)	3	0 (0)	4	1 (25)
25-34 years	26	17 (65)	14	5 (38)	40	22 (55)
35-44 years	20	14 (70)	7	2 (29)	27	16 (59)
45+ years	15	12 (80)	7	5 (71)	22	17 (77)
p value		0.801		0.207		0.151
2012						
<25 years	4	1 (25)	0	0 (0)	4	1 (25)
25-34 years	7	3 (42)	7	3 (43)	14	6 (43)
35-44 years	26	19 (73)	11	7 (64)	37	26 (70)
45+ years	16	11 (69)	7	6 (86)	23	17 (74)
p value		0.174		0.334		0.081
2013						
<25 years	3	1 (33)	1	0 (0)	4	1 (25)
25-34 years	12	7 (58)	15	8 (53)	28	15 (56)
35-44 years	27	21 (78)	10	7 (70)	37	28 (76)
45+ years	25	20 (80)	6	3 (50)	31	23 (74)
p value		0.181		0.600		0.059
2014						
<25 years	4	1 (25)	2	0 (0)	6	1 (17)
25-34 years	11	5 (45)	5	3 (60)	16	8 (50)
35-44 years	29	22 (76)	10	9 (90)	39	31 (79)
45+ years	26	20 (77)	6	0 (0)	32	20 (63)
p value		0.053		<0.001		0.009
2015						
<25 years	1	0 (0)	1	0 (0)	2	0 (0)
25-34 years	14	8 (57)	7	4 (57)	21	12 (57)
35-44 years	28	25 (89)	10	7 (70)	38	32 (84)
45+ years	26	20 (77)	11	10 (91)	37	30 (81)
p value		0.030		0.132		0.010

Table 2.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Aust. Capital Territory Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
<3 years	5	2 (100)	2	1 (50)	4	3 (75)
3 to 10 years	11	7 (64)	7	1 (14)	18	8 (44)
11+years	49	35 (71)	21	10 (48)	70	45 (64)
p value		0.859		0.312		0.307
2012						
<3 years	2	1 (50)	0	0 (0)	2	1 (50)
3 to 10 years	6	2 (33)	3	1 (33)	9	3 (33)
11+years	45	31 (69)	22	15 (68)	67	46 (69)
p value		0.189		0.530		0.070
2013						
<3 years	0	0 (0)	1	1 (100)	1	1 (100)
3 to 10 years	5	3 (60)	7	1 (14)	12	4 (33)
11+years	57	43 (75)	23	16 (70)	81	59 (73)
p value		0.597		0.025		0.016
2014						
<3 years	4	1 (25)	1	0 (0)	5	1 (20)
3 to 10 years	8	4 (50)	4	0 (0)	12	4 (33)
11+years	57	42 (74)	18	12 (52)	75	54 (72)
p value		0.043		0.014		0.003
2015						
<3 years	2	1 (50)	1	0 (0)	3	1 (33)
3 to 10 years	12	6 (50)	4	2 (50)	16	8 (50)
11+years	54	45 (83)	24	19 (79)	78	64 (82)
p value		0.017		0.112		0.005

Table 2.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Aust. Capital Territory Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No receptive sharing	2	1 (50)	69	47 (68)	71	48 (68)
Receptive sharing	0	0 (0)	8	2 (25)	8	2 (25)
p value		--		0.024		0.046
2012						
No receptive sharing	1	1 (100)	59	38 (64)	60	39 (65)
Receptive sharing	0	0 (0)	13	9 (69)	13	9 (69)
p value		--		1.000		1.000
2013						
No receptive sharing	0	0 (0)	68	45 (66)	74	48 (65)
Receptive sharing	0	0 (0)	17	13 (76)	17	13 (76)
p value		--		0.564		0.408
2014						
No receptive sharing	4	1 (25)	71	47 (66)	77	50 (65)
Receptive sharing	0	0 (0)	12	8 (67)	12	8 (67)
p value		--		0.975		0.907
2015						
No receptive sharing	3	1 (33)	74	57 (77)	79	60 (76)
Receptive sharing	0	0 (0)	14	11 (79)	14	11 (79)
p value		--		1.000		1.000

Table 2.3.6 HCV antibody prevalence by last drug injected, years since first injection, and survey year

Aust. Capital Territory	<3 years		3+ years		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Heroin	0	0 (0)	40	20 (50)	41	20 (49)
Methamphetamine	0	0 (0)	24	14 (58)	24	14 (58)
Other opioids	1	1 (100)	18	15 (83)	19	16 (84)
Other drugs	3	2 (67)	6	4 (67)	8	6 (75)
p value		0.505		0.117		0.072
2012						
Heroin	0	0 (0)	30	22 (73)	30	22 (73)
Methamphetamine	1	1 (100)	22	12 (55)	23	13 (57)
Other opioids	0	0 (0)	15	11 (73)	15	11 (73)
Other drugs	1	0 (0)	8	4 (50)	9	4 (44)
p value		0.157		0.357		0.288
2013						
Heroin	0	0 (0)	54	37 (69)	56	37 (66)
Methamphetamine	1	1 (100)	26	16 (62)	30	19 (63)
Other opioids	0	0 (0)	10	8 (80)	11	9 (82)
Other drugs	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		0.762		0.730
2014						
Heroin	0	0 (0)	40	25 (63)	42	27 (64)
Methamphetamine	2	0 (0)	27	15 (56)	29	15 (52)
Other opioids	2	1 (50)	13	11 (85)	15	12 (80)
Other drugs	1	0 (0)	7	7 (100)	8	7 (88)
p value		0.392		0.066		0.138
2015						
Heroin	1	0 (0)	43	37 (86)	44	37 (84)
Methamphetamine	2	1 (50)	38	26 (68)	41	28 (68)
Other opioids	0	0 (0)	8	6 (75)	9	7 (78)
Other drugs	0	0 (0)	4	3 (75)	4	3 (75)
p value		0.386		0.304		0.397

Table 2.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Aust. Capital Territory Frequency of injection last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Less than daily	2	1 (50)	34	22 (65)	36	23 (64)
Daily or more	1	1 (100)	45	28 (62)	45	28 (62)
Not last month	0	0 (0)	8	2 (25)	10	3 (30)
p value		1.000		0.122		0.171
2012						
Less than daily	0	0 (0)	32	20 (63)	32	20 (63)
Daily or more	1	1 (100)	43	28 (65)	44	29 (66)
Not last month	1	0 (0)	1	1 (100)	2	1 (50)
p value		1.000		1.000		0.912
2013						
Less than daily	0	0 (0)	40	29 (73)	45	31 (69)
Daily or more	0	0 (0)	46	30 (65)	47	31 (66)
Not last month	1	1 (100)	4	2 (50)	5	3 (60)
p value		--		0.546		0.883
2014						
Less than daily	3	0 (0)	46	30 (65)	50	31 (62)
Daily or more	2	1 (50)	38	26 (68)	41	28 (68)
Not last month	0	0 (0)	3	2 (67)	3	2 (67)
p value		0.400		0.918		0.847
2015						
Less than daily	2	1 (50)	51	38 (75)	55	41 (75)
Daily or more	1	0 (0)	37	30 (81)	38	30 (79)
Not last month	0	0 (0)	5	4 (80)	5	4 (80)
p value		1.000		0.837		0.920

Table 2.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Aust. Capital Territory Imprisonment last year	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No imprisonment	2	1 (50)	80	47 (59)	83	48 (58)
Imprisonment	1	1 (100)	5	3 (60)	6	4 (67)
p value		1.000		1.000		1.000
2012						
No imprisonment	2	1 (50)	65	42 (65)	67	43 (64)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		0.617		0.620
2013						
No imprisonment	1	1 (100)	71	47 (66)	76	49 (64)
Imprisonment	0	0 (0)	16	11 (69)	16	11 (69)
p value		--		0.845		0.744
2014						
No imprisonment	5	1 (20)	72	49 (68)	79	52 (66)
Imprisonment	0	0 (0)	8	5 (63)	8	5 (63)
p value		--		0.750		0.851
2015						
No imprisonment	1	1 (100)	89	68 (76)	92	71 (77)
Imprisonment	1	0 (0)	4	3 (75)	5	3 (60)
p value		--		1.000		0.589

Table 2.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year

Aust. Capital Territory	<3 years		3+ years		Total	
Sex work last month	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No sex work	4	3 (75)	81	48 (59)	86	51 (59)
Sex work	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.515		0.515
2012						
No sex work	2	1 (50)	70	44 (63)	72	45 (63)
Sex work	0	0 (0)	3	3 (100)	3	3 (100)
p value		--		0.548		0.549
2013						
No sex work	1	1 (100)	86	58 (67)	92	61 (66)
Sex work	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000
2014						
No sex work	4	1 (25)	79	54 (68)	85	57 (67)
Sex work	1	0 (0)	2	1 (50)	3	1 (33)
p value		1.000		0.542		0.267
2015						
No sex work	2	1 (50)	91	69 (76)	95	72 (76)
Sex work	0	0 (0)	3	3 (100)	3	3 (100)
p value		--		1.000		1.000

Table 2.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aust. Capital Territory	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Non Indigenous	53	37 (70)	27	11 (41)	80	48 (60)
Indigenous	8	6 (75)	3	1 (33)	11	7 (64)
p value		1.000		1.000		1.000
2012						
Non Indigenous	46	29 (63)	25	16 (64)	71	45 (63)
Indigenous	4	2 (50)	0	0 (0)	4	2 (50)
p value		0.629		--		0.626
2013						
Non Indigenous	52	38 (73)	27	15 (56)	80	53 (66)
Indigenous	13	9 (69)	5	3 (60)	18	12 (67)
p value		0.743		1.000		0.973
2014						
Non Indigenous	62	41 (66)	21	41 (66)	83	51 (61)
Indigenous	8	7 (88)	8	7 (88)	10	9 (90)
p value		0.220		0.478		0.075
2015						
Non Indigenous	57	42 (74)	20	14 (70)	77	56 (73)
Indigenous	13	12 (93)	9	7 (78)	22	19 (86)
p value		0.272		1.000		0.263

Table 2.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Aust. Capital Territory Main language spoken at home by parents	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
English speaking	58	42 (72)	31	12 (39)	89	54 (61)
Non-English speaking	4	2 (50)	0	0 (0)	4	2 (50)
p value		0.573		--		1.000
2012						
English speaking	52	34 (65)	23	15 (65)	75	49 (65)
Non-English speaking	1	0 (0)	2	1 (50)	3	1 (33)
p value		0.358		1.000		0.291
2013						
English speaking	63	46 (73)	29	16 (55)	93	62 (67)
Non-English speaking	4	3 (75)	3	2 (67)	7	5 (71)
p value		1.000		1.000		1.000
2014						
English speaking	67	48 (72)	20	12 (60)	87	60 (69)
Non-English speaking	3	0 (0)	3	0 (0)	6	0 (0)
p value		0.028		0.093		0.001
2015						
English speaking	62	49 (79)	28	21 (75)	90	70 (78)
Non-English speaking	7	4 (57)	1	0 (0)	8	4 (50)
p value		0.340		0.276		0.098

Table 2.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Aust. Capital Territory		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2011							
Australia	57	41 (72)	26	11 (42)	83	52 (63)	
Other Oceania	2	2 (100)	2	0 (0)	4	2 (50)	
Asia	0	0 (0)	0	0 (0)	4	2 (50)	
UK & Ireland	1	1 (100)	3	1 (33)	0	0 (0)	
Other	2	0 (0)	0	0 (0)	2	0 (0)	
p value		0.156		0.774		0.258	
2012							
Australia	49	31 (63)	22	13 (59)	71	44 (62)	
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)	
Asia	1	1 (100)	0	0 (0)	1	1 (100)	
UK & Ireland	2	1 (50)	3	3 (100)	5	4 (80)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		1.000		0.280		0.856	
2013							
Australia	61	45 (74)	27	15 (56)	88	60 (68)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	2	2 (100)	0	0 (0)	2	2 (100)	
UK & Ireland	2	1 (50)	3	1 (33)	5	2 (40)	
Other	2	1 (50)	1	1 (100)	4	2 (50)	
p value		0.516		0.773		0.386	
2014							
Australia	62	43 (69)	21	11 (52)	83	54 (65)	
Other Oceania	3	3 (100)	0	0 (0)	3	3 (100)	
Asia	2	0 (0)	0	0 (0)	2	0 (0)	
UK & Ireland	3	2 (67)	1	1 (100)	4	3 (75)	
Other	0	0 (0)	0	0 (0)	1	0 (0)	
p value		0.128		1.000		0.105	
2015							
Australia	59	45 (76)	26	19 (73)	85	64 (75)	
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)	
Asia	3	2 (67)	0	0 (0)	3	2 (67)	
UK & Ireland	2	1 (50)	2	2 (100)	4	3 (75)	
Other	3	3 (100)	1	0 (0)	4	3 (75)	
p value		0.681		0.330		1.000	

New South Wales

Table 3.1.1 Number (percentage) of respondents by demographic characteristics and survey year

New South Wales	2011	2012	2013	2014	2015
Number of sites	20	20	20	19	16
N° surveyed	N=694	N=712	N=686	N=761	N=639
Response rate (%)	36%	47%	38%	45%	35%
Gender (%)					
Male	463 (67)	476 (67)	475 (69)	539 (71)	464 (73)
Female	228 (33)	227 (32)	206 (30)	212 (28)	167 (26)
Transgender	3 (<1)	6 (1)	5 (<1)	9 (1)	7 (1)
Not reported	0 (0)	3 (<1)	0 (0)	1 (<1)	1 (<1)
Sexual identity (%)					
Heterosexual	563 (81)	576 (81)	548 (80)	610 (80)	515 (81)
Bisexual	61 (9)	60 (8)	50 (7)	69 (9)	61 (10)
Homosexual	38 (5)	25 (4)	45 (7)	44 (6)	33 (5)
Not reported	32 (5)	51 (7)	43 (6)	38 (5)	30 (5)
Aboriginal and Torres Strait Islander origin (%)					
No	582 (84)	609 (86)	543 (79)	609 (80)	510 (80)
Yes	91 (13)	90 (13)	124 (18)	136 (18)	117 (18)
Not reported	21 (3)	13 (2)	19 (3)	16 (2)	12 (2)
Region/country of birth (%)					
Australia	588 (85)	621 (87)	602 (88)	646 (85)	548 (86)
Other Oceania	21 (3)	22 (3)	19 (3)	30 (4)	25 (4)
Asia	12 (2)	8 (1)	9 (1)	11 (1)	11 (2)
UK & Ireland	27 (4)	30 (4)	22 (3)	27 (4)	27 (4)
Other	33 (5)	21 (3)	32 (5)	37 (5)	18 (3)
Not reported	13 (2)	10 (1)	2 (<1)	10 (1)	10 (2)
Main language spoken at home by parents (%)					
English	643 (93)	675 (95)	636 (93)	698 (92)	602 (94)
Non-English	40 (6)	32 (4)	48 (7)	56 (7)	32 (5)
Not reported	11 (2)	5 (1)	2 (<1)	7 (1)	5 (1)
Age and time since first injection (years)					
<i>Median age</i>	38	39	39	40	41
<i>Age range</i>	18-63	18-64	18-65	17-67	18-70
Age group (%)					
<25 years	51 (7)	55 (8)	52 (8)	57 (7)	27 (4)
25+ years	640 (92)	657 (92)	634 (92)	702 (92)	612 (96)
Not reported	3 (<1)	0 (0)	0 (0)	2 (<1)	0 (0)
Median age first injection					
<i>Median age first injection</i>	19	19	19	19	19
Age range					
<i>Age range</i>	10-47	10-64	10-54	10-47	10-63
N° not reported					
<i>N° not reported</i>	23	20	25	25	18
Median yrs since first injection					
<i>Median yrs since first injection</i>	17	18	19	19	19
Range					
<i>Range</i>	<1-46	<1-46	<1-48	<1-47	<1-52
Years since first injection					
<i><3 years</i>	64 (9)	66 (9)	61 (9)	66 (9)	60 (9)
<i>3+ years</i>	606 (87)	626 (88)	600 (87)	670 (88)	561 (88)
Not reported	24 (3)	20 (3)	25 (4)	25 (3)	18 (3)
Imprisonment last year (%)					
No	567 (82)	603 (85)	569 (83)	601 (79)	531 (83)
Yes	82 (12)	75 (11)	85 (12)	99 (13)	76 (12)
Not reported	45 (2)	34 (5)	32 (5)	61 (8)	32 (5)
N° in prison					
<i>N° in prison</i>	N=82	N=75	N=85	N=99	N=76
<i>Injected in prison</i>	18 (22)	27 (36)	31 (36)	38 (38)	31 (41)

Table 3.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

New South Wales N° surveyed	2011 N=694	2012 N=712	2013 N=686	2014 N=761	2015 N=639
Drug last injected (%)					
Cocaine	12 (2)	16 (2)	22 (3)	19 (3)	9 (1)
Methamphetamine	198 (29)	187 (26)	218 (32)	259 (34)	204 (32)
Heroin	211 (30)	216 (30)	178 (26)	216 (28)	194 (30)
Pharm. opioids	70 (10)	80 (11)	57 (8)	40 (5)	48 (8)
Methadone	79 (11)	69 (10)	75 (11)	70 (9)	60 (9)
Buprenorphine	16 (2)	10 (1)	11 (2)	9 (1)	10 (2)
Buprenorphine/naloxone	1 (<1)	7 (1)	2 (<1)	3 (<1)	5 (1)
PIEDs	64 (9)	83 (12)	73 (11)	77 (10)	76 (12)
More than one	27 (4)	33 (5)	33 (5)	33 (4)	25 (4)
Other	15 (2)	4 (<1)	9 (1)	32 (4)	8 (1)
Not reported	1 (<1)	7 (1)	8 (1)	3 (<1)	0 (0)
Frequency of injection last month (%)					
Not last month	105 (15)	110 (15)	102 (15)	89 (12)	71 (11)
Less than weekly	119 (17)	144 (20)	150 (22)	138 (18)	111 (17)
Weekly not daily	167 (24)	178 (25)	161 (23)	186 (24)	159 (25)
Daily or more	285 (41)	271 (38)	251 (37)	339 (44)	286 (45)
Not reported	18 (3)	9 (1)	22 (3)	9 (1)	12 (2)
Present when someone injected for the first time in the last 12 months (%)					
Yes	--	95 (13)	95 (14)	130 (17)	114 (18)
No	--	525 (74)	471 (69)	604 (79)	512 (80)
Not reported	--	92 (13)	120 (17)	27 (4)	13 (2)
Overdosed in last 12 months					
Yes	--	--	63 (9)	122 (16)	82 (13)
No	--	--	604 (88)	610 (80)	539 (84)
Not reported	--	--	19 (3)	29 (4)	19 (3)

Table 3.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

New South Wales	2011	2012	2013	2014	2015
N° injected last month	N=571	N=593	N=562	N=663	N=556
Places injected last month (%)					
Any public	169 (30)	166 (28)	166 (30)	212 (32)	166 (30)
All private	388 (68)	412 (69)	393 (70)	447 (67)	385 (69)
Not reported	14 (2)	15 (3)	3 (<1)	4 (<1)	5 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	439 (77)	439 (74)	445 (79)	527 (79)	429 (77)
Most of the time	95 (17)	112 (19)	87 (15)	103 (16)	98 (18)
Half of the time	9 (2)	10 (2)	11 (2)	10 (2)	13 (2)
Some of the time	7 (1)	6 (1)	11 (2)	4 (<1)	7 (1)
Not last month	1 (<1)	6 (1)	2 (<1)	6 (1)	3 (1)
Not reported	20 (4)	20 (3)	6 (1)	13 (2)	6 (1)
Re-used someone else's used needle & syringe last month (%)					
None	486 (85)	491 (83)	485 (86)	548 (83)	478 (86)
Once	25 (4)	35 (6)	24 (4)	45 (7)	23 (4)
Twice	16 (3)	12 (2)	27 (5)	27 (4)	18 (3)
3-5 times	12 (2)	20 (3)	11 (2)	20 (3)	16 (3)
>5 times	5 (1)	15 (3)	13 (2)	13 (2)	18 (3)
Not reported	27 (5)	20 (3)	2 (<1)	10 (2)	3 (1)
Number of people needle & syringe was re-used after last month (%)					
None	486 (85)	491 (83)	485 (86)	548 (83)	478 (86)
One	27 (5)	41 (7)	28 (5)	45 (7)	24 (4)
Two	4 (<1)	9 (2)	8 (1)	8 (1)	11 (2)
Three to five	2 (<1)	1 (<1)	2 (<1)	4 (<1)	3 (1)
More than five	0 (0)	4 (<1)	5 (1)	6 (1)	5 (1)
Don't know	16 (3)	9 (2)	16 (3)	18 (3)	18 (3)
Not reported	36 (6)	38 (6)	18 (3)	34 (5)	17 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	48 (8)	33 (6)	26 (5)	44 (7)	27 (5)
Casual sex partner	1 (<1)	1 (<1)	5 (1)	7 (1)	4 (1)
Close friend	21 (4)	25 (4)	22 (4)	16 (2)	16 (3)
Acquaintance	11 (2)	9 (2)	11 (2)	14 (2)	8 (1)
Other	12 (2)	0 (0)	8 (1)	7 (1)	4 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	94 (16)	95 (16)	118 (21)	128 (19)	97 (17)
Water	64 (11)	75 (13)	86 (15)	99 (15)	76 (14)
Filter	39 (7)	47 (8)	51 (9)	63 (10)	42 (8)
Drug mix	35 (6)	34 (6)	47 (8)	47 (7)	60 (11)
None	432 (76)	428 (72)	418 (74)	480 (72)	403 (72)
Injected by someone after that person injected themselves or others last month (%)					
No	484 (85)	486 (82)	487 (87)	544 (82)	491 (88)
Yes	66 (12)	80 (13)	61 (11)	89 (13)	54 (10)
Not reported	21 (4)	27 (5)	14 (2)	30 (5)	11 (2)
Source of needle acquisition					
Needle Syringe Program	521 (91)	527 (89)	518 (92)	585 (88)	494 (89)
Chemist/Pharmacy	96 (17)	101 (17)	96 (17)	132 (20)	103 (19)
Personal sources	39 (7)	56 (9)	55 (10)	70 (11)	65 (12)
Dispensing/Vending Machine	95 (17)	120 (20)	136 (24)	190 (29)	133 (24)
Other sources	18 (3)	3 (<1)	17 (3)	16 (2)	14 (3)

Table 3.1.4 Number (percentage) of respondents by treatment for drug use and survey year

New South Wales N° surveyed	2011 N=694	2012 N=712	2013 N=686	2014 N=761	2015 N=639
Ever any treatment/therapy for drug use (%)					
No	138 (20)	174 (24)	162 (24)	200 (26)	158 (25)
Yes	525 (76)	526 (74)	512 (75)	543 (71)	466 (73)
Not reported	31 (4)	12 (2)	12 (2)	18 (2)	15 (2)
History of methadone maintenance treatment (%)					
Currently	273 (39)	289 (41)	263 (38)	251 (33)	225 (35)
Previously	128 (18)	143 (20)	146 (21)	158 (21)	122 (19)
Never	245 (35)	275 (39)	269 (39)	336 (44)	278 (44)
Not reported	48 (7)	5 (<1)	8 (1)	16 (2)	14 (2)
History of buprenorphine (Subutex®) treatment (%)					
Currently	60 (9)	53 (7)	42 (6)	47 (6)	46 (7)
Previously	156 (22)	182 (26)	164 (24)	182 (24)	147 (23)
Never	443 (64)	466 (65)	468 (68)	511 (67)	428 (67)
Not reported	35 (5)	11 (2)	12 (2)	21 (3)	18 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	39 (6)	66 (9)	36 (5)	45 (6)	54 (8)
Previously	82 (12)	89 (13)	119 (17)	127 (17)	118 (18)
Never	535 (77)	542 (76)	513 (75)	571 (75)	451 (71)
Not reported	38 (5)	15 (2)	18 (3)	18 (2)	16 (3)

Table 3.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

New South Wales N° surveyed	2011 N=694	2012 N=712	2013 N=686	2014 N=761	2015 N=639
Previous HIV test (%)					
Yes, ever	575 (83)	582 (82)	576 (84)	610 (80)	545 (85)
Yes, last year	331 (48)	310 (44)	336 (49)	374 (49)	328 (51)
>1 year ago	244 (35)	272 (38)	240 (35)	236 (31)	217 (34)
Never tested	92 (13)	96 (13)	100 (15)	116 (15)	78 (12)
Not reported	27 (4)	34 (5)	10 (1)	35 (5)	16 (3)
Previous HCV test (%)					
Yes, ever	583 (84)	607 (85)	571 (83)	648 (85)	550 (86)
Yes, last year	354 (51)	364 (51)	342 (50)	389 (51)	339 (53)
>1 year ago	229 (33)	243 (34)	229 (33)	259 (34)	211 (33)
Never tested	67 (10)	64 (9)	62 (9)	80 (11)	60 (9)
Not reported	44 (6)	41 (6)	53 (8)	33 (4)	29 (5)
Lifetime treatment for HCV (%)					
N° self-reported chronic HCV[#]	N=168	N=173	N=193	N=190	N=150
Antiviral treatment	15 (9)	22 (13)	21 (11)	26 (14)	25 (17)
No antiviral treatment	147 (88)	149 (86)	168 (87)	159 (84)	120 (80)
Not reported	6 (4)	2 (1)	4 (2)	5 (3)	5 (3)
Treatment for HCV in past 12 months (%)					
N° self-reported chronic HCV[#]	N=159	N=165	N=180	N=169	N=136
Antiviral treatment	3 (2)	4 (2)	5 (3)	1 (1)	4 (3)
No antiviral treatment	152 (96)	160 (97)	164 (91)	160 (95)	130 (96)
Not reported	4 (3)	1 (1)	11 (6)	8 (5)	2 (1)

among people who tested HCV antibody positive

* includes people who reported treatment induced clearance

Table 3.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

New South Wales N° surveyed	2011 N=694	2012 N=712	2013 N=686	2014 N=761	2015 N=639
Sex with a regular partner last month (%)					
No	307 (44)	324 (46)	320 (47)	355 (47)	292 (46)
Yes	334 (48)	360 (51)	348 (51)	377 (50)	319 (50)
Not reported	53 (8)	28 (4)	18 (3)	29 (4)	28 (4)
Condom used with regular partner last month (%)					
N° surveyed	N=334	N=360	N=348	N=377	N=319
Never	238 (71)	254 (71)	232 (67)	265 (70)	250 (78)
Sometimes	32 (10)	47 (13)	62 (18)	49 (13)	28 (9)
Every time	46 (14)	39 (11)	42 (12)	43 (11)	29 (9)
Not reported	18 (5)	20 (6)	12 (3)	20 (5)	12 (4)
Sex with other partner(s) last month (%)					
No	557 (80)	584 (82)	540 (79)	588 (77)	527 (82)
Yes	102 (15)	94 (13)	120 (17)	133 (17)	95 (15)
Not reported	35 (5)	34 (5)	26 (4)	40 (5)	17 (3)
Condom used with other partner(s) last month (%)					
N° surveyed	N=102	N=94	N=120	N=133	N=95
Never	27 (26)	28 (30)	38 (32)	45 (34)	35 (37)
Sometimes	28 (27)	29 (31)	35 (29)	34 (26)	30 (32)
Every time	46 (45)	32 (34)	40 (33)	43 (32)	27 (28)
Not reported	1 (1)	5 (5)	7 (6)	11 (8)	3 (3)
Sex work last month (%)					
No	618 (89)	637 (89)	607 (88)	642 (84)	595 (93)
Yes	38 (5)	42 (6)	33 (5)	51 (7)	29 (5)
Not reported	38 (5)	33 (5)	46 (7)	68 (9)	15 (2)
Condom used at last sex work (%)					
Yes	30 (79)	35 (83)	27 (82)	35 (69)	21 (72)

HIV antibody prevalence

Table 3.2.1 HIV antibody prevalence by gender and survey year

New South Wales Survey year	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011	455	5 (1.1)	224	1 (0.5)	682	7 (1.0)
2012	465	7 (1.5)	223	0 (0.0)	697	8 (1.2)
2013	456	20 (4.4)	204	0 (0.0)	665	21 (3.2)
2014	505	15 (3.0)	202	0 (0.0)	714	18 (2.5)
2015	436	16 (3.7)	164	2 (1.2)	608	19 (3.1)
X ² p trend p value		0.008		0.316		0.002

Table 3.2.2 HIV antibody prevalence by sexual identity, gender and survey year

New South Wales Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
Heterosexual	397	1 (0.3)	158	0 (0.0)	555	1 (0.2)
Bisexual	17	1 (5.6)	40	1 (2.5)	59	3 (5.1)
Homosexual	21	3 (14.3)	15	0 (0.0)	37	3 (8.1)
p value		<0.001		0.258		<0.001
2012						
Heterosexual	410	1 (0.2)	153	0 (0.0)	565	1 (0.2)
Bisexual	14	0 (0.0)	42	0 (0.0)	58	1 (1.7)
Homosexual	15	5 (33.3)	7	0 (0.0)	24	5 (20.8)
p value		0.001		--		<0.001
2013						
Heterosexual	384	2 (0.5)	143	0 (0.0)	528	2 (0.4)
Bisexual	21	1 (4.8)	28	0 (0.0)	50	2 (4.0)
Homosexual	31	16 (51.6)	11	0 (0.0)	45	16 (35.6)
p value		<0.001		--		<0.001
2014						
Heterosexual	434	3 (0.7)	135	0 (0.0)	571	3 (0.5)
Bisexual	17	2 (11.8)	44	0 (0.0)	65	5 (7.7)
Homosexual	31	10 (32.3)	10	0 (0.0)	42	10 (23.8)
p value		<0.001		--		<0.001
2015						
Heterosexual	369	2 (0.5)	125	1 (0.8)	497	3 (0.6)
Bisexual	26	2 (7.7)	28	1 (3.6)	56	4 (7.1)
Homosexual	23	12 (52.2)	2	0 (0.0)	26	12 (46.2)
p value		<0.001		0.351		<0.001

Table 3.2.3 HIV antibody prevalence by age group, gender and survey year

New South Wales Age group	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
<25 years	40	1 (2.5)	10	0 (0.0)	50	1 (2.0)
25-34 years	123	0 (0.0)	88	1 (1.1)	212	1 (0.5)
35-44 years	150	2 (1.3)	70	0 (0.0)	222	3 (1.4)
45+ years	140	2 (1.4)	55	0 (0.0)	195	2 (1.0)
p value		0.410		1.000		0.524
2012						
<25 years	42	0 (0.0)	10	0 (0.0)	53	0 (0.0)
25-34 years	117	0 (0.0)	65	0 (0.0)	184	0 (0.0)
35-44 years	157	3 (1.9)	88	0 (0.0)	248	4 (1.6)
45+ years	149	4 (2.7)	60	0 (0.0)	212	4 (1.9)
p value		0.295		--		0.257
2013						
<25 years	38	1 (2.6)	11	0 (0.0)	49	1 (2.0)
25-34 years	105	3 (2.9)	50	0 (0.0)	157	3 (2.6)
35-44 years	173	8 (4.6)	77	0 (0.0)	251	8 (3.2)
45+ years	140	8 (5.7)	66	0 (0.0)	208	8 (3.9)
p value		0.756		--		0.912
2014						
<25 years	42	1 (2.4)	7	0 (0.0)	50	1 (2.0)
25-34 years	105	3 (2.9)	59	0 (0.0)	167	4 (2.4)
35-44 years	187	3 (1.6)	81	0 (0.0)	271	5 (1.9)
45+ years	171	8 (4.7)	53	0 (0.0)	224	8 (3.6)
p value		0.393		--		0.674
2015						
<25 years	21	0 (0.0)	6	1 (16.7)	27	1 (3.7)
25-34 years	101	2 (2.0)	51	1 (2.0)	155	4 (2.6)
35-44 years	138	3 (2.2)	52	0 (0.0)	192	3 (2.6)
45+ years	176	11 (6.3)	55	0 (0.0)	234	11 (4.7)
p value		0.179		0.024		0.249

Table 3.2.4 HIV antibody prevalence by last drug injected, gender and survey year

New South Wales Last drug injected	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
Heroin	123	0 (0.0)	82	0 (0.0)	207	1 (0.5)
Methamphetamine	118	4 (3.4)	76	0 (0.0)	195	4 (2.1)
Other opioids	109	1 (0.9)	54	1 (1.9)	163	2 (1.2)
PIEDs	62	0 (0.0)	1	0 (0.0)	63	0 (0.0)
Other drugs	42	0 (0.0)	11	0 (0.0)	53	0 (0.0)
p value		0.145		0.295		0.566
2012						
Heroin	144	0 (0.0)	67	0 (0.0)	214	1 (0.5)
Methamphetamine	103	4 (3.9)	74	0 (0.0)	181	4 (2.2)
Other opioids	106	2 (1.9)	59	0 (0.0)	165	2 (1.2)
PIEDs	78	1 (1.3)	1	0 (0.0)	81	1 (1.2)
Other drugs	30	0 (0.0)	19	0 (0.0)	49	0 (0.0)
p value		0.133		--		0.545
2013						
Heroin	109	2 (1.8)	61	0 (0.0)	171	2 (1.2)
Methamphetamine	137	10 (7.3)	71	0 (0.0)	211	10 (4.7)
Other opioids	100	4 (4.0)	44	0 (0.0)	144	4 (2.8)
PIEDs	67	1 (1.5)	1	0 (0.0)	68	1 (1.5)
Other drugs	37	3 (8.1)	25	0 (0.0)	63	4 (6.4)
p value		0.128		--		0.141
2014						
Heroin	130	1 (0.8)	70	0 (0.0)	202	2 (1.0)
Methamphetamine	164	9 (5.5)	80	0 (0.0)	245	9 (3.7)
Other opioids	81	2 (2.5)	33	0 (0.0)	115	2 (1.7)
PIEDs	69	1 (1.5)	2	0 (0.0)	72	1 (1.4)
Other drugs	60	2 (3.3)	16	0 (0.0)	78	4 (5.1)
p value		0.173		--		0.187
2015						
Heroin	124	3 (2.4)	60	0 (0.0)	187	4 (2.1)
Methamphetamine	134	10 (7.5)	54	2 (3.7)	191	12 (6.3)
Other opioids	85	2 (2.4)	32	0 (0.0)	119	2 (1.7)
PIEDs	70	1 (1.4)	4	0 (0.0)	74	1 (1.4)
Other drugs	23	0 (0.0)	14	0 (0.0)	37	0 (0.0)
p value		0.165		0.352		0.098

Table 3.2.5 HIV antibody prevalence by years of injection, gender and survey year

New South Wales Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
<3 years	51	0 (0.0)	10	0 (0.0)	61	0 (0.0)
3 to 10 years	78	3 (3.9)	34	0 (0.0)	112	2 (2.7)
11 + years	306	2 (0.7)	177	1 (0.6)	486	4 (0.8)
p value		0.064		1.000		0.224
2012						
<3 years	52	1 (1.9)	11	0 (0.0)	64	1 (1.6)
3 to 10 years	75	1 (1.3)	43	0 (0.0)	119	1 (0.8)
11 + years	324	5 (1.5)	164	0 (0.0)	494	6 (1.2)
p value		0.840		--		0.845
2013						
<3 years	53	4 (7.6)	4	0 (0.0)	57	4 (7.0)
3 to 10 years	61	6 (9.8)	42	0 (0.0)	103	6 (5.8)
11 + years	324	9 (2.8)	151	0 (0.0)	480	10 (2.1)
p value		0.015		--		0.017
2014						
<3 years	53	1 (1.9)	8	0 (0.0)	62	1 (1.6)
3 to 10 years	81	6 (7.4)	39	0 (0.0)	120	6 (5)
11 + years	355	7 (2.0)	149	0 (0.0)	509	9 (1.8)
p value		0.042		--		0.111
2015						
<3 years	45	2 (4.4)	12	0 (0.0)	58	2 (3.5)
3 to 10 years	61	4 (6.6)	21	1 (4.8)	84	5 (6.0)
11 + years	317	9 (2.8)	126	1 (0.8)	448	11 (2.5)
p value		0.287		0.373		0.193

Table 3.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

New South Wales Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No receptive sharing	322	2 (0.6)	154	1 (0.7)	477	3 (0.6)
Receptive sharing	39	1 (2.6)	19	0 (0.0)	58	1 (1.7)
p value		0.291		1.000		0.369
2012						
No receptive sharing	327	4 (1.2)	146	0 (0.0)	481	5 (1.0)
Receptive sharing	48	0 (0.0)	32	0 (0.0)	80	0 (0.0)
p value		1.000		--		1.000
2013						
No receptive sharing	328	13 (4.0)	141	0 (0.0)	473	13 (2.8)
Receptive sharing	50	2 (4.0)	21	0 (0.0)	72	3 (4.2)
p value		1.000		--		0.456
2014						
No receptive sharing	362	9 (2.5)	143	0 (0.0)	510	11 (2.2)
Receptive sharing	70	2 (2.9)	28	0 (0.0)	99	3 (3.0)
p value		0.695		--		0.485
2015						
No receptive sharing	329	13 (4.0)	119	2 (1.7)	453	16 (3.5)
Receptive sharing	49	2 (4.1)	20	0 (0.0)	71	2 (2.8)
p value		1.000		1.000		1.000

Table 3.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

New South Wales Frequency of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
Less than daily	192	2 (1.0)	87	0 (0.0)	281	3 (1.1)
Daily or more	188	1 (0.5)	91	1 (1.1)	280	2 (0.7)
Not last month	60	1 (1.7)	43	0 (0.0)	103	1 (1.0)
p value		0.513		1.000		1.000
2012						
Less than daily	201	3 (1.5)	106	0 (0.0)	313	4 (1.3)
Daily or more	187	2 (1.1)	78	0 (0.0)	268	2 (0.8)
Not last month	70	2 (2.9)	37	0 (0.0)	107	2 (1.9)
p value		0.518		--		0.571
2013						
Less than daily	211	11 (5.2)	92	0 (0.0)	305	11 (3.6)
Daily or more	168	5 (3.0)	71	0 (0.0)	242	6 (2.5)
Not last month	66	3 (4.6)	33	0 (0.0)	99	3 (3.0)
p value		0.592		--		0.750
2014						
Less than daily	221	4 (1.8)	87	0 (0.0)	309	4 (1.3)
Daily or more	218	8 (3.7)	86	0 (0.0)	309	11 (3.6)
Not last month	60	3 (5)	26	0 (0.0)	87	3 (3.4)
p value		0.257		--		0.138
2015						
Less than daily	194	8 (4.1)	55	1 (1.8)	252	9 (3.6)
Daily or more	187	7 (3.7)	84	1 (1.2)	275	9 (3.3)
Not last month	47	1 (2.1)	21	0 (0.0)	69	1 (1.5)
p value		1.000		1.000		0.845

Table 3.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

New South Wales Imprisonment last year	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No imprisonment	385	5 (1.3)	185	0 (0.0)	572	6 (1.1)
Imprisonment	53	0 (0.0)	26	1 (3.9)	80	1 (1.3)
p value		1.000		0.123		0.602
2012						
No imprisonment	397	7 (1.8)	188	0 (0.0)	593	8 (1.4)
Imprisonment	46	0 (0.0)	24	0 (0.0)	71	0 (0.0)
p value		1.000		--		1.000
2013						
No imprisonment	378	17 (4.5)	172	0 (0.0)	553	18 (3.3)
Imprisonment	57	2 (3.5)	22	0 (0.0)	81	2 (2.5)
p value		1.000		--		1.000
2014						
No imprisonment	399	12 (3.0)	167	0 (0.0)	568	12 (2.1)
Imprisonment	65	0 (0.0)	22	0 (0.0)	91	3 (3.3)
p value		0.389		--		0.448
2015						
No imprisonment	355	13 (3.7)	143	2 (1.4)	504	16 (3.2)
Imprisonment	56	1 (1.8)	16	0 (0.0)	74	1 (1.4)
p value		0.703		1.000		0.711

Table 3.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

New South Wales Condom use at last sex	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No condom use	152	3 (2.0)	83	0 (0.0)	235	3 (1.3)
Condom use	51	2 (3.9)	24	1 (4.2)	76	3 (4.0)
p value		0.601		0.224		0.159
2012						
No condom use	145	2 (1.4)	102	0 (0.0)	250	2 (0.8)
Condom use	60	2 (3.3)	22	0 (0.0)	82	2 (2.4)
p value		0.582		--		0.256
2013						
No condom use	138	3 (2.2)	87	0 (0.0)	226	3 (1.3)
Condom use	72	2 (2.8)	26	0 (0.0)	101	3 (3.0)
p value		1.000		--		0.378
2014						
No condom use	157	1 (0.6)	96	0 (0.0)	253	1 (0.4)
Condom use	65	2 (3.1)	20	0 (0.0)	88	4 (4.6)
p value		0.206		--		0.017
2015						
No condom use	166	6 (3.6)	73	0 (0.0)	240	7 (2.9)
Condom use	42	1 (2.4)	13	1 (7.7)	55	2 (3.6)
p value		1.000		0.151		0.676

Table 3.2.10 HIV antibody prevalence by sex work last month, gender and survey year

New South Wales Sex work last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No sex work	416	4 (1.0)	192	0 (0.0)	609	4 (0.7)
Sex work	6	0 (0.0)	28	1 (3.6)	36	2 (5.6)
p value		1.000		0.127		0.039
2012						
No sex work	432	6 (1.4)	188	0 (0.0)	625	6 (1.0)
Sex work	10	1 (10.0)	26	0 (0.0)	40	2 (5.0)
p value		0.149		--		0.078
2013						
No sex work	411	15 (3.7)	173	0 (0.0)	588	15 (2.6)
Sex work	12	3 (25.0)	20	0 (0.0)	33	4 (12.1)
p value		0.011		--		0.015
2014						
No sex work	439	8 (1.8)	165	0 (0.0)	606	9 (1.5)
Sex work	17	3 (17.7)	22	0 (0.0)	44	5 (11.4)
p value		0.006		--		<0.001
2015						
No sex work	414	11 (2.7)	147	2 (1.4)	567	13 (2.3)
Sex work	11	3 (27.3)	15	0 (0.0)	28	4 (14.3)
p value		0.004		1.000		0.006

Table 3.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

New South Wales Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Non Indigenous	395	5 (1.3)	178	0 (0.0)	574	5 (0.9)
Indigenous	47	0 (0.0)	40	1 (2.5)	88	2 (2.3)
p value		1.000		0.183		0.236
2012						
Non Indigenous	413	7 (1.7)	177	0 (0.0)	597	7 (1.2)
Indigenous	45	0 (0.0)	41	0 (0.0)	88	1 (1.1)
p value		1.000		--		1.000
2013						
Non Indigenous	376	17 (4.5)	147	0 (0.0)	526	18 (3.4)
Indigenous	68	1 (1.5)	51	0 (0.0)	121	1 (0.8)
p value		0.332		--		0.226
2014						
Non Indigenous	421	12 (2.9)	142	0 (0.0)	569	14 (2.5)
Indigenous	73	1 (1.4)	57	0 (0.0)	131	2 (1.5)
p value		0.703		--		0.749
2015						
Non Indigenous	358	15 (4.2)	122	0 (0.0)	486	16 (3.3)
Indigenous	71	1 (1.4)	41	2 (4.9)	112	3 (2.7)
p value		0.489		0.062		1.000

Table 3.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

New South Wales Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
English speaking	419	5 (1.2)	211	1 (0.5)	633	7 (1.1)
Non-English speaking	29	0 (0.0)	10	0 (0.0)	39	39 (0.0)
p value		1.000		1.000		0.602
2012						
English speaking	440	6 (1.4)	213	0 (0.0)	660	7 (1.1)
Non-English speaking	23	1 (4.4)	7	0 (0.0)	32	1 (3.1)
p value		0.302		--		0.317
2013						
English speaking	419	19 (4.5)	193	0 (0.0)	616	20 (3.3)
Non-English speaking	35	1 (2.9)	11	0 (0.0)	47	1 (2.1)
p value		1.000		--		1.000
2014						
English speaking	459	13 (2.8)	189	0 (0.0)	654	16 (2.5)
Non-English speaking	41	0 (0.0)	11	0 (0.0)	53	0 (0.0)
p value		0.613		--		0.624
2015						
English speaking	408	15 (3.7)	157	2 (1.3)	573	18 (3.1)
Non-English speaking	25	1 (4.0)	7	0 (0.0)	32	1 (3.1)
p value		1.000		1.000		1.000

Table 3.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

New South Wales						
Region/country of birth	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
Australia	378	5 (1.3)	199	1 (0.5)	579	7 (1.2)
Other Oceania	10	0 (0.0)	11	0 (0.0)	21	0 (0.0)
Asia	10	0 (0.0)	2	0 (0.0)	12	0 (0.0)
UK & Ireland	19	0 (0.0)	6	0 (0.0)	26	0 (0.0)
Other	28	0 (0.0)	4	0 (0.0)	32	0 (0.0)
p value		1.000		1.000		1.000
2012						
Australia	402	3 (0.8)	196	0 (0.0)	606	4 (0.7)
Other Oceania	14	2 (14.2)	8	0 (0.0)	22	2 (9.1)
Asia	7	0 (0.0)	0	0 (0.0)	8	0 (0.0)
UK & Ireland	23	0 (0.0)	7	0 (0.0)	30	0 (0.0)
Other	12	2 (16.7)	9	0 (0.0)	21	2 (9.5)
p value		0.001		--		0.003
2013						
Australia	392	15 (3.8)	188	0 (0.0)	582	15 (2.6)
Other Oceania	12	1 (8.3)	6	0 (0.0)	19	2 (10.5)
Asia	8	1 (12.5)	1	0 (0.0)	9	1 (11.1)
UK & Ireland	14	1 (7.1)	7	0 (0.0)	22	1 (4.6)
Other	28	2 (7.1)	2	0 (0.0)	31	2 (6.5)
p value		0.602		--		0.131
2014						
Australia	421	11 (2.6)	179	0 (0.0)	604	12 (2.0)
Other Oceania	20	0 (0.0)	7	0 (0.0)	29	2 (6.9)
Asia	10	0 (0.0)	1	0 (0.0)	11	0 (0.0)
UK & Ireland	19	0 (0.0)	7	0 (0.0)	26	0 (0.0)
Other	28	2 (7.1)	5	0 (0.0)	34	2 (5.9)
p value		0.508		--		0.169
2015						
Australia	373	13 (3.5)	143	2 (1.4)	523	15 (2.9)
Other Oceania	17	1 (5.9)	6	0 (0.0)	24	2 (8.3)
Asia	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)
UK & Ireland	19	1 (5.3)	7	0 (0.0)	26	1 (3.9)
Other	12	0 (0.0)	5	0 (0.0)	17	0 (0.0)
p value		0.704		1.000		0.401

HCV ANTIBODY PREVALENCE

Table 3.3.1 HCV antibody prevalence by gender and survey year

New South Wales Survey year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011	448	220 (49)	219	129 (59)	670	350 (52)
2012	453	213 (47)	220	121 (55)	682	338 (50)
2013	453	232 (51)	204	120 (59)	661	354 (54)
2014	502	264 (53)	200	123 (62)	709	390 (55)
2015	371	215 (58)	143	96 (67)	521	316 (61)
X ² p trend value		0.099		0.358		0.070

Table 3.3.2 HCV antibody prevalence by sexual identity, gender and survey year

New South Wales Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Heterosexual	391	192 (49)	154	91 (59)	545	283 (52)
Bisexual	17	9 (53)	40	23 (58)	59	32 (54)
Homosexual	21	7 (33)	14	8 (57)	36	16 (44)
p value		0.340		0.969		0.641
2012						
Heterosexual	339	195 (49)	152	85 (56)	553	281 (51)
Bisexual	14	4 (29)	41	23 (56)	57	27 (47)
Homosexual	15	3 (20)	6	1 (17)	23	5 (22)
p value		0.033		0.163		0.021
2013						
Heterosexual	383	206 (54)	143	84 (59)	527	291 (55)
Bisexual	21	11 (52)	28	17 (61)	49	28 (57)
Homosexual	30	6 (20)	11	5 (45)	44	12 (27)
p value		0.002		0.720		0.001
2014						
Heterosexual	432	233 (54)	133	80 (60)	567	314 (55)
Bisexual	17	8 (47)	44	27 (61)	65	37 (57)
Homosexual	31	10 (32)	10	6 (60)	42	16 (38)
p value		0.060		0.989		0.087
2015						
Heterosexual	313	185 (59)	108	71 (66)	424	258 (61)
Bisexual	21	12 (57)	25	18 (72)	48	31 (65)
Homosexual	22	9 (41)	2	1 (50)	25	11 (44)
p value		0.247		0.737		0.202

Table 3.3.3 HCV antibody prevalence by age group, gender and survey year

New South Wales Age group	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
<25 years	40	4 (10)	10	5 (50)	50	9 (18)
25-34 years	120	49 (41)	86	46 (53)	207	95 (46)
35-44 years	149	79 (53)	69	49 (71)	220	129 (59)
45+ years	137	88 (64)	53	29 (55)	190	117 (62)
p value		<0.001		0.115		<0.001
2012						
<25 years	41	0 (0)	10	5 (50)	52	5 (10)
25-34 years	114	34 (30)	65	38 (58)	181	74 (41)
35-44 years	153	84 (55)	86	49 (57)	242	134 (55)
45+ years	145	95 (66)	59	29 (49)	207	125 (60)
p value		<0.001		0.713		<0.001
2013						
<25 years	38	2 (5)	11	4 (36)	49	6 (12)
25-34 years	105	38 (36)	50	25 (50)	156	64 (41)
35-44 years	172	102 (59)	77	47 (61)	250	149 (60)
45+ years	138	90 (65)	66	44 (67)	206	135 (66)
p value		<0.001		0.127		<0.001
2014						
<25 years	42	5 (12)	7	2 (29)	50	7 (14)
25-34 years	104	39 (38)	59	38 (64)	166	79 (48)
35-44 years	187	116 (62)	79	44 (56)	269	161 (60)
45+ years	169	104 (62)	53	37 (70)	222	141 (64)
p value		<0.001		0.116		<0.001
2015						
<25 years	16	2 (13)	3	0 (0)	19	2 (11)
25-34 years	87	31 (36)	46	30 (65)	136	63 (46)
35-44 years	126	82 (65)	45	30 (67)	173	113 (65)
45+ years	142	100 (70)	49	36 (73)	193	138 (72)
p value		<0.001		0.089		<0.001

Table 3.3.4 HCV antibody prevalence by years since first injection, gender and survey year

New South Wales Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
<3 years	51	5 (10)	10	3 (30)	61	8 (13)
3 to 10 years	78	27 (35)	33	19 (58)	111	46 (41)
11+years	299	183 (61)	173	107 (62)	475	291 (61)
p value		<0.001		0.156		<0.001
2012						
<3 years	51	3 (6)	11	3 (27)	63	7 (11)
3 to 10 years	73	18 (25)	43	26 (60)	117	44 (38)
11+years	315	187 (59)	161	91 (57)	482	281 (58)
p value		<0.001		0.134		<0.001
2013						
<3 years	53	0 (0)	4	2 (50)	57	2 (4)
3 to 10 years	61	14 (23)	42	21 (50)	103	35 (34)
11+years	321	207 (65)	151	94 (62)	476	303 (64)
p value		<0.001		0.334		0
2014						
<3 years	53	1 (20)	8	1 (13)	62	2 (3)
3 to 10 years	80	22 (28)	39	22 (56)	119	44 (37)
11+years	353	231 (65)	147	96 (65)	505	330 (65)
p value		<0.001		0.009		<0.001
2015						
<3 years	36	5 (14)	8	2 (25)	44	7 (16)
3 to 10 years	50	16 (32)	17	8 (57)	69	25 (36)
11+years	275	191 (69)	113	84 (74)	393	279 (71)
p value		<0.001		0.002		<0.001

Table 3.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

New South Wales Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No receptive sharing	42	6 (14)	414	234 (57)	468	243 (52)
Receptive sharing	1	1 (100)	55	41 (75)	56	42 (75)
p value		0.163		0.013		0.001
2012						
No receptive sharing	45	6 (13)	417	228 (55)	474	238 (50)
Receptive sharing	5	1 (20)	71	42 (59)	77	44 (57)
p value		0.546		0.520		0.271
2013						
No receptive sharing	33	1 (3)	430	249 (58)	472	256 (54)
Receptive sharing	5	0 (0)	59	34 (58)	69	38 (55)
p value		1.000		0.967		0.896
2014						
No receptive sharing	44	2 (5)	454	259 (57)	507	267 (53)
Receptive sharing	2	0 (0)	90	69 (77)	99	75 (76)
p value		1.000		0.001		<0.001
2015						
No receptive sharing	32	5 (16)	350	232 (66)	389	238 (61)
Receptive sharing	3	1 (33)	56	36 (64)	60	38 (63)
p value		0.442		0.769		0.750

Table 3.3.6 HCV antibody prevalence by last drug injected, years since first injection, and survey year

New South Wales Last drug injected	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Heroin	5	3 (60)	196	104 (53)	206	109 (53)
Methamphetamine	7	2 (29)	178	98 (55)	190	100 (53)
Other opioids	6	1 (17)	151	103 (68)	156	105 (66)
PIEDs	36	1 (3)	21	2 (10)	62	3 (5)
Other drugs	6	1 (17)	40	30 (75)	52	33 (63)
p value		0.006		<0.001		<0.001
2012						
Heroin	10	2 (20)	198	114 (58)	211	118 (56)
Methamphetamine	7	2 (29)	165	86 (52)	177	91 (51)
Other opioids	4	2 (50)	156	99 (63)	160	101 (63)
PIEDs	39	1 (3)	35	1 (3)	80	2 (3)
Other drugs	3	0 (0)	43	24 (56)	47	25 (53)
p value		0.015		<0.001		<0.001
2013						
Heroin	3	1 (33)	163	116 (71)	171	119 (70)
Methamphetamine	8	1 (13)	198	107 (54)	209	111 (53)
Other opioids	4	0 (0)	137	85 (62)	143	87 (61)
PIEDs	36	0 (0)	30	1 (3)	68	1 (1)
Other drugs	3	0 (0)	50	28 (56)	62	34 (55)
p value		0.029		<0.001		<0.001
2014						
Heroin	4	1 (25)	192	130 (68)	200	133 (67)
Methamphetamine	14	1 (7)	221	130 (59)	243	135 (56)
Other opioids	2	0 (0)	111	73 (66)	114	74 (65)
PIEDs	36	0 (0)	33	1 (3)	72	2 (3)
Other drugs	5	0 (0)	67	40 (60)	78	46 (59)
p value		0.089		<0.001		<0.001
2015						
Heroin	5	1 (20)	158	120 (76)	165	123 (75)
Methamphetamine	12	2 (17)	145	86 (59)	161	90 (56)
Other opioids	3	2 (67)	96	74 (77)	99	76 (77)
PIEDs	20	1 (5)	32	0 (0)	56	1 (2)
Other drugs	3	1 (33)	26	21 (81)	30	22 (73)
p value		0.086		<0.001		<0.001

Table 3.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

New South Wales Frequency of injection last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Less than daily	28	4 (14)	242	127 (52)	275	132 (48)
Daily or more	18	3 (17)	247	155 (63)	275	160 (58)
Not last month	15	1 (7)	84	47 (56)	103	48 (47)
p value		0.793		0.069		0.029
2012						
Less than daily	27	5 (19)	275	162 (59)	309	170 (55)
Daily or more	23	2 (9)	231	116 (50)	261	121 (46)
Not last month	12	0 (0)	87	44 (51)	103	44 (43)
p value		0.291		0.112		0.036
2013						
Less than daily	28	1 (4)	268	144 (54)	302	150 (50)
Daily or more	11	1 (9)	222	139 (63)	241	145 (60)
Not last month	16	0 (0)	75	44 (59)	99	46 (46)
p value		0.444		0.139		0.018
2014						
Less than daily	26	1 (4)	275	151 (55)	307	157 (51)
Daily or more	20	1 (5)	277	183 (66)	308	191 (62)
Not last month	15	0 (0)	65	35 (54)	85	36 (42)
p value		1.000		0.016		0.001
2015						
Less than daily	22	2 (9)	186	113 (61)	213	115 (54)
Daily or more	13	4 (31)	222	156 (70)	238	162 (68)
Not last month	8	1 (13)	49	32 (65)	60	35 (58)
p value		0.291		0.125		0.008

Table 3.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

New South Wales Imprisonment last year	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No imprisonment	59	7 (12)	475	260 (55)	550	269 (49)
Imprisonment	1	1 (100)	73	55 (75)	77	58 (75)
p value		0.133		0.001		<0.001
2012						
No imprisonment	61	7 (11)	504	263 (52)	581	274 (47)
Imprisonment	1	0 (0)	66	40 (61)	69	41 (59)
p value		1.000		0.197		0.057
2013						
No imprisonment	52	1 (2)	479	261 (54)	550	272 (49)
Imprisonment	4	0 (0)	74	56 (76)	80	58 (73)
p value		1.000		0.001		<0.001
2014						
No imprisonment	58	1 (2)	492	275 (56)	564	285 (51)
Imprisonment	3	1 (33)	84	67 (80)	91	71 (78)
p value		0.097		<0.001		<0.001
2015						
No imprisonment	38	6 (16)	376	235 (63)	427	244 (57)
Imprisonment	2	1 (50)	64	53 (83)	67	55 (82)
p value		0.323		0.002		<0.001

Table 3.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year

New South Wales	<3 years		3+ years		Total	
Sex work last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
No sex work	55	7 (13)	527	305 (58)	600	315 (53)
Sex work	0	0 (0)	32	18 (56)	34	19 (56)
p value		--		0.856		0.728
2012						
No sex work	56	5 (9)	537	290 (54)	610	301 (49)
Sex work	3	1 (33)	35	18 (51)	40	19 (48)
p value		0.279		0.767		0.821
2013						
No sex work	53	1 (2)	514	296 (58)	586	308 (53)
Sex work	1	0 (0)	29	18 (62)	32	20 (63)
p value		1.000		0.634		0.273
2014						
No sex work	57	2 (4)	533	318 (60)	602	327 (54)
Sex work	2	0 (0)	39	31 (79)	44	33 (75)
p value		1.000		0.014		0.008
2015						
No sex work	41	7 (17)	427	276 (65)	483	288 (60)
Sex work	2	0 (0)	23	20 (87)	25	20 (80)
p value		1.000		0.028		0.042

Table 3.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

New South Wales	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Non Indigenous	390	187 (48)	174	102 (59)	565	289 (51)
Indigenous	45	21 (47)	39	24 (62)	85	45 (53)
p value		1.000		0.857		0.816
2012						
Non Indigenous	401	189 (47)	175	95 (54)	583	287 (49)
Indigenous	45	21 (47)	40	24 (60)	87	46 (53)
p value		1.000		0.598		0.566
2013						
Non Indigenous	373	186 (50)	147	83 (56)	522	269 (52)
Indigenous	68	41 (60)	51	33 (65)	121	76 (63)
p value		0.114		0.303		0.025
2014						
Non Indigenous	418	206 (49)	140	84 (60)	564	293 (52)
Indigenous	73	53 (73)	57	36 (63)	131	89 (68)
p value		<0.001		0.680		0.001
2015						
Non Indigenous	311	167 (54)	105	67 (64)	421	237 (56)
Indigenous	55	44 (80)	37	28 (76)	92	72 (78)
p value		<0.001		0.187		<0.001

Table 3.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

New South Wales Main language spoken at home by parents	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
English speaking	413	197 (48)	206	125 (61)	622	323 (52)
Non-English speaking	28	17 (61)	10	4 (40)	38	21 (55)
p value		0.241		0.207		0.740
2012						
English speaking	428	197 (46)	210	118 (56)	645	318 (49)
Non-English speaking	23	15 (65)	7	1 (14)	32	17 (53)
p value		0.087		0.048		0.720
2013						
English speaking	416	216 (52)	193	112 (58)	612	330 (54)
Non-English speaking	35	15 (43)	11	8 (73)	47	23 (49)
p value		0.303		0.531		0.509
2014						
English speaking	456	242 (53)	187	114 (61)	649	358 (55)
Non-English speaking	41	20 (49)	11	7 (64)	53	28 (53)
p value		0.598		0.860		0.743
2015						
English speaking	346	201 (58)	137	93 (68)	490	299 (61)
Non-English speaking	23	13 (57)	6	3 (50)	29	16 (55)
p value		0.883		0.395		0.531

Table 3.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

New South Wales						
Region/Country of birth	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Australia	373	177 (47)	194	118 (61)	569	296 (52)
Other Oceania	8	6 (75)	11	7 (64)	19	13 (68)
Asia	10	6 (60)	2	0 (0)	12	6 (50)
UK & Ireland	20	10 (50)	6	2 (33)	27	12 (44)
Other	28	14 (50)	4	2 (50)	32	16 (50)
p value		0.571		0.296		0.609
2012						
Australia	392	183 (47)	194	105 (54)	594	292 (49)
Other Oceania	13	5 (38)	7	6 (86)	20	11 (55)
Asia	7	5 (71)	0	0 (0)	8	5 (63)
UK & Ireland	22	14 (64)	7	3 (43)	29	17 (59)
Other	12	3 (25)	9	5 (56)	21	8 (38)
p value		0.149		0.361		0.584
2013						
Australia	390	204 (52)	188	110 (59)	580	316 (54)
Other Oceania	12	6 (50)	6	4 (67)	18	10 (56)
Asia	8	3 (38)	1	0 (0)	9	3 (33)
UK & Ireland	14	8 (57)	7	4 (57)	22	12 (55)
Other	27	11 (41)	2	2 (100)	30	13 (43)
p value		0.711		0.724		0.566
2014						
Australia	420	230 (55)	177	108 (61)	601	339 (56)
Other Oceania	20	10 (50)	7	3 (43)	29	14 (48)
Asia	10	5 (50)	1	0 (0)	11	5 (45)
UK & Ireland	18	7 (39)	7	5 (71)	25	12 (48)
Other	27	10 (37)	5	5 (100)	33	16 (49)
p value		0.305		0.179		0.635
2015						
Australia	324	198 (61)	127	89 (70)	457	291 (64)
Other Oceania	11	4 (36)	4	1 (25)	16	6 (38)
Asia	8	1 (13)	2	2 (100)	10	3 (30)
UK & Ireland	14	7 (50)	5	2 (40)	19	9 (47)
Other	10	4 (40)	5	2 (40)	15	6 (40)
p value		0.016		0.057		0.009

Northern Territory

Table 4.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Northern Territory	2011	2012	2013	2014	2015
Number of sites	3	3	3	3	3
N° surveyed	N=70	N=50	N=70	N=70	N=60
Response rate (%)	33%	21%	33%	39%	27%
Gender (%)					
Male	46 (66)	33 (66)	49 (70)	54 (77)	46 (77)
Female	23 (33)	16 (32)	21 (30)	16 (23)	14 (23)
Transgender	1 (1)	1 (2)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	56 (80)	39 (78)	61 (87)	63 (90)	54 (90)
Bisexual	12 (17)	8 (16)	5 (7)	3 (4)	3 (5)
Homosexual	1 (1)	2 (4)	1 (1)	0 (0)	1 (2)
Not reported	1 (1)	1 (2)	3 (4)	4 (6)	2 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	56 (80)	37 (74)	55 (79)	55 (79)	42 (70)
Yes	13 (19)	12 (24)	13 (19)	14 (20)	16 (27)
Not reported	1 (1)	1 (2)	2 (3)	1 (1)	2 (3)
Region/country of birth (%)					
Australia	60 (86)	44 (88)	59 (84)	61 (87)	53 (88)
Other Oceania	0 (0)	1 (2)	1 (1)	2 (3)	3 (5)
Asia	2 (3)	0 (0)	0 (0)	1 (1)	1 (2)
UK & Ireland	8 (11)	2 (4)	7 (10)	3 (4)	2 (3)
Other	0 (0)	3 (6)	3 (4)	3 (4)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Main language spoken at home by parents (%)					
English	65 (93)	48 (96)	68 (97)	66 (94)	57 (95)
Non-English	5 (7)	2 (4)	2 (3)	4 (6)	2 (3)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Age and time since first injection (years)					
<i>Median age</i>	40	39	42	42	42
<i>Age range</i>	17-64	20-59	19-62	21-61	26-57
<i>Age group (%)</i>					
<25 years	4 (6)	2 (4)	2 (3)	3 (4)	0 (0)
25+ years	66 (94)	48 (96)	68 (97)	67 (96)	60 (100)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age first injection</i>					
	19	18	20	20	18
<i>Age range</i>	12-44	12-40	13-40	10-45	12-43
<i>N° not reported</i>	3	3	2	0	2
<i>Median yrs since first injection</i>					
	16	17	21	21	20
<i>Range</i>	1-46	1-41	3-46	0-45	2-41
<i>Years since first injection</i>					
<3 years	7 (10)	3 (6)	0 (0)	4 (6)	1 (2)
3+ years	60 (86)	44 (88)	68 (97)	65 (93)	57 (95)
Not reported	3 (4)	3 (6)	2 (3)	1 (1)	2 (3)
Imprisonment last year (%)					
No	65 (93)	45 (90)	62 (89)	63 (90)	50 (83)
Yes	3 (4)	4 (8)	7 (14)	2 (3)	7 (12)
Not reported	2 (3)	1 (2)	1 (1)	5 (7)	3 (5)
N° in prison					
	N=3	N=4	N=7	N=2	N=7
Injected in prison	1 (33)	0 (0)	1 (14)	0 (0)	0 (0)

Table 4.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Northern Territory N° surveyed	2011 N=70	2012 N=50	2013 N=70	2014 N=70	2015 N=60
Drug last injected (%)					
Cocaine	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Methamphetamine	16 (23)	9 (18)	8 (11)	19 (27)	21 (35)
Heroin	2 (3)	2 (4)	7 (10)	6 (9)	1 (2)
Pharm. opioids	44 (63)	35 (70)	43 (61)	35 (50)	25 (42)
Methadone	2 (3)	1 (2)	1 (1)	6 (9)	4 (7)
Buprenorphine	0 (0)	0 (0)	1 (1)	1 (1)	5 (8)
Buprenorphine/naloxone	2 (3)	1 (2)	0 (0)	1 (1)	3 (5)
PIEDs	1 (1)	1 (2)	3 (4)	1 (1)	0 (0)
More than one	1 (1)	1 (2)	5 (7)	0 (0)	1 (2)
Other	2 (3)	0 (0)	1 (1)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Frequency of injection last month (%)					
Not last month	10 (14)	5 (10)	8 (11)	3 (4)	2 (3)
Less than weekly	7 (10)	3 (6)	11 (16)	9 (13)	7 (12)
Weekly not daily	7 (10)	10 (20)	12 (17)	9 (13)	8 (13)
Daily or more	46 (66)	32 (64)	39 (56)	48 (69)	43 (72)
Not reported	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Present when someone injected for the first time in the last 12 months (%)					
Yes	--	12 (24)	4 (6)	7 (10)	7 (12)
No	--	37 (74)	54 (77)	63 (90)	50 (83)
Not reported	--	1 (2)	12 (17)	0 (0)	3 (5)
Overdosed in last 12 months					
Yes	--	--	10 (14)	2 (3)	9 (15)
No	--	--	57 (81)	68 (97)	50 (83)
Not reported	--	--	3 (4)	0 (0)	1 (2)

Table 4.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Northern Territory N° injected last month	2011 N=60	2012 N=45	2013 N=62	2014 N=66	2015 N=58
Places injected last month (%)					
Any public	18 (30)	16 (36)	18 (29)	14 (21)	20 (34)
All private	39 (65)	29 (64)	43 (69)	52 (79)	38 (66)
Not reported	3 (5)	0 (0)	1 (2)	0 (0)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	49 (82)	33 (73)	51 (82)	56 (85)	47 (81)
Most of the time	9 (15)	9 (20)	9 (15)	7 (11)	9 (16)
Half of the time	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)
Some of the time	0 (0)	1 (2)	1 (2)	2 (3)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	2 (3)	2 (4)	1 (2)	0 (0)	1 (2)
Re-used someone else's used needle & syringe last month (%)					
None	48 (80)	39 (87)	55 (89)	62 (94)	56 (97)
Once	3 (5)	1 (2)	3 (5)	2 (3)	1 (2)
Twice	4 (7)	4 (9)	2 (3)	1 (2)	1 (2)
3-5 times	1 (2)	1 (2)	0 (0)	1 (2)	0 (0)
>5 times	1 (2)	0 (0)	1 (2)	0 (0)	0 (0)
Not reported	3 (5)	0 (0)	1 (2)	0 (0)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	48 (80)	39 (87)	55 (89)	62 (94)	56 (97)
One	6 (10)	4 (9)	1 (2)	1 (2)	0 (0)
Two	1 (2)	0 (0)	0 (0)	2 (3)	0 (0)
Three to five	1 (1)	2 (4)	0 (0)	0 (0)	0 (0)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Don't know	2 (5)	0 (0)	2 (3)	0 (0)	1 (2)
Not reported	2 (5)	0 (0)	4 (6)	1 (2)	1 (2)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	8 (13)	5 (11)	1 (2)	0 (0)	1 (2)
Casual sex partner	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Close friend	5 (8)	1 (2)	0 (0)	0 (0)	0 (0)
Acquaintance	2 (3)	0 (0)	1 (2)	3 (5)	0 (0)
Other	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	17 (28)	10 (22)	22 (35)	11 (17)	10 (17)
Water	8 (13)	3 (7)	7 (11)	2 (3)	7 (12)
Filter	4 (7)	4 (9)	7 (11)	9 (14)	4 (7)
Drug mix	4 (7)	3 (7)	3 (5)	1 (2)	4 (7)
None	38 (63)	32 (71)	39 (63)	55 (83)	43 (74)
Injected by someone after that person injected themselves or others last month (%)					
No	54 (90)	36 (80)	58 (94)	57 (86)	54 (93)
Yes	4 (6)	9 (20)	2 (3)	7 (11)	4 (7)
Not reported	2 (3)	0 (0)	2 (3)	2 (3)	0 (0)
Source of needle acquisition					
Needle Syringe Program	58 (97)	43 (96)	58 (94)	62 (94)	57 (98)
Chemist/Pharmacy	8 (13)	9 (20)	6 (10)	7 (11)	9 (16)
Personal sources	8 (13)	12 (27)	7 (11)	9 (14)	5 (9)
Dispensing/Vending Machine	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)
Other sources	0 (0)	0 (0)	0 (0)	3 (5)	1 (2)

Table 4.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Northern Territory N° surveyed	2011 N=70	2012 N=50	2013 N=70	2014 N=70	2015 N=60
Ever any treatment/therapy for drug use (%)					
No	22 (31)	14 (28)	29 (41)	24 (34)	18 (30)
Yes	47 (67)	36 (72)	41 (59)	45 (64)	40 (67)
Not reported	1 (1)	0 (0)	0 (0)	1 (1)	2 (3)
History of methadone maintenance treatment (%)					
Currently	7 (10)	6 (12)	11 (16)	2 (3)	5 (8)
Previously	22 (31)	11 (22)	18 (26)	15 (21)	18 (30)
Never	39 (56)	32 (64)	41 (59)	48 (69)	36 (60)
Not reported	2 (3)	1 (2)	0 (0)	5 (7)	1 (2)
History of buprenorphine (Subutex®) treatment (%)					
Currently	3 (4)	6 (12)	3 (4)	3 (4)	2 (3)
Previously	21 (30)	18 (36)	16 (23)	22 (31)	15 (25)
Never	45 (64)	26 (52)	50 (71)	43 (61)	43 (72)
Not reported	1 (1)	0 (0)	1 (1)	2 (3)	0 (0)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	6 (9)	6 (12)	9 (13)	5 (7)	4 (7)
Previously	13 (19)	6 (12)	11 (16)	19 (27)	16 (27)
Never	51 (73)	38 (76)	48 (69)	45 (64)	36 (60)
Not reported	0 (0)	0 (0)	2 (3)	1 (1)	4 (7)

Table 4.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Northern Territory N° surveyed	2011 N=70	2012 N=50	2013 N=70	2014 N=70	2015 N=60
Previous HIV test (%)					
Yes, ever	64 (91)	44 (88)	60 (86)	60 (86)	51 (85)
Yes, last year	32 (46)	29 (58)	35 (50)	28 (40)	22 (37)
>1 year ago	32 (46)	15 (30)	25 (36)	32 (46)	29 (48)
Never tested	6 (9)	5 (10)	10 (14)	10 (14)	8 (13)
Not reported	0 (0)	1 (2)	0 (0)	0 (0)	1 (2)
Previous HCV test (%)					
Yes, ever	67 (96)	46 (92)	60 (86)	66 (94)	50 (83)
Yes, last year	37 (53)	30 (60)	36 (51)	31 (44)	26 (43)
>1 year ago	30 (43)	16 (32)	24 (34)	35 (50)	24 (40)
Never tested	2 (3)	3 (6)	7 (10)	4 (6)	5 (8)
Not reported	1 (1)	1 (2)	3 (4)	0 (0)	5 (8)
Lifetime treatment for HCV (%)					
N° self-reported chronic HCV#*					
Antiviral treatment	0 (0)	0 (0)	2 (13)	9 (47)	0 (0)
No antiviral treatment	15 (94)	4 (100)	14 (88)	10 (53)	8 (100)
Not reported	1 (6)	0 (0)	0 (0)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)					
N° self-reported chronic HCV#					
Antiviral treatment	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
No antiviral treatment	15 (100)	4 (100)	15 (100)	11 (92)	8 (100)
Not reported	0 (0)	0 (0)	0 (0)	1 (8)	0 (0)

among people who tested HCV antibody positive

* includes people who reported treatment induced clearance

Table 4.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Northern Territory	2011	2012	2013	2014	2015
N° surveyed	N=70	N=50	N=70	N=70	N=60
Sex with a regular partner last month (%)					
No	35 (50)	30 (60)	43 (61)	41 (59)	40 (67)
Yes	34 (49)	19 (38)	26 (37)	29 (41)	19 (32)
Not reported	1 (1)	1 (2)	1 (1)	0 (0)	1 (2)
Condom used with regular partner last month (%)					
N° surveyed	N=34	N=19	N=26	N=29	N=19
Never	23 (68)	12 (63)	24 (92)	16 (55)	15 (79)
Sometimes	0 (0)	1 (5)	0 (0)	5 (17)	1 (5)
Every time	8 (24)	5 (26)	1 (4)	4 (14)	3 (16)
Not reported	3 (9)	1 (5)	1 (4)	4 (14)	0 (0)
Sex with other partner(s) last month (%)					
No	64 (91)	40 (80)	57 (81)	60 (86)	52 (87)
Yes	6 (9)	10 (20)	13 (19)	10 (14)	6 (10)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	2 (3)
Condom used with other partner(s) last month (%)					
N° surveyed	N=6	N=10	N=13	N=10	N=6
Never	1 (17)	5 (50)	5 (38)	1 (10)	2 (33)
Sometimes	1 (17)	2 (20)	2 (15)	6 (60)	1 (17)
Every time	3 (50)	3 (30)	5 (38)	3 (30)	3 (50)
Not reported	1 (17)	0 (0)	1 (8)	0 (0)	0 (0)
Sex work last month (%)					
No	66 (94)	46 (92)	64 (91)	64 (91)	56 (93)
Yes	4 (6)	4 (8)	3 (4)	6 (9)	2 (3)
Not reported	0 (0)	0 (0)	3 (4)	0 (0)	2 (3)
Condom used at last sex work (%)					
Yes	4 (100)	3 (75)	2 (67)	4 (67)	1 (50)

HIV antibody prevalence

Table 4.2.1 HIV antibody prevalence by gender and survey year

Northern Territory Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011	46	1 (2.2)	21	0 (0.0)	68	1 (1.5)
2012	30	1 (3.3)	15	0 (0.0)	46	1 (2.2)
2013	47	2 (4.3)	19	0 (0.0)	66	2 (3.0)
2014	54	0 (0.0)	16	0 (0.0)	70	0 (0.0)
2015	45	0 (0.0)	14	0 (0.0)	59	0 (0.0)
X ² p trend p value		0.234		--		0.281

HCV antibody prevalence

Table 4.3.1 HCV antibody prevalence by gender and survey year

Northern Territory Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011	40	22 (50)	21	10 (48)	61	32 (52)
2012	30	11 (37)	15	5 (33)	46	16 (35)
2013	46	21 (46)	19	12 (63)	65	33 (51)
2014	53	30 (57)	16	8 (50)	69	38 (55)
2015	31	19 (61)	12	7 (58)	43	26 (60)
X ² p trend value		0.543		0.612		0.415

Table 4.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Northern Territory Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Heterosexual	35	21 (60)	14	7 (50)	49	28 (57)
Bisexual	4	1 (25)	7	3 (43)	11	4 (36)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.195		1.000		0.247
2012						
Heterosexual	26	11 (42)	10	4 (40)	37	15 (41)
Bisexual	3	0 (0)	3	1 (33)	6	1 (17)
Homosexual	0	0 (0)	2	0 (0)	2	0 (0)
p value		0.268		0.760		0.355
2013						
Heterosexual	40	21 (53)	17	12 (71)	57	33 (58)
Bisexual	4	0 (0)	0	0 (0)	4	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.075		--		0.018
2014						
Heterosexual	50	29 (58)	12	6 (50)	62	35 (56)
Bisexual	2	0 (0)	1	0 (0)	3	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.191		1.000		0.093
2015						
Heterosexual	31	19 (61)	7	5 (71)	38	24 (63)
Bisexual	0	0 (0)	2	1 (50)	2	1 (50)
Homosexual	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		1.000		1.000

Table 4.3.3 HCV antibody prevalence by age group, gender and survey year

Northern Territory Age group	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
<25 years	1	1 (100)	2	0 (0)	3	1 (33)
25-34 years	9	3 (33)	7	4 (57)	16	7 (44)
35-44 years	15	7 (73)	9	3 (33)	24	10 (42)
45+ years	15	11 (73)	3	3 (100)	18	14 (78)
p value		0.141		0.138		0.063
2012						
<25 years	2	1 (50)	0	0 (0)	2	1 (50)
25-34 years	5	0 (0)	6	2 (33)	11	2 (18)
35-44 years	16	6 (38)	5	2 (40)	21	8 (38)
45+ years	7	4 (57)	4	1 (25)	11	5 (45)
p value		0.228		1.000		0.521
2013						
<25 years	1	0 (0)	1	0 (0)	2	0 (0)
25-34 years	9	4 (44)	3	0 (0)	12	4 (33)
35-44 years	17	8 (47)	8	7 (88)	25	15 (60)
45+ years	19	9 (47)	7	5 (71)	26	14 (54)
p value		1.000		0.026		0.237
2014						
<25 years	1	0 (0)	2	1 (50)	3	1 (33)
25-34 years	10	4 (40)	3	2 (67)	13	6 (46)
35-44 years	20	11 (55)	5	3 (60)	25	14 (56)
45+ years	22	15 (68)	6	2 (33)	28	17 (61)
p value		0.311		0.814		0.722
2015						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	11	3 (27)	1	0 (0)	12	3 (25)
35-44 years	11	10 (91)	5	3 (60)	16	13 (81)
45+ years	9	6 (67)	6	4 (67)	15	10 (67)
p value		0.010		0.747		0.008

Table 4.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Northern Territory Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
<3 years	5	1 (20)	1	0 (0)	6	1 (17)
3 to 10 years	3	3 (100)	4	3 (75)	7	6 (86)
11+years	30	16 (53)	15	6 (40)	45	22 (49)
p value		0.117		0.285		0.050
2012						
<3 years	2	0 (0)	1	0 (0)	3	0 (0)
3 to 10 years	3	1 (33)	0	0 (0)	3	1 (33)
11+years	24	10 (42)	12	4 (33)	37	14 (38)
p value		0.773		1.000		0.788
2013						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	6	0 (0)	3	0 (0)	9	0 (0)
11+years	39	20 (51)	15	12 (80)	54	32 (59)
p value		0.027		0.025		0.001
2014						
<3 years	1	0 (0)	3	0 (0)	4	0 (0)
3 to 10 years	6	3 (50)	2	2 (100)	8	5 (63)
11+years	45	27 (60)	11	6 (55)	56	33 (59)
p value		0.509		0.097		0.070
2015						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	8	3 (38)	0	0 (0)	8	3 (38)
11+years	26	16 (70)	9	5 (56)	32	21 (66)
p value		0.206		1.000		0.158

Table 4.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Northern Territory Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No receptive sharing	4	0 (0)	35	19 (54)	41	21 (51)
Receptive sharing	1	1 (100)	8	2 (25)	9	3 (33)
p value		0.200		0.240		0.467
2012						
No receptive sharing	1	0 (0)	32	13 (41)	35	13 (37)
Receptive sharing	0	0 (0)	5	2 (40)	6	3 (50)
p value		--		1.000		0.662
2013						
No receptive sharing	0	0 (0)	49	27 (55)	50	28 (56)
Receptive sharing	0	0 (0)	6	4 (67)	6	4 (67)
p value		--		0.686		0.691
2014						
No receptive sharing	3	0 (0)	57	34 (60)	61	34 (56)
Receptive sharing	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		1.000		0.628
2015						
No receptive sharing	1	0 (0)	36	23 (64)	39	25 (64)
Receptive sharing	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.149		0.146

Table 4.3.6 HCV antibody prevalence by last drug injected, years since first injection, and survey year

Northern Territory Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Methamphetamine	2	0 (0)	13	5 (38)	15	5 (33)
Pharm. Opioids	1	0 (0)	33	21 (63)	36	23 (64)
OST*	1	1 (100)	3	2 (67)	4	3 (75)
Other drugs	2	0 (0)	3	0 (0)	6	1 (17)
p value		0.112		0.102		0.046
2012						
Methamphetamine	1	0 (0)	5	1 (20)	7	2 (29)
Pharm. Opioids	1	0 (0)	30	12 (40)	33	12 (36)
OST	0	0 (0)	2	1 (50)	2	1 (50)
Other drugs	1	0 (0)	3	1 (33)	4	1 (25)
p value		--		0.828		0.913
2013						
Methamphetamine	0	0 (0)	6	2 (33)	6	2 (33)
Pharm. Opioids	0	0 (0)	43	24 (56)	43	24 (56)
OST*	0	0 (0)	2	2 (100)	2	2 (100)
Other drugs	0	0 (0)	12	4 (33)	14	5 (36)
p value		--		0.206		0.224
2014						
Methamphetamine	3	0 (0)	16	8 (50)	19	8 (42)
Pharm. Opioids	0	0 (0)	33	25 (76)	34	25 (74)
OST*	1	0 (0)	7	2 (29)	8	2 (25)
Other drugs	0	0 (0)	8	3 (38)	8	3 (38)
p value		--		0.035		0.019
2015						
Methamphetamine	1	0 (0)	14	6 (43)	15	6 (40)
Pharm. Opioids	0	0 (0)	15	10 (67)	17	12 (71)
OST*	0	0 (0)	10	7 (70)	10	7 (70)
Other drugs	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		0.380		0.222

*OST = methadone, buprenorphine & burpenorphine/naloxone

Table 4.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Northern Territory Frequency of injection last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Less than daily	3	0 (0)	10	3 (30)	13	3 (28)
Daily or more	2	1 (50)	36	21 (58)	40	24 (60)
Not last month	1	0 (0)	6	4 (67)	8	5 (63)
p value		0.500		0.239		0.062
2012						
Less than daily	0	0 (0)	12	6 (50)	12	6 (50)
Daily or more	1	0 (0)	25	9 (36)	29	10 (34)
Not last month	2	0 (0)	3	0 (0)	5	0 (0)
p value		--		0.299		0.170
2013						
Less than daily	0	0 (0)	20	14 (70)	20	14 (70)
Daily or more	0	0 (0)	36	17 (47)	37	18 (49)
Not last month	0	0 (0)	7	1 (14)	8	1 (13)
p value		--		0.037		0.020
2014						
Less than daily	1	0 (0)	17	11 (65)	18	11 (61)
Daily or more	2	0 (0)	44	26 (59)	47	26 (55)
Not last month	1	0 (0)	2	1 (50)	3	1 (33)
p value		--		0.891		0.677
2015						
Less than daily	1	0 (0)	8	5 (63)	11	7 (64)
Daily or more	0	0 (0)	30	18 (60)	30	18 (60)
Not last month	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000

Table 4.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Northern Territory Imprisonment last year	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No imprisonment	5	0 (0)	49	26 (53)	57	29 (51)
Imprisonment	1	1 (100)	2	1 (50)	3	2 (67)
p value		0.167		1.000		1.000
2012						
No imprisonment	3	0 (0)	35	13 (37)	41	14 (34)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		0.631		0.608
2013						
No imprisonment	0	0 (0)	55	25 (45)	57	26 (46)
Imprisonment	0	0 (0)	7	7 (100)	7	7 (100)
p value		--		0.011		0.011
2014						
No imprisonment	2	0 (0)	59	36 (61)	62	36 (58)
Imprisonment	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.164		0.187
2015						
No imprisonment	1	0 (0)	32	18 (56)	35	20 (57)
Imprisonment	0	0 (0)	5	4 (80)	5	5 (4)
p value		--		0.629		0.631

Table 4.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year

Northern Territory Sex work last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
No sex work	5	1 (20)	49	27 (55)	57	31 (54)
Sex work	1	0 (0)	3	1 (33)	4	1 (25)
p value		1.000		0.590		0.338
2012						
No sex work	3	0 (0)	36	14 (39)	42	15 (36)
Sex work	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		1.000		1.000
2013						
No sex work	0	0 (0)	58	29 (50)	60	30 (50)
Sex work	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.492		0.492
2014						
No sex work	4	0 (0)	58	36 (62)	63	36 (57)
Sex work	0	0 (0)	6	2 (33)	6	2 (33)
p value		--		0.213		0.397
2015						
No sex work	1	0 (0)	37	24 (65)	40	26 (65)
Sex work	0	0 (0)	2	0 (0)	2	2 (0)
p value		--		0.142		0.139

Table 4.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Northern Territory Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Non Indigenous	32	18 (56)	16	7 (44)	48	25 (52)
Indigenous	7	3 (43)	5	3 (60)	12	6 (50)
p value		0.682		0.635		1.000
2012						
Non Indigenous	26	9 (35)	10	3 (30)	36	12 (33)
Indigenous	4	2 (50)	4	1 (25)	9	3 (33)
p value		0.611		1.000		1.000
2013						
Non Indigenous	39	18 (46)	11	5 (45)	50	23 (46)
Indigenous	5	2 (40)	8	7 (88)	13	9 (69)
p value		1.000		0.147		0.213
2014						
Non Indigenous	44	24 (55)	11	5 (45)	55	29 (53)
Indigenous	9	6 (67)	4	2 (50)	13	8 (62)
p value		0.504		1.000		0.566
2015						
Non Indigenous	21	16 (76)	7	5 (71)	28	21 (75)
Indigenous	10	3 (30)	4	2 (50)	14	5 (36)
p value		0.021		0.576		0.020

Table 4.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Northern Territory Main language spoken at home by parents	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
English speaking	36	19 (53)	20	10 (50)	56	29 (52)
Non-English speaking	4	3 (75)	1	0 (0)	5	3 (60)
p value		0.613		1.000		1.000
2012						
English speaking	30	11 (37)	13	5 (38)	44	16 (36)
Non-English speaking	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.524		0.536
2013						
English speaking	44	20 (45)	19	12 (63)	63	32 (51)
Non-English speaking	2	1 (50)	0	0 (0)	2	1 (50)
p value		1.000		--		1.000
2014						
English speaking	49	27 (55)	16	8 (50)	65	35 (54)
Non-English speaking	4	3 (75)	0	0 (0)	4	3 (75)
p value		0.624		--		0.622
2015						
English speaking	30	18 (60)	11	6 (55)	41	24 (59)
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)
p value		1.000		--		1.000

Table 4.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Northern Territory		Male		Female		Total	
Region/Country of birth	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	
2011							
Australia	35	18 (51)	18	9 (50)	53	27 (50)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	2	0 (0)	2	2 (100)	
UK & Ireland	5	4 (80)	1	1 (100)	6	5 (83)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.355		0.476		0.111	
2012							
Australia	25	9 (36)	14	5 (36)	40	14 (35)	
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	2	1 (50)	0	0 (0)	2	1 (50)	
Other	2	1 (50)	1	0 (0)	3	1 (33)	
p value		1.000		1.000		1.000	
2013							
Australia	41	20 (49)	15	10 (67)	56	30 (54)	
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	3	1 (33)	2	2 (100)	5	3 (60)	
Other	1	0 (0)	2	0 (0)	3	0 (0)	
p value		1.000		0.237		0.196	
2014							
Australia	47	28 (60)	13	7 (54)	60	35 (58)	
Other Oceania	2	0 (0)	0	0 (0)	2	0 (0)	
Asia	1	1 (100)	0	0 (0)	1	1 (100)	
UK & Ireland	2	0 (0)	1	1 (100)	3	1 (33)	
Other	1	1 (100)	2	0 (0)	3	1 (33)	
p value		0.053		0.467		0.353	
2015							
Australia	28	17 (61)	10	6 (60)	38	23 (61)	
Other Oceania	2	1 (50)	0	0 (0)	2	1 (50)	
Asia	0	0 (0)	1	0 (0)	1	0 (0)	
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		1.000		0.455		0.828	

Queensland

Table 5.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Queensland	2011	2012	2013	2014	2015
Number of sites	8	8	8	7	8
N° surveyed	N=552	N=624	N=565	N=490	N=532
Response rate (%)	40%	45%	45%	51%	36%
Gender (%)					
Male	394 (71)	454 (73)	397 (70)	356 (73)	386 (73)
Female	154 (28)	168 (27)	167 (30)	133 (27)	144 (27)
Transgender	2 (<1)	1 (<1)	1 (<1)	1 (<1)	2 (<1)
Not reported	2 (<1)	1 (<1)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	467 (85)	529 (85)	471 (83)	398 (81)	453 (85)
Bisexual	44 (8)	49 (8)	42 (7)	36 (7)	41 (8)
Homosexual	20 (4)	18 (3)	19 (3)	22 (4)	19 (4)
Not reported	21 (4)	28 (4)	33 (6)	34 (7)	19 (4)
Aboriginal and Torres Strait Islander origin (%)					
No	481 (87)	537 (86)	493 (87)	428 (87)	459 (86)
Yes	55 (10)	78 (13)	58 (10)	49 (10)	67 (13)
Not reported	16 (3)	9 (1)	14 (2)	13 (3)	6 (1)
Region/country of birth (%)					
Australia	465 (84)	549 (88)	504 (89)	421 (86)	467 (88)
Other Oceania	29 (5)	35 (6)	29 (5)	30 (6)	24 (5)
Asia	4 (1)	1 (<1)	0 (0)	2 (<1)	5 (1)
UK & Ireland	22 (4)	22 (4)	13 (2)	15 (3)	17 (3)
Other	22 (4)	14 (2)	17 (3)	17 (3)	9 (2)
Not reported	10 (2)	3 (<1)	2 (<1)	5 (1)	10 (2)
Main language spoken at home by parents (%)					
English	530 (96)	606 (97)	544 (96)	468 (96)	515 (97)
Non-English	15 (3)	16 (3)	19 (3)	17 (3)	9 (2)
Not reported	7 (1)	2 (<1)	2 (<1)	5 (1)	8 (2)
Age and time since first injection (years)					
<i>Median age</i>	35	36	37	37	38
<i>Age range</i>	17-62	16-71	16-65	14-64	16-62
<i>Age group (%)</i>					
<25 years	59 (11)	73 (12)	68 (12)	52 (11)	44 (8)
25+ years	492 (89)	551 (88)	495 (88)	436 (89)	487 (92)
Not reported	1 (<1)	0 (0)	2 (<1)	2 (<1)	1 (<1)
<i>Median age first injection</i>					
	18	18	19	19	19
<i>Age range</i>					
	11-56	10-70	11-61	10-49	11-50
<i>N° not reported</i>					
	12	15	15	15	13
<i>Median yrs since first injection</i>					
	15	16	15	16	17
<i>Range</i>					
	<1-47	<1-53	<1-46	<1-47	<1-44
<i>Years since first injection</i>					
<3 years	55 (10)	71 (11)	68 (12)	55 (11)	46 (9)
3+ years	486 (88)	538 (86)	482 (85)	420 (86)	472 (89)
Not reported	11 (2)	15 (2)	15 (3)	15 (3)	14 (3)
Imprisonment last year (%)					
No	474 (86)	543 (88)	497 (88)	415 (85)	468 (88)
Yes	49 (9)	64 (10)	45 (8)	48 (10)	43 (8)
Not reported	29 (5)	17 (3)	23 (4)	27 (6)	21 (4)
N° in prison					
	N=49	N=64	N=45	N=48	N=43
Injected in prison	26 (53)	30 (47)	17 (38)	18 (38)	22 (51)

Table 5.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Queensland N° surveyed	2011 N=552	2012 N=624	2013 N=565	2014 N=490	2015 N=532
Drug last injected (%)					
Cocaine	6 (1)	3 (<1)	3 (<1)	3 (<1)	5 (1)
Methamphetamine	162 (29)	165 (26)	162 (29)	155 (31)	183 (34)
Heroin	112 (20)	129 (21)	91 (16)	75 (15)	107 (20)
Pharm. opioids	130 (24)	124 (20)	117 (21)	94 (19)	92 (17)
Methadone	22 (4)	45 (7)	36 (6)	22 (4)	31 (6)
Buprenorphine	39 (7)	41 (7)	32 (6)	20 (4)	21 (4)
Buprenorphine/naloxone	10 (2)	17 (3)	16 (3)	14 (3)	6 (1)
PIEDs	41 (7)	70 (11)	71 (13)	71 (14)	62 (12)
More than one	24 (4)	20 (3)	35 (6)	16 (3)	18 (3)
Other	6 (1)	8 (1)	1 (<1)	16 (3)	7 (1)
Not reported	0 (0)	2 (<1)	1 (<1)	4 (<1)	0 (0)
Frequency of injection last month (%)					
Not last month	51 (9)	67 (11)	41 (7)	47 (10)	54 (10)
Less than weekly	99 (18)	112 (18)	107 (19)	64 (13)	92 (17)
Weekly not daily	136 (25)	133 (21)	153 (27)	134 (27)	114 (21)
Daily or more	260 (47)	305 (49)	254 (45)	238 (49)	268 (50)
Not reported	6 (1)	7 (1)	10 (2)	7 (1)	4 (1)
Present when someone injected for the first time in the last 12 months (%)					
Yes	--	105 (17)	82 (15)	88 (18)	80 (15)
No	--	456 (73)	428 (76)	392 (80)	442 (83)
Not reported	--	63 (10)	55 (10)	10 (2)	10 (2)
Overdosed in last 12 months					
Yes	--	--	65 (12)	65 (13)	67 (13)
No	--	--	493 (87)	415 (85)	458 (86)
Not reported	--	--	7 (1)	10 (2)	7 (1)

Table 5.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Queensland N° injected last month	2011 N=495	2012 N=550	2013 N=514	2014 N=436	2015 N=474
Places injected last month (%)					
Any public	174 (35)	193 (35)	163 (32)	140 (32)	146 (31)
All private	303 (61)	347 (63)	347 (68)	294 (67)	326 (69)
Not reported	18 (4)	10 (2)	4 (1)	2 (<1)	2 (<1)
Use of new and sterile needles and syringes last month (%)					
All injections	368 (74)	426 (77)	391 (76)	340 (78)	350 (74)
Most of the time	92 (19)	85 (15)	101 (20)	84 (19)	98 (21)
Half of the time	12 (2)	12 (2)	12 (2)	3 (1)	14 (3)
Some of the time	6 (1)	2 (<1)	5 (1)	3 (1)	2 (<1)
Not last month	2 (<1)	4 (<1)	1 (<1)	0 (0)	3 (1)
Not reported	15 (3)	21 (4)	4 (1)	6 (1)	7 (1)
Re-used someone else's used needle & syringe last month (%)					
None	379 (77)	463 (84)	437 (85)	361 (83)	400 (84)
Once	29 (6)	31 (6)	21 (4)	24 (6)	26 (5)
Twice	15 (3)	12 (2)	18 (4)	18 (4)	10 (2)
3-5 times	19 (4)	12 (2)	13 (3)	15 (3)	18 (4)
>5 times	18 (4)	21 (4)	19 (4)	11 (3)	17 (4)
Not reported	35 (7)	11 (2)	6 (1)	7 (2)	3 (1)
Number of people needle & syringe was re-used after last month (%)					
None	379 (77)	463 (84)	437 (85)	361 (83)	400 (84)
One	43 (9)	36 (7)	39 (8)	27 (6)	33 (7)
Two	6 (1)	4 (<1)	7 (1)	6 (1)	5 (1)
Three to five	3 (<1)	1 (<1)	3 (<1)	4 (1)	6 (1)
More than five	4 (1)	6 (1)	2 (<1)	2 (<1)	3 (1)
Don't know	9 (2)	10 (2)	15 (3)	13 (3)	14 (3)
Not reported	51 (10)	30 (5)	11 (2)	23 (5)	13 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	45 (9)	27 (5)	33 (6)	27 (6)	25 (5)
Casual sex partner	2 (<1)	1 (<1)	4 (1)	0 (0)	3 (1)
Close friend	28 (6)	19 (3)	20 (4)	10 (2)	21 (4)
Acquaintance	11 (2)	8 (1)	12 (2)	5 (1)	9 (2)
Other	10 (2)	7 (1)	6 (1)	3 (1)	10 (2)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	111 (22)	114 (21)	104 (20)	75 (17)	97 (20)
Water	77 (16)	73 (13)	85 (17)	82 (19)	82 (17)
Filter	54 (11)	58 (11)	55 (11)	36 (8)	53 (11)
Drug mix	42 (8)	51 (9)	45 (9)	38 (9)	46 (10)
None	318 (64)	387 (70)	379 (74)	305 (70)	332 (70)
Injected by someone after that person injected themselves or others last month (%)					
No	404 (82)	466 (85)	438 (85)	351 (81)	404 (85)
Yes	69 (14)	73 (13)	65 (13)	72 (17)	68 (14)
Not reported	22 (4)	11 (2)	11 (2)	13 (3)	2 (<1)
Source of needle acquisition					
Needle Syringe Program	444 (90)	500 (91)	487 (95)	394 (90)	437 (92)
Chemist/Pharmacy	118 (24)	159 (29)	109 (21)	107 (25)	122 (26)
Personal sources	38 (7)	50 (9)	34 (7)	36 (8)	38 (8)
Dispensing/Vending Machine	72 (15)	78 (14)	52 (10)	38 (9)	70 (15)
Other sources	5 (1)	6 (1)	3 (1)	6 (1)	9 (2)

Table 5.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Queensland N° surveyed	2011 N=552	2012 N=624	2013 N=565	2014 N=490	2015 N=532
Ever any treatment/therapy for drug use (%)					
No	152 (28)	176 (28)	188 (33)	168 (34)	171 (32)
Yes	380 (69)	442 (71)	373 (66)	308 (63)	351 (66)
Not reported	20 (4)	6 (1)	4 (1)	14 (3)	10 (2)
History of methadone maintenance treatment (%)					
Currently	92 (17)	106 (17)	95 (17)	80 (16)	79 (15)
Previously	121 (22)	151 (24)	114 (20)	94 (19)	117 (22)
Never	322 (58)	362 (58)	354 (63)	303 (62)	329 (62)
Not reported	17 (3)	5 (1)	2 (1)	13 (3)	7 (1)
History of buprenorphine (Subutex®) treatment (%)					
Currently	67 (12)	74 (12)	51 (9)	48 (10)	41 (8)
Previously	120 (22)	144 (23)	149 (26)	100 (20)	144 (27)
Never	343 (62)	401 (64)	358 (63)	330 (67)	340 (64)
Not reported	22 (4)	5 (1)	7 (1)	12 (2)	7 (1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	46 (8)	60 (10)	56 (10)	35 (7)	42 (8)
Previously	110 (20)	132 (21)	110 (19)	99 (20)	119 (22)
Never	376 (68)	427 (68)	389 (70)	340 (69)	362 (68)
Not reported	20 (4)	5 (1)	10 (2)	16 (3)	9 (2)

Table 5.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Queensland N° surveyed	2011 N=552	2012 N=624	2013 N=565	2014 N=490	2015 N=532
Previous HIV test (%)					
Yes, ever	474 (86)	517 (83)	477 (84)	408 (83)	437 (82)
Yes, last year	281 (51)	291 (47)	277 (49)	253 (52)	250 (47)
>1 year ago	193 (35)	226 (36)	200 (35)	155 (32)	187 (35)
Never tested	63 (11)	87 (14)	82 (15)	68 (14)	82 (15)
Not reported	15 (3)	20 (3)	6 (1)	14 (3)	13 (2)
Previous HCV test (%)					
Yes, ever	472 (86)	533 (85)	466 (82)	414 (84)	449 (84)
Yes, last year	290 (53)	328 (53)	269 (48)	273 (56)	279 (52)
>1 year ago	182 (33)	205 (33)	197 (35)	141 (29)	170 (32)
Never tested	47 (9)	60 (10)	56 (10)	52 (11)	64 (12)
Not reported	33 (6)	31 (5)	43 (8)	24 (5)	19 (4)
Lifetime treatment for HCV (%)					
N° self-reported chronic HCV#					
Antiviral treatment	8 (6)	13 (7)	18 (13)	13 (13)	10 (10)
No antiviral treatment	113 (90)	170 (92)	119 (85)	84 (82)	81 (84)
Not reported	4 (3)	2 (1)	3 (2)	5 (5)	6 (6)
Treatment for HCV in past 12 months (%)					
N° self-reported chronic HCV#					
Antiviral treatment	2 (2)	4 (2)	6 (5)	2 (2)	1 (1)
No antiviral treatment	115 (96)	173 (98)	121 (91)	84 (94)	81 (93)
Not reported	3 (3)	0 (0)	6 (5)	3 (3)	5 (6)

among people who tested HCV antibody positive

* includes people who reported treatment induced clearance

Table 5.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Queensland N° surveyed	2011 N=552	2012 N=624	2013 N=565	2014 N=490	2015 N=532
Sex with a regular partner last month (%)					
No	250 (45)	280 (45)	255 (45)	229 (47)	239 (45)
Yes	280 (51)	334 (54)	304 (54)	250 (51)	274 (52)
Not reported	22 (4)	10 (2)	6 (1)	11 (2)	19 (4)
Condom used with regular partner last month (%)					
N° surveyed	N=280	N=334	N=304	N=250	N=274
Never	199 (71)	256 (77)	221 (73)	174 (70)	212 (77)
Sometimes	34 (12)	39 (12)	40 (13)	39 (16)	30 (11)
Every time	30 (11)	31 (9)	27 (9)	25 (10)	26 (9)
Not reported	17 (6)	8 (2)	16 (5)	12 (5)	6 (2)
Sex with other partner(s) last month (%)					
No	449 (81)	526 (84)	461 (82)	398 (81)	440 (83)
Yes	81 (15)	77 (12)	83 (15)	74 (15)	79 (15)
Not reported	22 (4)	21 (3)	21 (4)	18 (4)	13 (2)
Condom used with other partner(s) last month (%)					
N° surveyed	N=81	N=77	N=83	N=74	N=79
Never	30 (37)	24 (31)	26 (31)	23 (31)	26 (33)
Sometimes	20 (25)	20 (26)	22 (37)	25 (34)	25 (32)
Every time	24 (30)	23 (30)	34 (41)	13 (18)	24 (30)
Not reported	7 (9)	10 (13)	1 (1)	13 (18)	4 (5)
Sex work last month (%)					
No	509 (92)	593 (95)	525 (93)	439 (90)	508 (95)
Yes	19 (3)	17 (3)	9 (2)	19 (4)	14 (3)
Not reported	24 (4)	14 (2)	31 (5)	32 (7)	10 (2)
Condom used at last sex work (%)					
Yes	12 (63)	13 (76)	6 (67)	10 (53)	9 (64)

HIV antibody prevalence

Table 5.2.1 HIV antibody prevalence by gender and survey year

Queensland Survey year	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011	376	8 (2.1)	148	0 (0.0)	528	8 (1.5)
2012	415	7 (1.7)	153	2 (1.3)	570	9 (1.6)
2013	372	7 (1.9)	160	0 (0.0)	533	7 (1.3)
2014	349	11 (3.2)	131	0 (0.0)	481	11 (2.3)
2015	382	6 (1.6)	144	0 (0.0)	528	7 (1.3)
X ² p trend p value		0.901		0.334		0.878

Table 5.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Queensland Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
Heterosexual	340	2 (0.6)	109	0 (0.0)	451	2 (0.4)
Bisexual	13	0 (0.0)	29	0 (0.0)	43	0 (0.0)
Homosexual	11	6 (54.6)	6	0 (0.0)	17	6 (35.3)
p value		<0.001		---		<0.001
2012						
Heterosexual	368	1 (0.3)	112	2 (1.8)	480	3 (0.6)
Bisexual	20	2 (10.0)	27	0 (0.0)	48	2 (4.2)
Homosexual	11	2 (18.2)	6	0 (0.0)	17	2 (11.8)
p value		<0.001		1.000		0.002
2013						
Heterosexual	322	1 (0.3)	119	0 (0.0)	442	1 (0.2)
Bisexual	13	1 (7.7)	28	0 (0.0)	41	1 (2.4)
Homosexual	17	5 (29.4)	2	0 (0.0)	19	5 (26.3)
p value		<0.001		--		<0.001
2014						
Heterosexual	297	1 (0.3)	95	0 (0.0)	392	1 (0.3)
Bisexual	11	1 (9.1)	24	0 (0.0)	35	1 (2.9)
Homosexual	17	8 (47.1)	3	0 (0.0)	20	8 (40.0)
p value		<0.001		--		<0.001
2015						
Heterosexual	339	1 (0.3)	111	0 (0.0)	450	1 (0.2)
Bisexual	18	1 (5.6)	22	0 (0.0)	41	1 (2.4)
Homosexual	14	4 (28.6)	5	0 (0.0)	19	4 (21.1)
p value		<0.001		--		<0.001

Table 5.2.3 HIV antibody prevalence by age group, gender and survey year

Queensland Age group	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
<25 years	45	0 (0.0)	9	0 (0.0)	56	0 (0.0)
25-34 years	129	0 (0.0)	67	0 (0.0)	197	0 (0.0)
35-44 years	122	4 (3.3)	45	0 (0.0)	168	4 (2.4)
45+ years	79	4 (5.1)	27	0 (0.0)	106	4 (3.8)
p value		0.033		--		0.022
2012						
<25 years	56	0 (0.0)	13	0 (0.0)	69	0 (0.0)
25-34 years	128	1 (0.8)	63	0 (0.0)	192	1 (0.5)
35-44 years	144	1 (0.7)	46	1 (2.2)	190	2 (1.0)
45+ years	87	5 (5.8)	31	1 (3.2)	119	6 (5.0)
p value		0.025		0.415		0.015
2013						
<25 years	43	0 (0.0)	20	0 (0.0)	63	0 (0.0)
25-34 years	111	0 (0.0)	49	0 (0.0)	160	0 (0.0)
35-44 years	106	5 (4.7)	52	0 (0.0)	158	5 (3.2)
45+ years	110	2 (1.8)	39	0 (0.0)	150	2 (1.3)
p value		0.074		--		0.084
2014						
<25 years	35	0 (0.0)	16	0 (0.0)	51	0 (0.0)
25-34 years	110	1 (0.9)	45	0 (0.0)	155	1 (0.7)
35-44 years	107	4 (3.7)	45	0 (0.0)	152	4 (2.6)
45+ years	95	6 (6.3)	25	0 (0.0)	121	6 (5.0)
p value		0.119		--		0.091
2015						
<25 years	32	0 (0.0)	12	0 (0.0)	44	0 (0.0)
25-34 years	120	2 (1.7)	44	0 (0.0)	165	3 (1.8)
35-44 years	135	1 (0.7)	47	0 (0.0)	182	1 (0.6)
45+ years	94	3 (3.2)	41	0 (0.0)	136	3 (2.2)
p value		0.489		--		0.529

Table 5.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Queensland Last drug injected	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
Heroin	75	0 (0.0)	32	0 (0.0)	107	0 (0.0)
Methamphetamine	102	4 (3.9)	54	0 (0.0)	156	4 (2.6)
Other opioids	141	4 (2.8)	49	0 (0.0)	193	4 (2.1)
PIEDs	36	0 (0.0)	3	0 (0.0)	39	0 (0.0)
Other drugs	22	0 (0.0)	10	0 (0.0)	33	0 (0.0)
p value		0.420		--		0.491
2012						
Heroin	70	0 (0.0)	48	1 (2.1)	118	1 (0.9)
Methamphetamine	103	2 (1.9)	46	0 (0.0)	149	2 (1.3)
Other opioids	158	5 (3.2)	50	1 (2.0)	209	6 (2.9)
PIEDs	59	0 (0.0)	3	0 (0.0)	62	0 (0.0)
Other drugs	23	0 (0.0)	6	0 (0.0)	30	0 (0.0)
p value		0.522		1.000		0.601
2013						
Heroin	58	0 (0.0)	30	0 (0.0)	88	0 (0.0)
Methamphetamine	91	6 (6.6)	62	0 (0.0)	153	6 (3.9)
Other opioids	133	1 (0.8)	60	0 (0.0)	194	1 (0.5)
PIEDs	60	0 (0.0)	0	0 (0.0)	60	0 (0.0)
Other drugs	29	0 (0.0)	8	0 (0.0)	37	0 (0.0)
p value		0.020		--		0.065
2014						
Heroin	53	1 (1.9)	21	0 (0.0)	74	1 (1.4)
Methamphetamine	98	8 (8.2)	54	0 (0.0)	152	8 (5.3)
Other opioids	103	1 (1.0)	44	0 (0.0)	148	1 (0.7)
PIEDs	67	1 (1.5)	3	0 (0.0)	70	1 (1.4)
Other drugs	25	0 (0.0)	9	0 (0.0)	34	0 (0.0)
p value		0.051		--		0.106
2015						
Heroin	76	1 (1.3)	31	0 (0.0)	107	1 (0.9)
Methamphetamine	120	5 (4.2)	60	0 (0.0)	182	6 (3.3)
Other opioids	107	0 (0.0)	42	0 (0.0)	149	0 (0.0)
PIEDs	61	0 (0.0)	1	0 (0.0)	62	0 (0.0)
Other drugs	18	0 (0.0)	10	0 (0.0)	28	0 (0.0)
p value		0.126		--		0.108

Table 5.2.5 HIV antibody prevalence by years of injection, gender and survey year

Queensland Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
<3 years	41	1 (2.4)	12	0 (0.0)	84	1 (1.9)
3 to 10 years	71	1 (1.4)	36	0 (0.0)	108	1 (0.9)
11 + years	254	6 (2.4)	99	0 (0.0)	355	6 (1.7)
p value		1.000		---		1.000
2012						
<3 years	52	0 (0.0)	11	0 (0.0)	63	0 (0.0)
3 to 10 years	77	1 (1.3)	31	0 (0.0)	108	1 (0.9)
11 + years	275	6 (2.2)	109	2 (1.8)	386	8 (2.1)
p value		0.847		1.000		0.653
2013						
<3 years	51	1 (2.0)	10	0 (0.0)	61	1 (1.6)
3 to 10 years	74	1 (1.4)	34	0 (0.0)	108	1 (0.9)
11 + years	237	5 (2.1)	113	0 (0.0)	351	5 (1.4)
p value		1.000		--		1.000
2014						
<3 years	39	2 (5.1)	15	0 (0.0)	54	2 (3.7)
3 to 10 years	59	1 (1.7)	27	0 (0.0)	86	1 (1.2)
11 + years	238	8 (3.4)	88	0 (0.0)	327	8 (2.5)
p value		0.555		--		0.559
2015						
<3 years	41	1 (2.4)	4	0 (0.0)	45	1 (2.2)
3 to 10 years	81	2 (2.5)	28	0 (0.0)	110	2 (1.8)
11 + years	250	3 (1.2)	108	0 (0.0)	359	4 (1.1)
p value		0.526		--		0.533

Table 5.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Queensland Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No receptive sharing	260	6 (2.3)	101	0 (0.0)	363	6 (1.7)
Receptive sharing	48	0 (0.0)	28	0 (0.0)	77	0 (0.0)
p value		0.595		---		0.596
2012						
No receptive sharing	307	6 (2.0)	115	2 (1.7)	422	8 (1.9)
Receptive sharing	52	0 (0.0)	19	0 (0.0)	71	0 (0.0)
p value		0.599		1.000		0.609
2013						
No receptive sharing	289	2 (0.7)	124	0 (0.0)	414	2 (0.5)
Receptive sharing	45	2 (4.4)	26	0 (0.0)	71	2 (2.8)
p value		0.089		--		0.104
2014						
No receptive sharing	258	8 (3.1)	96	0 (0.0)	355	8 (2.3)
Receptive sharing	46	0 (0.0)	22	0 (0.0)	68	0 (0.0)
p value		0.612		--		0.365
2015						
No receptive sharing	284	5 (1.8)	110	0 (0.0)	396	6 (1.5)
Receptive sharing	49	1 (2.0)	22	0 (0.0)	71	1 (1.4)
p value		1.000		--		1.000

Table 5.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Queensland Frequency of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
Less than daily	162	4 (2.5)	61	0 (0.0)	224	4 (1.8)
Daily or more	169	2 (1.2)	76	0 (0.0)	247	2 (0.8)
Not last month	41	2 (4.9)	10	0 (0.0)	51	2 (3.9)
p value		0.196		---		0.176
2012						
Less than daily	163	2 (1.2)	60	0 (0.0)	224	2 (0.9)
Daily or more	201	4 (2.0)	78	2 (2.6)	279	6 (2.2)
Not last month	47	1 (2.1)	14	0 (0.0)	61	1 (1.6)
p value		0.756		0.592		0.484
2013						
Less than daily	173	3 (1.7)	75	0 (0.0)	249	3 (1.2)
Daily or more	164	2 (1.2)	78	0 (0.0)	242	2 (0.8)
Not last month	27	1 (3.7)	6	0 (0.0)	33	1 (3.0)
p value		0.508		--		0.470
2014						
Less than daily	144	5 (3.5)	53	0 (0.0)	197	5 (2.5)
Daily or more	162	3 (1.9)	69	0 (0.0)	232	3 (1.3)
Not last month	38	3 (7.9)	7	0 (0.0)	45	3 (6.7)
p value		0.139		--		0.090
2015						
Less than daily	154	3 (2.0)	48	0 (0.0)	204	4 (2.0)
Daily or more	182	3 (1.7)	84	0 (0.0)	266	3 (1.1)
Not last month	43	0 (0.0)	11	0 (0.0)	54	0 (0.0)
p value		1.000		--		0.532

Table 5.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Queensland Imprisonment last year	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No imprisonment	325	8 (2.5)	135	0 (0.0)	463	8 (1.7)
Imprisonment	40	0 (0.0)	8	0 (0.0)	48	0 (0.0)
p value		0.606		---		1.000
2012						
No imprisonment	350	6 (1.7)	141	2 (1.4)	493	8 (1.6)
Imprisonment	52	1 (1.9)	9	0 (0.0)	61	1 (1.6)
p value		1.000		1.000		1.000
2013						
No imprisonment	319	7 (2.2)	150	0 (0.0)	470	7 (1.5)
Imprisonment	37	0 (0.0)	6	0 (0.0)	43	0 (0.0)
p value		1.000		--		1.000
2014						
No imprisonment	289	7 (2.4)	118	0 (0.0)	407	7 (1.7)
Imprisonment	38	0 (0.0)	10	0 (0.0)	48	0 (0)
p value		1.000		--		1.000
2015						
No imprisonment	334	6 (1.8)	129	0 (0.0)	465	7 (1.5)
Imprisonment	30	0 (0.0)	12	0 (0.0)	42	0 (0.0)
p value		1.000		--		1.000

Table 5.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Queensland	Male		Female		Total	
Condom use at last sex	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No condom use	121	2 (1.7)	70	0 (0.0)	192	2 (1.0)
Condom use	44	1 (2.3)	14	0 (0.0)	59	1 (1.7)
p value		1.000		---		0.554
2012						
No condom use	155	0 (0.0)	73	0 (0.0)	229	0 (0.0)
Condom use	48	3 (6.3)	18	1 (5.6)	66	4 (6.1)
p value		0.013		0.198		0.002
2013						
No condom use	132	2 (1.5)	76	0 (0.0)	208	2 (1.0)
Condom use	47	3 (6.4)	15	0 (0.0)	62	3 (4.8)
p value		0.114		--		0.081
2014						
No condom use	121	4 (3.3)	48	0 (0.0)	170	4 (2.4)
Condom use	48	2 (4.2)	16	0 (0.0)	64	2 (3.1)
p value		1.000		--		0.666
2015						
No condom use	140	2 (1.4)	70	0 (0.0)	211	3 (1.4)
Condom use	41	0 (0.0)	14	0 (0.0)	55	0 (0.0)
p value		1.000		--		1.000

Table 5.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Queensland	Male		Female		Total	
Sex work last month	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No sex work	355	7 (2.0)	135	0 (0.0)	492	7 (1.4)
Sex work	4	0 (0.0)	11	0 (0.0)	16	0 (0.0)
p value		1.000		---		1.000
2012						
No sex work	399	7 (1.8)	141	1 (0.7)	542	8 (1.5)
Sex work	4	0 (0.0)	11	1 (9.1)	15	1 (6.7)
p value		1.000		0.140		0.219
2013						
No sex work	346	7 (2.0)	148	0 (0.0)	495	7 (1.4)
Sex work	3	0 (0.0)	5	0 (0.0)	8	0 (0.0)
p value		1.000		--		1.000
2014						
No sex work	312	7 (2.2)	118	0 (0.0)	431	7 (1.6)
Sex work	13	2 (15.4)	6	0 (0.0)	19	2 (10.5)
p value		0.045		--		0.051
2015						
No sex work	368	5 (1.4)	135	0 (0.0)	505	6 (1.2)
Sex work	5	1 (20)	9	0 (0.0)	14	1 (7.1)
p value		0.078		--		0.175

Table 5.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Queensland Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Non Indigenous	329	8 (2.4)	128	0 (0.0)	460	8 (1.8)
Indigenous	36	0 (0.0)	18	0 (0.0)	54	0 (0.0)
p value		1.000		---		1.000
2012						
Non Indigenous	357	7 (2.0)	128	1 (0.8)	487	8 (1.6)
Indigenous	52	0 (0.0)	22	0 (0.0)	74	0 (0.0)
p value		0.603		1.000		0.605
2013						
Non Indigenous	330	7 (2.1)	135	0 (0.0)	466	7 (1.5)
Indigenous	33	0 (0.0)	21	0 (0.0)	54	0 (0.0)
p value		1.000		--		1.000
2014						
Non Indigenous	311	10 (3.2)	108	0 (0.0)	420	10 (2.4)
Indigenous	30	0 (0.0)	19	0 (0.0)	49	0 (0.0)
p value		1.000		--		0.609
2015						
Non Indigenous	337	6 (1.8)	118	0 (0.0)	457	7 (1.5)
Indigenous	41	0 (0.0)	21	0 (0.0)	65	0 (0.0)
p value		1.000		--		0.605

Table 5.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Queensland Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
English speaking	360	8 (2.2)	145	0 (0.0)	509	8 (1.6)
Non-English speaking	11	0 (0.0)	3	0 (0.0)	14	0 (0.0)
p value		1.000		---		1.000
2012						
English speaking	405	5 (1.2)	148	2 (1.4)	554	7 (1.3)
Non-English speaking	9	2 (22.2)	4	0 (0.0)	14	2 (14.3)
p value		0.008		1.000		0.018
2013						
English speaking	362	7 (1.9)	154	0 (0.0)	517	7 (1.4)
Non-English speaking	8	0 (0.0)	6	0 (0.0)	14	0 (0.0)
p value		1.000		--		1.000
2014						
English speaking	334	10 (3.0)	125	0 (0.0)	460	10 (2.2)
Non-English speaking	12	1 (8.3)	5	0 (0.0)	17	1 (5.9)
p value		0.326		--		0.332
2015						
English speaking	367	6 (1.6)	142	0 (0.0)	511	7 (1.4)
Non-English speaking	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)
p value		1.000		--		1.000

Table 5.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Queensland						
Region/country of birth	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Australia	316	8 (2.5)	126	0 (0.0)	446	8 (1.8)
Other Oceania	18	0 (0.0)	11	0 (0.0)	29	0 (0.0)
Asia	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)
UK & Ireland	15	0 (0.0)	6	0 (0.0)	21	0 (0.0)
Other	18	0 (0.0)	2	0 (0.0)	20	0 (0.0)
p value		1.000		---		1.000
2012						
Australia	369	5 (1.4)	134	2 (1.5)	505	7 (1.4)
Other Oceania	19	0 (0.0)	12	0 (0.0)	31	0 (0.0)
Asia	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
UK & Ireland	14	1 (7.1)	5	0 (0.0)	19	1 (5.3)
Other	9	1 (11.1)	2	0 (0.0)	11	1 (9.1)
p value		0.080		1.000		0.122
2013						
Australia	334	6 (1.8)	141	0 (0.0)	476	6 (1.3)
Other Oceania	21	1 (4.8)	7	0 (0.0)	28	1 (3.6)
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
UK & Ireland	8	0 (0.0)	4	0 (0.0)	12	0 (0.0)
Other	8	0 (0.0)	7	0 (0.0)	15	0 (0.0)
p value		0.739		--		0.690
2014						
Australia	298	9 (3.0)	116	0 (0.0)	415	9 (2.2)
Other Oceania	21	1 (4.8)	7	0 (0.0)	28	1 (3.6)
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
UK & Ireland	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)
Other	14	1 (7.1)	3	0 (0.0)	17	1 (5.9)
p value		0.480		--		0.441
2015						
Australia	333	6 (1.8)	129	0 (0.0)	464	7 (1.5)
Other Oceania	18	0 (0.0)	6	0 (0.0)	24	0 (0.0)
Asia	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
UK & Ireland	10	0 (0.0)	6	0 (0.0)	16	0 (0.0)
Other	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)
p value		1.000		--		1.000

HCV ANTIBODY PREVALENCE

Table 5.3.1 HCV antibody prevalence by gender and survey year

Queensland Survey year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011	368	158 (43)	146	63 (43)	518	221 (43)
2012	409	183 (45)	154	83 (54)	565	267 (47)
2013	372	167 (45)	160	79 (49)	533	247 (46)
2014	327	120 (37)	123	49 (40)	451	169 (37)
2015	379	161 (42)	139	64 (46)	520	226 (43)
X ² p trend value		0.507		0.724		0.482

Table 5.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Queensland Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Heterosexual	334	145 (43)	107	45 (42)	443	190 (43)
Bisexual	12	4 (33)	28	13 (46)	41	17 (41)
Homosexual	10	3 (30)	6	1 (17)	16	4 (25)
p value		0.620		0.440		0.403
2012						
Heterosexual	363	161 (44)	112	59 (53)	474	220 (46)
Bisexual	20	10 (50)	27	16 (59)	48	26 (54)
Homosexual	11	5 (45)	7	3 (43)	18	8 (44)
p value		0.916		0.736		0.604
2013						
Heterosexual	322	142 (44)	119	58 (49)	442	201 (45)
Bisexual	13	6 (46)	28	16 (57)	41	22 (54)
Homosexual	17	6 (35)	2	0 (0)	19	6 (32)
p value		0.763		0.303		0.275
2014						
Heterosexual	275	103 (37)	87	36 (41)	362	139 (38)
Bisexual	11	6 (55)	24	8 (33)	35	14 (40)
Homosexual	18	3 (17)	3	2 (67)	21	5 (24)
p value		0.094		0.565		0.416
2015						
Heterosexual	336	144 (43)	107	47 (44)	443	191 (43)
Bisexual	18	11 (61)	22	12 (55)	41	23 (56)
Homosexual	14	0 (0)	4	2 (50)	18	2 (11)
p value		<0.001		0.655		0.004

Table 5.3.3 HCV antibody prevalence by age group, gender and survey year

Queensland Age group	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
<25 years	45	3 (7)	9	3 (33)	56	6 (11)
25-34 years	128	44 (34)	65	24 (37)	194	68 (35)
35-44 years	119	64 (54)	45	19 (42)	165	83 (50)
45+ years	75	46 (61)	27	17 (63)	102	63 (62)
p value		<0.001		0.128		<0.001
2012						
<25 years	55	6 (11)	13	4 (31)	68	10 (15)
25-34 years	129	49 (38)	64	38 (59)	194	88 (45)
35-44 years	139	73 (52)	46	23 (50)	185	96 (52)
45+ years	86	55 (64)	31	18 (58)	118	73 (62)
p value		<0.001		0.257		<0.001
2013						
<25 years	43	5 (12)	20	5 (25)	63	10 (16)
25-34 years	111	38 (34)	49	24 (49)	160	62 (39)
35-44 years	106	57 (54)	52	24 (46)	158	81 (52)
45+ years	110	66 (60)	39	26 (67)	150	93 (62)
p value		<0.001		0.022		<0.001
2014						
<25 years	35	2 (6)	16	2 (13)	51	4 (8)
25-34 years	105	25 (24)	42	18 (43)	147	43 (29)
35-44 years	97	44 (45)	44	16 (36)	141	60 (43)
45+ years	88	49 (56)	21	13 (62)	110	62 (56)
p value		<0.001		0.020		<0.001
2015						
<25 years	32	7 (22)	12	4 (33)	44	11 (25)
25-34 years	120	37 (31)	43	19 (44)	164	57 (35)
35-44 years	133	56 (42)	46	18 (39)	179	74 (41)
45+ years	93	61 (66)	38	23 (61)	132	84 (64)
p value		<0.001		0.185		<0.001

Table 5.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Queensland Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
<3 years	41	3 (7)	11	2 (18)	53	5 (9)
3 to 10 years	70	18 (26)	36	11 (31)	107	29 (27)
11+years	247	136 (55)	98	50 (51)	347	186 (54)
p value		<0.001		0.023		<0.001
2012						
<3 years	52	4 (8)	11	3 (27)	63	7 (11)
3 to 10 years	76	17 (22)	31	6 (19)	107	23 (22)
11+years	271	157 (58)	110	72 (65)	383	230 (60)
p value		<0.001		<0.001		<0.001
2013						
<3 years	51	3 (6)	10	2 (20)	61	5 (8)
3 to 10 years	74	16 (22)	34	15 (44)	108	31 (29)
11+years	237	139 (59)	113	61 (54)	351	201 (57)
p value		<0.001		0.087		<0.001
2014						
<3 years	39	3 (8)	15	1 (7)	54	4 (7)
3 to 10 years	59	9 (15)	27	7 (26)	86	16 (19)
11+years	215	106 (49)	80	41 (51)	296	147 (50)
p value		<0.001		0.001		<0.001
2015						
<3 years	42	4 (10)	4	1 (25)	46	5 (11)
3 to 10 years	81	16 (20)	28	10 (36)	110	26 (24)
11+years	246	138 (56)	103	52 (50)	350	191 (55)
p value		<0.001		0.293		<0.001

Table 5.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Queensland Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No receptive sharing	38	4 (11)	311	141 (45)	356	146 (41)
Receptive sharing	5	0 (0)	68	39 (57)	74	39 (53)
p value		1.000		0.082		0.071
2012						
No receptive sharing	37	5 (14)	376	184 (49)	417	192 (46)
Receptive sharing	3	0 (0)	64	45 (70)	71	48 (68)
p value		0.002		0.002		0.001
2013						
No receptive sharing	49	3 (6)	356	176 (49)	414	187 (45)
Receptive sharing	5	2 (40)	64	38 (59)	71	41 (58)
p value		0.062		0.143		0.050
2014						
No receptive sharing	38	3 (8)	288	113 (39)	336	118 (35)
Receptive sharing	2	1 (50)	57	38 (67)	59	39 (66)
p value		0.192		<0.001		<0.001
2015						
No receptive sharing	35	4 (11)	349	171 (49)	391	177 (45)
Receptive sharing	4	1 (25)	62	34 (55)	68	37 (54)
p value		0.436		0.397		0.163

Table 5.3.6 HCV antibody prevalence by last drug injected, years since first injection, and survey year

Queensland Last drug injected	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Heroin	7	2 (29)	98	53 (54)	106	55 (52)
Methamphetamine	11	1 (9)	139	50 (36)	152	52 (34)
Other opioids	5	1 (20)	183	97 (53)	189	98 (52)
PIEDs	26	1 (4)	8	1 (13)	39	2 (5)
Other drugs	4	0 (0)	26	14 (54)	32	14 (44)
p value		0.285		0.003		<0.001
2012						
Heroin	3	1 (33)	113	72 (64)	118	75 (64)
Methamphetamine	10	3 (30)	134	51 (38)	146	56 (38)
Other opioids	5	2 (40)	198	113 (57)	208	118 (57)
PIEDs	42	1 (2)	19	3 (16)	62	4 (6)
Other drugs	2	0 (0)	25	14 (56)	29	14 (48)
p value		0.013		<0.001		<0.001
2013						
Heroin	3	1 (33)	83	51 (61)	88	53 (60)
Methamphetamine	12	2 (17)	137	56 (41)	153	60 (39)
Other opioids	10	2 (20)	178	102 (57)	194	110 (57)
PIEDs	33	0 (0)	27	0 (0)	60	0 (0)
Other drugs	3	0 (0)	33	22 (67)	37	23 (62)
p value		0.068		<0.001		<0.001
2014						
Heroin	1	1 (100)	64	41 (64)	66	42 (64)
Methamphetamine	17	2 (12)	123	43 (35)	141	46 (33)
Other opioids	4	1 (25)	135	71 (53)	141	72 (51)
PIEDs	27	0 (0)	36	0 (0)	69	0 (0)
Other drugs	5	0 (0)	23	7 (30)	31	7 (23)
p value		0.002		<0.001		<0.001
2015						
Heroin	0	0 (0)	105	64 (61)	106	64 (60)
Methamphetamine	14	3 (21)	162	57 (35)	178	61 (34)
Other opioids	5	1 (20)	140	88 (63)	146	90 (62)
PIEDs	25	0 (0)	33	0 (0)	62	0 (0)
Other drugs	2	1 (50)	19	8 (42)	24	11 (46)
p value		0.041		<0.001		<0.001

Table 5.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Queensland Frequency of injection last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Less than daily	29	2 (7)	187	80 (43)	220	82 (37)
Daily or more	16	3 (19)	221	118 (53)	241	122 (51)
Not last month	7	0 (0)	41	16 (39)	51	16 (31)
p value		0.396		0.055		0.003
2012						
Less than daily	25	3 (12)	193	94 (49)	219	97 (44)
Daily or more	16	2 (13)	256	138 (54)	279	146 (52)
Not last month	21	2 (10)	37	19 (51)	61	22 (36)
p value		1.000		0.551		0.035
2013						
Less than daily	39	2 (5)	203	97 (48)	249	104 (42)
Daily or more	15	3 (20)	222	121 (55)	242	129 (53)
Not last month	7	0 (0)	25	8 (32)	33	8 (24)
p value		0.185		0.066		0.001
2014						
Less than daily	20	2 (10)	163	59 (36)	189	63 (33)
Daily or more	21	2 (10)	186	94 (51)	212	96 (45)
Not last month	13	0 (0)	27	8 (30)	44	8 (18)
p value		0.663		0.009		0.001
2015						
Less than daily	26	3 (12)	173	81 (47)	202	84 (42)
Daily or more	13	2 (15)	241	124 (51)	260	130 (50)
Not last month	7	0 (0)	45	12 (27)	54	12 (22)
p value		0.827		0.009		0.001

Table 5.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Queensland Imprisonment last year	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No imprisonment	51	5 (10)	385	170 (44)	446	176 (39)
Imprisonment	0	0 (0)	46	31 (67)	47	31 (66)
p value		--		0.004		0.001
2012						
No imprisonment	58	7 (12)	423	207 (49)	489	219 (45)
Imprisonment	3	0 (0)	37	37 (69)	60	39 (65)
p value		1.000		0.009		0.003
2013						
No imprisonment	58	5 (9)	400	196 (49)	470	210 (45)
Imprisonment	2	0 (0)	41	27 (66)	43	27 (63)
p value		1.000		0.040		0.023
2014						
No imprisonment	49	3 (6)	322	139 (43)	384	144 (38)
Imprisonment	2	0 (0)	39	19 (49)	42	19 (45)
p value		1.000		0.509		0.327
2015						
No imprisonment	42	4 (10)	403	175 (43)	459	183 (40)
Imprisonment	1	1 (100)	39	29 (74)	40	30 (75)
p value		0.116		<0.001		<0.001

Table 5.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year

Queensland	<3 years		3+ years		Total	
Sex work last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
No sex work	50	5 (10)	422	199 (47)	482	205 (43)
Sex work	1	0 (0)	14	7 (50)	16	7 (44)
p value		1.000		1.000		1.000
2012						
No sex work	61	7 (11)	464	234 (50)	535	248 (46)
Sex work	1	0 (0)	13	9 (69)	16	9 (56)
p value		1.000		0.261		0.457
2013						
No sex work	55	5 (9)	428	214 (50)	495	229 (46)
Sex work	1	0 (0)	7	4 (57)	8	4 (50)
p value		1.000		1.000		1.000
2014						
No sex work	49	3 (6)	340	142 (42)	402	147 (37)
Sex work	1	0 (0)	16	6 (38)	18	6 (33)
p value		1.000		0.735		0.780
2015						
No sex work	42	5 (12)	442	209 (47)	497	217 (44)
Sex work	1	0 (0)	12	6 (50)	14	7 (50)
p value		1.000		0.853		0.637

Table 5.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Queensland	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Non Indigenous	323	133 (41)	126	51 (40)	452	184 (41)
Indigenous	34	19 (56)	19	11 (58)	53	30 (57)
p value		0.105		0.213		0.028
2012						
Non Indigenous	352	152 (43)	129	67 (52)	483	220 (46)
Indigenous	51	28 (55)	22	14 (64)	73	42 (58)
p value		0.132		0.360		0.060
2013						
Non Indigenous	330	145 (44)	135	62 (46)	466	208 (45)
Indigenous	33	18 (55)	21	15 (71)	54	33 (61)
p value		0.243		0.030		0.022
2014						
Non Indigenous	293	105 (36)	104	43 (41)	398	148 (37)
Indigenous	27	14 (52)	15	6 (40)	42	20 (48)
p value		0.099		0.921		0.186
2015						
Non Indigenous	334	135 (40)	114	51 (45)	450	187 (42)
Indigenous	41	25 (61)	23	12 (52)	64	37 (59)
p value		0.012		0.514		0.014

Table 5.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Queensland Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
English speaking	352	147 (42)	144	62 (43)	500	209 (42)
Non-English speaking	11	7 (64)	2	1 (50)	13	8 (62)
p value		0.215		1.000		0.167
2012						
English speaking	400	178 (45)	149	79 (53)	550	258 (47)
Non-English speaking	8	5 (63)	4	3 (75)	13	8 (62)
p value		0.476		0.624		0.401
2013						
English speaking	362	162 (45)	154	76 (49)	517	239 (46)
Non-English speaking	8	5 (63)	6	3 (50)	14	8 (57)
p value		0.476		1.000		0.419
2014						
English speaking	313	115 (37)	117	47 (40)	431	162 (38)
Non-English speaking	12	5 (42)	5	2 (40)	17	7 (41)
p value		0.729		1.000		0.765
2015						
English speaking	364	153 (42)	137	62 (45)	503	216 (43)
Non-English speaking	8	4 (50)	1	1 (100)	9	5 (56)
p value		0.726		0.457		0.449

Table 5.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Queensland		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° with HCV (%)
2011							
Australia	308	131 (43)	125	55 (44)	437	186 (43)	
Other Oceania	18	5 (28)	10	4 (40)	28	9 (32)	
Asia	2	0 (0)	2	0 (0)	4	0 (0)	
UK & Ireland	15	8 (53)	6	2 (33)	21	10 (48)	
Other	18	9 (50)	2	1 (50)	20	10 (50)	
p value		0.428		0.877		0.335	
2012							
Australia	362	167 (46)	135	73 (54)	499	241 (48)	
Other Oceania	19	5 (26)	12	7 (58)	31	12 (39)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	14	4 (29)	5	2 (40)	19	6 (32)	
Other	10	5 (50)	2	1 (50)	12	6 (50)	
p value		0.235		0.923		0.406	
2013							
Australia	334	149 (45)	141	71 (50)	476	221 (46)	
Other Oceania	21	11 (52)	7	4 (57)	28	15 (54)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	8	4 (50)	4	1 (25)	12	5 (42)	
Other	8	3 (38)	7	2 (29)	15	5 (33)	
p value		0.864		0.589		0.646	
2014							
Australia	277	111 (40)	109	42 (39)	387	153 (40)	
Other Oceania	22	5 (23)	6	3 (50)	28	8 (29)	
Asia	2	0 (0)	0	0 (0)	2	0 (0)	
UK & Ireland	10	3 (30)	4	2 (50)	14	5 (36)	
Other	14	1 (7)	3	1 (33)	17	2 (12)	
p value		0.044		0.858		0.095	
2015							
Australia	330	143 (43)	124	62 (50)	456	206 (45)	
Other Oceania	18	7 (39)	6	1 (17)	24	8 (33)	
Asia	4	0 (0)	1	0 (0)	5	0 (0)	
UK & Ireland	10	5 (50)	6	1 (17)	16	6 (38)	
Other	8	2 (25)	1	0 (0)	9	2 (22)	
p value		0.401		0.111		0.132	

South Australia

Table 6.1.1 Number (percentage) of respondents by demographic characteristics and survey year

South Australia	2011	2012	2013	2014	2015
Number of sites	7	7	7	7	7
N° surveyed	N=213	N=203	N=248	N=228	N=238
Response rate (%)	51%	42%	56%	51%	55%
Gender (%)					
Male	133 (62)	127 (63)	169 (68)	143 (63)	137 (58)
Female	78 (37)	75 (37)	78 (31)	83 (36)	98 (41)
Transgender	2 (1)	1 (<1)	1 (<1)	2 (1)	3 (1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	178 (84)	155 (76)	193 (78)	177 (78)	187 (79)
Bisexual	22 (10)	18 (9)	26 (10)	28 (12)	26 (11)
Homosexual	6 (3)	12 (6)	8 (3)	5 (2)	12 (5)
Not reported	7 (3)	18 (9)	21 (8)	18 (8)	13 (5)
Aboriginal and Torres Strait Islander origin (%)					
No	183 (86)	183 (90)	201 (81)	197 (86)	210 (88)
Yes	29 (14)	17 (8)	35 (14)	28 (12)	25 (11)
Not reported	1 (<1)	3 (1)	12 (5)	3 (1)	3 (1)
Region/country of birth (%)					
Australia	185 (87)	178 (88)	214 (86)	202 (87)	214 (90)
Other Oceania	4 (2)	1 (<1)	4 (2)	4 (2)	0 (0)
Asia	4 (2)	1 (<1)	3 (1)	2 (1)	2 (1)
UK & Ireland	9 (4)	10 (5)	18 (7)	11 (5)	9 (4)
Other	9 (4)	12 (6)	9 (4)	8 (4)	8 (3)
Not reported	2 (1)	1 (<1)	0 (0)	1 (<1)	5 (2)
Main language spoken at home by parents (%)					
English	193 (91)	182 (90)	230 (93)	213 (93)	221 (93)
Non-English	18 (8)	21 (10)	18 (7)	13 (6)	14 (6)
Not reported	2 (1)	0 (0)	0 (0)	2 (1)	3 (1)
Age and time since first injection (years)					
<i>Median age</i>	39	40	40	40	43
<i>Age range</i>	17-61	18-60	17-60	18-68	17-70
Age group (%)					
<25 years	13 (6)	14 (7)	21 (8)	6 (3)	7 (3)
25+ years	200 (94)	189 (93)	225 (91)	222 (97)	231 (97)
Not reported	0 (0)	0 (0)	2 (1)	0 (0)	0 (0)
Median age first injection					
<i>Median age first injection</i>	19	18	18	18	19
<i>Age range</i>	11-45	10-55	12-48	10-57	12-51
<i>N° not reported</i>	4	3	8	1	5
Median yrs since first injection					
<i>Median yrs since first injection</i>	20	20	18	20	22
<i>Range</i>	<1-37	<1-43	<1-46	<1-41	<1-51
Years since first injection					
<3 years	12 (6)	8 (4)	13 (5)	8 (4)	10 (4)
3+ years	197 (92)	192 (95)	227 (92)	218 (96)	223 (94)
Not reported	4 (2)	3 (1)	8 (3)	2 (1)	5 (2)
Imprisonment last year (%)					
No	175 (82)	184 (92)	200 (81)	195 (86)	214 (90)
Yes	19 (9)	15 (8)	25 (10)	19 (8)	13 (5)
Not reported	19 (9)	4 (2)	23 (9)	14 (6)	11 (5)
N° in prison					
<i>N° in prison</i>	N=19	N=15	N=25	N=19	N=13
Injected in prison	4 (21)	2 (13)	4 (16)	1 (5)	2 (15)

Table 6.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

South Australia N° surveyed	2011 N=213	2012 N=203	2013 N=248	2014 N=228	2015 N=238
Drug last injected (%)					
Cocaine	2 (1)	0 (0)	1 (<1)	0 (0)	1 (0)
Methamphetamine	75 (35)	72 (35)	93 (38)	116 (51)	125 (53)
Heroin	77 (36)	74 (36)	83 (33)	65 (29)	73 (31)
Pharm. opioids	28 (13)	26 (13)	41 (17)	14 (6)	12 (5)
Methadone	13 (6)	9 (4)	8 (3)	9 (4)	11 (5)
Buprenorphine	3 (1)	4 (2)	0 (0)	2 (1)	1 (<1)
Buprenorphine/naloxone	2 (1)	1 (<1)	3 (1)	1 (<1)	1 (<1)
PIEDs	1 (<1)	4 (2)	1 (<1)	1 (<1)	1 (<1)
More than one	8 (4)	11 (5)	16 (6)	18 (8)	10 (4)
Other	4 (2)	1 (<1)	2 (1)	2 (1)	3 (1)
Not reported	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)
Frequency of injection last month (%)					
Not last month	12 (6)	10 (5)	10 (4)	9 (4)	17 (7)
Less than weekly	41 (19)	41 (20)	41 (17)	42 (18)	48 (20)
Weekly not daily	49 (23)	57 (28)	70 (28)	66 (29)	82 (34)
Daily or more	108 (51)	95 (47)	121 (49)	106 (46)	90 (38)
Not reported	3 (1)	0 (0)	6 (2)	5 (2)	1 (<1)
Present when someone injected for the first time in the last 12 months (%)					
Yes	--	28 (14)	41 (17)	34 (15)	34 (14)
No	--	155 (76)	176 (71)	190 (83)	202 (85)
Not reported	--	20 (10)	31 (13)	4 (2)	2 (1)
Overdosed in last 12 months					
Yes	--	--	22 (9)	25 (11)	18 (8)
No	--	--	212 (85)	198 (87)	218 (92)
Not reported	--	--	14 (6)	5 (2)	2 (1)

Table 6.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

South Australia N° injected last month	2011 N=198	2012 N=193	2013 N=232	2014 N=214	2015 N=220
Places injected last month (%)					
Any public	91 (46)	91 (47)	103 (44)	69 (32)	67 (30)
All private	98 (50)	91 (47)	128 (55)	143 (67)	153 (70)
Not reported	9 (5)	11 (6)	1 (<1)	2 (1)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	146 (74)	149 (77)	187 (81)	174 (81)	178 (81)
Most of the time	36 (18)	28 (15)	35 (15)	30 (14)	36 (16)
Half of the time	3 (2)	0 (0)	3 (1)	4 (2)	2 (1)
Some of the time	1 (<1)	1 (<1)	2 (1)	2 (1)	1 (<1)
Not last month	1 (<1)	1 (<1)	2 (1)	0 (0)	1 (<1)
Not reported	11 (6)	14 (7)	3 (1)	4 (2)	2 (1)
Re-used someone else's used needle & syringe last month (%)					
None	163 (82)	162 (84)	197 (85)	183 (86)	189 (86)
Once	5 (3)	12 (6)	17 (7)	10 (5)	11 (5)
Twice	6 (3)	5 (3)	6 (3)	12 (6)	13 (6)
3-5 times	6 (3)	0 (0)	5 (2)	4 (2)	4 (2)
>5 times	5 (3)	1 (<1)	6 (3)	3 (1)	3 (1)
Not reported	13 (7)	13 (7)	1 (<1)	2 (1)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	163 (82)	162 (84)	197 (85)	183 (86)	189 (86)
One	14 (7)	7 (4)	14 (6)	11 (5)	14 (6)
Two	2 (1)	1 (<1)	3 (1)	1 (<1)	2 (1)
Three to five	1 (<1)	1 (<1)	3 (1)	0 (0)	1 (<1)
More than five	0 (0)	0 (0)	3 (1)	2 (1)	0 (0)
Don't know	4 (2)	2 (1)	9 (4)	10 (5)	10 (5)
Not reported	14 (7)	20 (10)	3 (1)	7 (3)	4 (2)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	18 (9)	7 (4)	18 (8)	14 (7)	14 (6)
Casual sex partner	0 (0)	0 (0)	2 (1)	1 (<1)	3 (1)
Close friend	7 (4)	3 (2)	9 (4)	9 (4)	2 (1)
Acquaintance	3 (2)	2 (1)	5 (2)	2 (1)	4 (2)
Other	4 (2)	1 (<1)	5 (2)	3 (1)	4 (2)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	33 (17)	21 (11)	51 (22)	32 (15)	34 (15)
Water	27 (14)	22 (11)	43 (19)	28 (13)	43 (20)
Filter	19 (10)	13 (7)	26 (11)	12 (6)	19 (9)
Drug mix	17 (9)	15 (8)	21 (9)	12 (6)	19 (9)
None	131 (66)	134 (69)	147 (63)	155 (72)	161 (73)
Injected by someone after that person injected themselves or others last month (%)					
No	156 (79)	164 (85)	182 (78)	166 (78)	178 (81)
Yes	32 (16)	15 (8)	39 (17)	40 (19)	42 (19)
Not reported	10 (5)	14 (7)	11 (5)	8 (4)	0 (0)
Source of needle acquisition					
Needle Syringe Program	176 (89)	159 (82)	211 (91)	191 (89)	201 (91)
Chemist/Pharmacy	30 (15)	41 (21)	41 (18)	34 (16)	44 (20)
Personal sources	19 (10)	23 (12)	27 (12)	18 (8)	23 (10)
Dispensing/Vending Machine	17 (9)	27 (14)	20 (9)	22 (10)	37 (17)
Other sources	3 (2)	2 (1)	4 (2)	1 (<1)	4 (2)

Table 6.1.4 Number (percentage) of respondents by treatment for drug use and survey year

South Australia N° surveyed	2011 N=213	2012 N=203	2013 N=248	2014 N=228	2015 N=238
Ever any treatment/therapy for drug use (%)					
No	49 (23)	60 (30)	72 (29)	72 (33)	76 (32)
Yes	163 (77)	142 (70)	170 (69)	153 (67)	161 (68)
Not reported	1 (<1)	1 (<1)	6 (2)	3 (1)	1 (<1)
History of methadone maintenance treatment (%)					
Currently	48 (22)	58 (29)	65 (26)	57 (25)	53 (22)
Previously	61 (29)	44 (22)	41 (17)	46 (20)	56 (24)
Never	96 (45)	100 (49)	140 (56)	122 (54)	125 (53)
Not reported	8 (4)	1 (<1)	2 (1)	3 (1)	4 (2)
History of buprenorphine (Subutex®) treatment (%)					
Currently	13 (6)	18 (9)	19 (8)	15 (7)	18 (8)
Previously	55 (26)	46 (23)	64 (26)	54 (24)	74 (31)
Never	138 (65)	139 (68)	158 (64)	157 (69)	143 (60)
Not reported	7 (3)	0 (0)	7 (3)	2 (1)	3 (1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	21 (10)	26 (13)	23 (9)	23 (10)	16 (7)
Previously	37 (17)	29 (14)	57 (23)	37 (16)	48 (20)
Never	149 (70)	144 (71)	163 (66)	164 (72)	170 (71)
Not reported	6 (3)	4 (2)	5 (2)	4 (2)	4 (2)

Table 6.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

South Australia N° surveyed	2011 N=213	2012 N=203	2013 N=248	2014 N=228	2015 N=238
Previous HIV test (%)					
Yes, ever	174 (82)	175 (86)	207 (83)	176 (77)	212 (89)
Yes, last year	93 (44)	101 (50)	132 (53)	98 (43)	127 (53)
>1 year ago	81 (38)	74 (36)	75 (30)	78 (34)	85 (36)
Never tested	29 (14)	21 (10)	34 (14)	45 (20)	22 (9)
Not reported	10 (5)	7 (3)	7 (3)	7 (3)	4 (2)
Previous HCV test (%)					
Yes, ever	182 (85)	182 (90)	214 (86)	183 (80)	211 (89)
Yes, last year	105 (49)	112 (55)	140 (56)	116 (51)	131 (55)
>1 year ago	77 (36)	70 (34)	74 (30)	67 (29)	80 (34)
Never tested	15 (7)	13 (6)	22 (9)	35 (15)	15 (6)
Not reported	16 (8)	8 (4)	12 (5)	10 (4)	12 (5)
Lifetime treatment for HCV (%)					
N° self-reported chronic HCV#*					
Antiviral treatment	6 (12)	3 (6)	11 (18)	6 (15)	9 (20)
No antiviral treatment	41 (82)	45 (94)	45 (75)	32 (80)	33 (75)
Not reported	3 (6)	0 (0)	4 (7)	2 (5)	2 (5)
Treatment for HCV in past 12 months (%)					
N° self-reported chronic HCV#					
Antiviral treatment	1 (2)	0 (0)	2 (4)	1 (3)	1 (3)
No antiviral treatment	46 (96)	47 (100)	48 (91)	33 (87)	36 (97)
Not reported	1 (2)	0 (0)	3 (6)	4 (11)	0(0)

among people who tested HCV antibody positive

* includes people who reported treatment induced clearance

Table 6.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

South Australia	2011	2012	2013	2014	2015
N° surveyed	N=213	N=203	N=248	N=228	N=238
Sex with a regular partner last month (%)					
No	96 (45)	91 (45)	124 (50)	102 (45)	108 (45)
Yes	102 (48)	108 (53)	118 (48)	119 (52)	116 (49)
Not reported	15 (7)	4 (2)	6 (2)	7 (3)	14 (6)
Condom used with regular partner last month (%)					
N° surveyed	N=102	N=108	N=118	N=119	N=116
Never	69 (68)	73 (68)	86 (73)	89 (75)	87 (75)
Sometimes	10 (10)	11 (10)	14 (12)	14 (12)	11 (9)
Every time	15 (15)	13 (12)	6 (5)	11 (9)	14 (12)
Not reported	8 (8)	11 (10)	12 (10)	5 (4)	4 (3)
Sex with other partner(s) last month (%)					
No	179 (84)	176 (87)	216 (87)	185 (81)	205 (86)
Yes	22 (10)	22 (11)	23 (9)	34 (15)	21 (9)
Not reported	12 (6)	5 (2)	9 (4)	9 (4)	12 (5)
Condom used with other partner(s) last month (%)					
N° surveyed	N=22	N=22	N=23	N=34	N=21
Never	6 (27)	9 (41)	11 (48)	10 (29)	11 (52)
Sometimes	6 (27)	4 (18)	5 (22)	10 (29)	1 (5)
Every time	10 (45)	8 (36)	6 (26)	11 (32)	9 (43)
Not reported	0 (0)	1 (5)	1 (4)	3 (9)	0 (0)
Sex work last month (%)					
No	194 (91)	192 (95)	217 (88)	207 (91)	221 (93)
Yes	9 (4)	6 (3)	20 (8)	10 (4)	9 (4)
Not reported	10 (5)	5 (2)	11 (4)	11 (5)	8 (3)
Condom used at last sex work (%)					
Yes	8 (89)	6 (100)	14 (70)	8 (80)	6 (67)

HIV antibody prevalence

Table 6.2.1 HIV antibody prevalence by gender and survey year

South Australia Survey year	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011	129	2 (1.6)	76	3 (4.0)	207	5 (2.4)
2012	123	2 (1.6)	73	4 (5.5)	197	6 (3.1)
2013	154	4 (2.6)	74	3 (4.1)	229	7 (3.1)
2014	137	2 (1.5)	82	0 (0.0)	220	2 (0.9)
2015	122	0 (0.0)	88	0 (0.0)	213	0 (0.0)
X ² p trend p value		0.361		0.018		0.020

Table 6.2.2 HIV antibody prevalence by sexual identity, gender and survey year

South Australia Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
Heterosexual	118	2 (1.7)	56	2 (3.6)	174	4 (2.3)
Bisexual	6	0 (0.0)	14	1 (7.1)	21	1 (4.8)
Homosexual	1	0 (0.0)	4	0 (0.0)	6	0 (0.0)
p value		1.000		0.572		0.518
2012						
Heterosexual	99	0 (0.0)	54	4 (7.4)	153	4 (2.6)
Bisexual	6	0 (0.0)	10	0 (0.0)	16	0 (0.0)
Homosexual	8	2 (25.0)	2	0 (0.0)	11	2 (18.2)
p value		0.007		1.000		0.072
2013						
Heterosexual	127	2 (1.6)	52	3 (5.8)	180	5 (2.8)
Bisexual	6	1 (16.7)	16	0 (0.0)	22	1 (4.6)
Homosexual	5	1 (20.0)	2	0 (0.0)	7	1 (14.3)
p value		0.032		1.000		0.141
2014						
Heterosexual	110	0 (0.0)	61	0 (0.0)	171	0 (0.0)
Bisexual	9	1 (11.1)	16	0 (0.0)	26	1 (3.9)
Homosexual	2	1 (50.0)	3	0 (0.0)	5	1 (20.0)
p value		0.003		--		0.007
2015						
Heterosexual	109	0 (0.0)	55	0 (0.0)	165	0 (0.0)
Bisexual	4	0 (0.0)	18	0 (0.0)	24	0 (0.0)
Homosexual	3	0 (0.0)	8	0 (0.0)	11	0 (0.0)
p value		--		--		--

Table 6.2.3 HIV antibody prevalence by age group, gender and survey year

South Australia Age group	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
<25 years	5	0 (0.0)	8	2 (25.0)	13	2 (15.4)
25-34 years	25	0 (0.0)	13	0 (0.0)	39	0 (0.0)
35-44 years	64	1 (1.6)	32	1 (3.1)	96	2 (2.1)
45+ years	35	1 (2.9)	23	0 (0.0)	59	1 (1.7)
p value		1.000		0.041		0.069
2012						
<25 years	9	0 (0.0)	5	0 (0.0)	14	0 (0.0)
25-34 years	22	0 (0.0)	18	2 (11.1)	40	2 (5.0)
35-44 years	50	0 (0.0)	26	0 (0.0)	76	0 (0.0)
45+ years	42	2 (4.8)	24	2 (8.3)	67	4 (6.0)
p value		0.287		0.336		0.109
2013						
<25 years	7	0 (0.0)	11	0 (0.0)	18	0 (0.0)
25-34 years	25	0 (0.0)	19	2 (10.5)	44	2 (4.6)
35-44 years	57	1 (1.8)	27	0 (0.0)	84	1 (1.2)
45+ years	63	3 (4.8)	17	1 (5.9)	81	4 (4.9)
p value		0.606		0.218		0.483
2014						
<25 years	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)
25-34 years	22	0 (0.0)	19	0 (0.0)	41	0 (0.0)
35-44 years	62	1 (1.6)	43	0 (0.0)	105	1 (1.0)
45+ years	48	1 (2.1)	19	0 (0.0)	68	1 (1.5)
p value		1.000		--		1.000
2015						
<25 years	1	0 (0.0)	3	0 (0.0)	4	0 (0.0)
25-34 years	14	0 (0.0)	16	0 (0.0)	31	0 (0.0)
35-44 years	43	0 (0.0)	35	0 (0.0)	78	0 (0.0)
45+ years	64	0 (0.0)	34	0 (0.0)	100	0 (0.0)
p value		--		--		--

Table 6.2.4 HIV antibody prevalence by last drug injected, gender and survey year

South Australia		Male		Female		Total	
Last drug injected	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2011							
Heroin	51	0 (0.0)	24	1 (4.2)	75	1 (1.3)	
Methamphetamine	43	0 (0.0)	28	1 (3.6)	72	1 (1.4)	
Other opioids	25	1 (4.0)	20	1 (5.0)	46	2 (4.4)	
Other drugs	10	2 (5.7)	4	0 (0.0)	14	1 (7.1)	
p value		0.036		1.000		0.330	
2012							
Heroin	42	1 (2.4)	29	2 (6.9)	72	3 (4.2)	
Methamphetamine	42	1 (2.4)	27	2 (7.4)	69	3 (4.4)	
Other opioids	26	0 (0.0)	13	0 (0.0)	39	0 (0.0)	
Other drugs	12	0 (0.0)	4	0 (0.0)	16	0 (0.0)	
p value		1.000		1.000		0.741	
2013							
Heroin	44	0 (0.0)	29	1 (3.5)	73	1 (1.4)	
Methamphetamine	57	3 (5.3)	28	2 (7.1)	85	5 (5.9)	
Other opioids	40	1 (2.5)	11	0 (0.0)	51	1 (2.0)	
Other drugs	13	0 (0.0)	6	0 (0.0)	20	0 (0.0)	
p value		0.456		0.825		0.434	
2014							
Heroin	37	0 (0.0)	27	0 (0.0)	64	0 (0.0)	
Methamphetamine	71	2 (2.8)	39	0 (0.0)	111	2 (1.8)	
Other opioids	14	0 (0.0)	11	0 (0.0)	25	0 (0.0)	
Other drugs	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)	
p value		0.718		--		0.705	
2015							
Heroin	40	0 (0.0)	24	0 (0.0)	65	0 (0.0)	
Methamphetamine	61	0 (0.0)	50	0 (0.0)	113	0 (0.0)	
Other opioids	14	0 (0.0)	9	0 (0.0)	23	0 (0.0)	
Other drugs	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)	
p value		--		--		--	

Table 6.2.5 HIV antibody prevalence by years of injection, gender and survey year

South Australia Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
<3 years	5	0 (0.0)	7	0 (0.0)	12	0 (0.0)
3 to 10 years	14	0 (0.0)	12	2 (16.7)	26	2 (7.7)
11 + years	107	2 (1.9)	56	1 (1.8)	165	3 (1.8)
p value		1.000		0.087		0.235
2012						
<3 years	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
3 to 10 years	14	1 (7.1)	17	2 (11.8)	32	3 (9.4)
11 + years	100	1 (1.0)	54	2 (3.7)	154	3 (2.0)
p value		0.307		0.322		0.113
2013						
<3 years	3	0 (0.0)	8	0 (0.0)	11	0 (0.0)
3 to 10 years	21	0 (0.0)	9	0 (0.0)	30	0 (0.0)
11 + years	123	4 (3.3)	56	3 (5.4)	180	7 (3.9)
p value		1.000		1.000		0.719
2014						
<3 years	3	0 (0.0)	4	0 (0.0)	7	0 (0.0)
3 to 10 years	26	1 (4.4)	10	0 (0.0)	33	1 (3.0)
11 + years	109	1 (0.9)	68	0 (0.0)	178	1 (0.6)
p value		0.349		--		0.334
2015						
<3 years	5	0 (0.0)	5	0 (0.0)	10	0 (0.0)
3 to 10 years	10	0 (0.0)	8	0 (0.0)	18	0 (0.0)
11 + years	106	0 (0.0)	74	0 (0.0)	183	0 (0.0)
p value		--		--		--

Table 6.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

South Australia Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No receptive sharing	103	2 (1.9)	56	3 (5.4)	160	5 (3.1)
Receptive sharing	11	0 (0.0)	9	0 (0.0)	21	0 (0.0)
p value		1.000		1.000		1.000
2012						
No receptive sharing	99	1 (1.0)	56	4 (7.1)	156	5 (3.2)
Receptive sharing	14	0 (0.0)	4	0 (0.0)	18	0 (0.0)
p value		1.000		1.000		1.000
2013						
No receptive sharing	123	3 (2.4)	60	3 (5.0)	184	6 (3.3)
Receptive sharing	20	0 (0.0)	11	0 (0.0)	31	0 (0.0)
p value		1.000		1.000		0.597
2014						
No receptive sharing	109	2 (1.8)	69	0 (0.0)	179	2 (1.1)
Receptive sharing	21	0 (0.0)	7	0 (0.0)	28	0 (0.0)
p value		1.000		--		1.000
2015						
No receptive sharing	95	0 (0.0)	73	0 (0.0)	170	0 (0.0)
Receptive sharing	16	0 (0.0)	11	0 (0.0)	27	0 (0.0)
p value		--		--		--

Table 6.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

South Australia	Male		Female		Total	
Frequency of injection	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
Less than daily	61	0 (0.0)	28	2 (7.1)	89	2 (2.3)
Daily or more	60	2 (3.3)	42	1 (2.4)	104	3 (2.9)
Not last month	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)
p value		0.325		0.643		1.000
2012						
Less than daily	60	2 (3.3)	35	4 (11.4)	95	6 (6.3)
Daily or more	60	0 (0.0)	31	0 (0.0)	92	0 (0.0)
Not last month	3	0 (0.0)	7	0 (0.0)	10	0 (0.0)
p value		0.520		0.192		0.067
2013						
Less than daily	63	2 (3.2)	38	3 (7.9)	101	5 (5.0)
Daily or more	80	1 (1.3)	33	0 (0.0)	114	1 (0.9)
Not last month	7	1 (14.3)	2	0 (0.0)	9	1 (11.1)
p value		0.136		0.304		0.061
2014						
Less than daily	58	1 (1.7)	45	0 (0.0)	104	1 (1.0)
Daily or more	72	1 (1.4)	32	0 (0.0)	104	1 (1.0)
Not last month	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
p value		1.000		--		1.000
2015						
Less than daily	68	0 (0.0)	47	0 (0.0)	116	0 (0.0)
Daily or more	43	0 (0.0)	37	0 (0.0)	81	0 (0.0)
Not last month	10	0 (0.0)	4	0 (0.0)	15	0 (0.0)
p value		--		--		--

Table 6.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

South Australia	Male		Female		Total	
Imprisonment last year	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No imprisonment	106	2 (1.9)	69	3 (4.4)	177	5 (2.8)
Imprisonment	13	0 (0.0)	5	0 (0.0)	18	0 (0.0)
p value		1.000		1.000		1.000
2012						
No imprisonment	110	2 (1.8)	68	4 (5.9)	179	6 (3.4)
Imprisonment	12	0 (0.0)	2	0 (0.0)	14	0 (0.0)
p value		1.000		1.000		1.000
2013						
No imprisonment	122	3 (2.5)	63	3 (4.8)	186	6 (3.2)
Imprisonment	20	1 (5.0)	1	0 (0.0)	21	1 (4.8)
p value		0.459		1.000		0.533
2014						
No imprisonment	114	2 (1.8)	73	0 (0.0)	188	2 (1.1)
Imprisonment	15	0 (0.0)	4	0 (0.0)	19	0 (0.0)
p value		1.000		--		1.000
2015						
No imprisonment	106	0 (0.0)	84	0 (0.0)	193	0 (0.0)
Imprisonment	9	0 (0.0)	1	0 (0.0)	10	0 (0.0)
p value		--		--		--

Table 6.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

South Australia	Male		Female		Total	
Condom use at last sex	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No condom use	40	0 (0.0)	27	1 (3.7)	67	1 (1.5)
Condom use	16	0 (0.0)	8	0 (0.0)	24	0 (0.0)
p value		---		1.000		1.000
2012						
No condom use	42	0 (0.0)	28	2 (7.1)	70	2 (2.9)
Condom use	12	1 (8.3)	11	1 (9.1)	23	2 (8.7)
p value		0.222		1.000		0.255
2013						
No condom use	43	0 (0.0)	38	1 (2.6)	82	1 (1.2)
Condom use	12	0 (0.0)	6	2 (33.3)	18	2 (11.1)
p value		--		0.045		0.083
2014						
No condom use	48	1 (2.1)	39	0 (0.0)	87	1 (1.2)
Condom use	18	0 (0.0)	7	0 (0.0)	25	0 (0.0)
p value		1.000		--		1.000
2015						
No condom use	37	0 (0.0)	41	0 (0.0)	78	0 (0.0)
Condom use	8	0 (0.0)	11	0 (0.0)	21	0 (0.0)
p value		--		--		--

Table 6.2.10 HIV antibody prevalence by sex work last month, gender and survey year

South Australia	Male		Female		Total	
Sex work last month	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No sex work	124	2 (1.6)	65	3 (4.6)	191	5 (2.6)
Sex work	2	0 (0.0)	6	0 (0.0)	8	0 (0.0)
p value		1.000		1.000		1.000
2012						
No sex work	118	2 (1.7)	68	4 (5.9)	187	6 (3.2)
Sex work	1	0 (0.0)	4	0 (0.0)	5	0 (0.0)
p value		1.000		1.000		1.000
2013						
No sex work	139	3 (2.2)	60	3 (5.0)	200	6 (3.0)
Sex work	9	1 (11.1)	10	0 (0.0)	19	1 (5.3)
p value		0.224		1.000		0.475
2014						
No sex work	126	2 (1.6)	73	0 (0.0)	200	2 (1.0)
Sex work	2	0 (0.0)	8	0 (0.0)	10	0 (0.0)
p value		1.000		--		1.000
2015						
No sex work	114	0 (0.0)	82	0 (0.0)	197	0 (0.0)
Sex work	4	0 (0.0)	3	0 (0.0)	9	0 (0.0)
p value		--		--		--

Table 6.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

South Australia Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Non Indigenous	112	2 (1.8)	63	2 (3.2)	177	4 (2.3)
Indigenous	17	0 (0.0)	12	1 (8.3)	29	1 (3.5)
p value		1.000		0.412		0.535
2012						
Non Indigenous	113	2 (1.8)	64	4 (6.3)	178	6 (3.4)
Indigenous	9	0 (0.0)	7	0 (0.0)	16	0 (0.0)
p value		1.000		1.000		1.000
2013						
Non Indigenous	123	3 (2.4)	62	3 (4.9)	186	6 (3.2)
Indigenous	21	0 (0.0)	10	0 (0.0)	31	0 (0.0)
p value		1.000		1.000		0.597
2014						
Non Indigenous	120	2 (1.7)	68	0 (0.0)	189	2 (1.1)
Indigenous	14	0 (0.0)	14	0 (0.0)	28	0 (0.0)
p value		1.000		--		1.000
2015						
Non Indigenous	109	0 (0.0)	77	0 (0.0)	189	0 (0.0)
Indigenous	11	0 (0.0)	10	0 (0.0)	21	0 (0.0)
p value		--		--		--

Table 6.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

South Australia Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
English speaking	117	2 (1.7)	69	3 (4.4)	188	5 (2.7)
Non-English speaking	11	0 (0.0)	6	0 (0.0)	17	0 (0.0)
p value		1.000		1.000		1.000
2012						
English speaking	103	2 (1.9)	72	4 (5.6)	176	6 (3.4)
Non-English speaking	20	0 (0.0)	1	0 (0.0)	21	0 (0.0)
p value		1.000		1.000		1.000
2013						
English speaking	140	3 (2.1)	70	3 (4.3)	211	6 (2.8)
Non-English speaking	14	1 (7.1)	4	0 (0.0)	18	1 (5.6)
p value		0.320		1.000		0.441
2014						
English speaking	125	2 (1.6)	79	0 (0.0)	205	2 (1.0)
Non-English speaking	10	0 (0.0)	3	0 (0.0)	13	0 (0.0)
p value		1.000		--		1.000
2015						
English speaking	108	0 (0.0)	85	0 (0.0)	196	0 (0.0)
Non-English speaking	12	0 (0.0)	2	0 (0.0)	14	0 (0.0)
p value		--		--		--

Table 6.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

South Australia		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2011							
Australia	112	2 (1.8)	66	3 (4.6)	180	5 (2.8)	
Other Oceania	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)	
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
UK & Ireland	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)	
Other	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)	
p value		1.000		1.000		1.000	
2012							
Australia	103	2 (1.9)	69	4 (5.8)	173	6 (3.5)	
Other Oceania	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)	
Asia	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)	
UK & Ireland	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)	
Other	12	0 (0.0)	0	0 (0.0)	12	0 (0.0)	
p value		1.000		1.000		1.000	
2013							
Australia	128	4 (3.1)	68	3 (4.4)	197	7 (3.6)	
Other Oceania	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)	
Asia	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)	
UK & Ireland	15	0 (0.0)	2	0 (0.0)	17	0 (0.0)	
Other	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)	
p value		0.934		0.991		0.883	
2014							
Australia	116	2 (1.7)	78	0 (0.0)	195	2 (1.0)	
Other Oceania	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)	
UK & Ireland	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)	
Other	7	0 (0.0)	0	0 (0.0)	7	0 (0.0)	
p value		1.000		--		1.000	
2015							
Australia	105	0 (0.0)	82	0 (0.0)	190	0 (0.0)	
Other Oceania	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)	
UK & Ireland	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)	
Other	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)	
p value		--		--		--	

HCV ANTIBODY PREVALENCE

Table 6.3.1 HCV antibody prevalence by gender and survey year

South Australia Survey year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011	128	67 (52)	75	31 (41)	205	98 (48)
2012	122	51 (42)	71	28 (39)	194	79 (41)
2013	153	78 (51)	74	32 (43)	228	111 (49)
2014	128	68 (53)	79	40 (51)	208	109 (52)
2015	120	60 (50)	88	40 (45)	211	100 (47)
X ² p trend value		0.794		0.506		0.569

Table 6.3.2 HCV antibody prevalence by sexual identity, gender and survey year

South Australia Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Heterosexual	117	60 (51)	55	23 (42)	172	83 (48)
Bisexual	6	4 (67)	14	5 (36)	21	9 (43)
Homosexual	1	0 (0)	4	1 (25)	6	1 (17)
p value		0.553		0.756		0.325
2012						
Heterosexual	98	44 (45)	52	19 (37)	150	63 (42)
Bisexual	7	3 (43)	10	5 (50)	17	8 (47)
Homosexual	7	2 (29)	2	1 (50)	10	3 (30)
p value		0.767		0.653		0.692
2013						
Heterosexual	126	65 (52)	52	23 (44)	179	89 (50)
Bisexual	6	1 (17)	16	6 (38)	22	7 (32)
Homosexual	5	0 (0)	2	1 (50)	7	1 (14)
p value		0.021		0.888		0.055
2014						
Heterosexual	103	55 (53)	59	30 (51)	162	85 (52)
Bisexual	8	1 (13)	16	8 (50)	25	10 (40)
Homosexual	1	1 (100)	3	2 (67)	4	3 (75)
p value		0.030		1.000		0.314
2015						
Heterosexual	107	53 (50)	55	25 (45)	163	78 (48)
Bisexual	4	1 (25)	18	10 (56)	24	11 (46)
Homosexual	3	2 (67)	8	2 (25)	11	4 (36)
p value		0.711		0.389		0.812

Table 6.3.3 HCV antibody prevalence by age group, gender and survey year

South Australia Age group	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
<25 years	5	0 (0)	8	1 (13)	13	1 (8)
25-34 years	25	9 (36)	13	3 (23)	39	12 (31)
35-44 years	63	35 (56)	31	15 (48)	94	50 (53)
45+ years	35	23 (66)	23	12 (52)	59	35 (59)
p value		0.010		0.103		<0.001
2012						
<25 years	9	0 (0)	5	1 (20)	14	1 (7)
25-34 years	22	7 (32)	18	5 (28)	40	12 (30)
35-44 years	50	18 (36)	26	9 (35)	76	27 (36)
45+ years	42	26 (63)	24	13 (59)	67	39 (61)
p value		0.001		0.147		<0.001
2013						
<25 years	7	1 (14)	11	1 (9)	18	2 (11)
25-34 years	25	11 (44)	19	9 (47)	44	20 (45)
35-44 years	57	26 (46)	27	12 (44)	84	38 (46)
45+ years	63	40 (63)	17	10 (59)	81	51 (63)
p value		0.035		0.060		<0.001
2014						
<25 years	5	1 (20)	1	0 (0)	6	1 (17)
25-34 years	22	7 (32)	19	8 (42)	41	15 (37)
35-44 years	56	28 (50)	41	18 (44)	97	46 (47)
45+ years	45	32 (71)	18	14 (78)	64	47 (73)
p value		0.005		0.034		<0.001
2015						
<25 years	1	0 (0)	3	0 (0)	4	0 (0)
25-34 years	14	7 (50)	16	7 (44)	31	14 (45)
35-44 years	43	16 (37)	35	13 (37)	78	29 (37)
45+ years	62	37 (60)	34	20 (59)	98	57 (58)
p value		0.085		0.121		0.007

Table 6.3.4 HCV antibody prevalence by years since first injection, gender and survey year

South Australia Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
<3 years	5	0 (0)	7	0 (0)	12	0 (0)
3 to 10 years	14	3 (21)	12	1 (8)	26	4 (15)
11+years	106	63 (59)	55	29 (53)	163	92 (56)
p value		0.001		0.001		<0.001
2012						
<3 years	6	0 (0)	2	1 (50)	8	1 (13)
3 to 10 years	13	3 (23)	16	4 (25)	30	7 (23)
11+years	100	47 (47)	53	23 (43)	153	70 (46)
p value		0.023		0.361		0.016
2013						
<3 years	3	0 (0)	8	2 (25)	11	2 (18)
3 to 10 years	21	4 (19)	9	3 (33)	30	7 (23)
11+years	122	71 (58)	56	26 (46)	179	98 (55)
p value		<0.001		0.557		0.001
2014						
<3 years	3	1 (33)	4	0 (0)	7	1 (14)
3 to 10 years	22	8 (36)	10	4 (40)	32	12 (38)
11+years	101	58 (57)	65	36 (55)	167	95 (57)
p value		0.129		0.074		0.016
2015						
<3 years	5	1 (20)	5	2 (40)	10	3 (30)
3 to 10 years	10	3 (30)	8	1 (13)	18	4 (22)
11+years	104	55 (53)	75	37 (49)	182	92 (51)
p value		0.177		0.129		0.035

Table 6.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

South Australia Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No receptive sharing	8	0 (0)	149	79 (53)	159	80 (50)
Receptive sharing	1	0 (0)	19	9 (47)	20	9 (45)
p value		--		0.808		0.813
2012						
No receptive sharing	6	1 (17)	146	61 (42)	155	63 (41)
Receptive sharing	0	0 (0)	17	8 (47)	17	8 (47)
p value		--		0.797		0.614
2013						
No receptive sharing	9	1 (11)	170	83 (49)	183	87 (48)
Receptive sharing	2	1 (50)	27	17 (63)	31	18 (58)
p value		0.345		0.172		0.278
2014						
No receptive sharing	5	1 (20)	163	91 (56)	170	93 (55)
Receptive sharing	1	0 (0)	25	10 (40)	26	10 (38)
p value		1.000		0.139		0.122
2015						
No receptive sharing	8	2 (25)	161	77 (48)	170	80 (47)
Receptive sharing	0	0 (0)	26	14 (54)	26	14 (54)
p value		--		0.569		0.519

Table 6.3.6 HCV antibody prevalence by last drug injected, years since first injection, and survey year

South Australia	<3 years		3+ years		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Heroin	4	0 (0)	68	46 (68)	74	47 (64)
Methamphetamine	3	0 (0)	66	20 (30)	71	21 (30)
Other opioids	2	0 (0)	44	26 (59)	46	26 (57)
Other drugs	3	0 (0)	11	4 (36)	14	4 (29)
p value		--		<0.001		<0.001
2012						
Heroin	1	0 (0)	68	30 (44)	71	31 (44)
Methamphetamine	2	0 (0)	64	15 (23)	66	15 (23)
Other opioids	1	1 (100)	39	22 (56)	40	23 (58)
Other drugs	4	0 (0)	11	9 (82)	16	9 (56)
p value		0.046		<0.001		0.002
2013						
Heroin	3	1 (33)	70	42 (60)	73	43 (59)
Methamphetamine	7	1 (14)	73	26 (36)	84	30 (36)
Other opioids	0	0 (0)	49	25 (51)	51	26 (51)
Other drugs	1	0 (0)	17	12 (71)	20	12 (60)
p value		0.685		0.008		0.020
2014						
Heroin	2	0 (0)	59	36 (61)	62	36 (58)
Methamphetamine	3	0 (0)	103	52 (50)	106	52 (49)
Other opioids	1	1 (100)	19	9 (47)	21	11 (52)
Other drugs	1	0 (0)	18	10 (56)	19	10 (53)
p value		0.072		0.566		0.736
2015						
Heroin	0	0 (0)	63	45 (71)	64	46 (72)
Methamphetamine	8	2 (25)	104	36 (35)	112	38 (34)
Other opioids	1	0 (0)	22	9 (41)	23	9 (39)
Other drugs	1	1 (100)	10	5 (50)	11	6 (55)
p value		0.240		<0.001		<0.001

Table 6.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

South Australia Frequency of injection last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Less than daily	3	0 (0)	83	43 (52)	88	44 (50)
Daily or more	7	0 (0)	96	49 (51)	103	49 (48)
Not last month	1	0 (0)	10	4 (40)	12	4 (33)
p value		--		0.812		0.568
2012						
Less than daily	5	1 (20)	86	36 (42)	92	38 (41)
Daily or more	1	0 (0)	89	40 (45)	92	40 (43)
Not last month	2	0 (0)	8	1 (13)	10	1 (10)
p value		1.000		0.237		0.127
2013						
Less than daily	7	1 (14)	90	46 (51)	101	50 (50)
Daily or more	4	1 (25)	107	54 (50)	113	55 (49)
Not last month	0	0 (0)	8	3 (38)	9	3 (33)
p value		1.000		0.828		0.687
2014						
Less than daily	3	0 (0)	97	55 (57)	100	55 (55)
Daily or more	3	1 (33)	92	46 (50)	97	48 (49)
Not last month	1	0 (0)	7	3 (43)	8	3 (38)
p value		1.000		0.555		0.529
2015						
Less than daily	4	1 (25)	111	58 (52)	116	60 (52)
Daily or more	4	1 (25)	76	33 (43)	80	34 (43)
Not last month	2	1 (50)	12	4 (33)	14	5 (36)
p value		1.000		0.310		0.301

Table 6.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

South Australia Imprisonment last year	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No imprisonment	10	0 (0)	156	78 (50)	170	80 (47)
Imprisonment	1	0 (0)	16	13 (81)	17	13 (76)
p value		--		0.019		0.023
2012						
No imprisonment	7	1 (14)	169	69 (41)	178	71 (40)
Imprisonment	1	0 (0)	11	5 (45)	13	5 (38)
p value		1.000		0.762		1.000
2013						
No imprisonment	10	2 (20)	169	79 (47)	186	84 (45)
Imprisonment	0	0 (0)	19	13 (68)	20	14 (70)
p value		--		0.073		0.035
2014						
No imprisonment	7	1 (14)	167	91 (54)	176	9 (53)
Imprisonment	0	0 (0)	19	8 (42)	19	8 (42)
p value		--		0.305		0.374
2015						
No imprisonment	8	2 (25)	182	84 (46)	191	87 (46)
Imprisonment	2	1 (50)	8	6 (75)	10	7 (70)
p value		1.000		0.110		0.131

Table 6.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year

South Australia	<3 years		3+ years		Total	
Sex work last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
No sex work	10	0 (0)	176	91 (52)	189	92 (49)
Sex work	0	0 (0)	7	2 (29)	8	3 (38)
p value		--		0.273		0.722
2012						
No sex work	8	1 (13)	173	73 (42)	184	75 (41)
Sex work	0	0 (0)	5	0 (0)	5	0 (0)
p value		--		0.790		0.159
2013						
No sex work	9	0 (0)	185	93 (50)	200	97 (49)
Sex work	1	1 (100)	16	8 (50)	18	9 (50)
p value		0.100		0.983		0.903
2014						
No sex work	5	1 (20)	182	101 (55)	188	103 (55)
Sex work	1	0 (0)	9	2 (22)	10	2 (20)
p value		1.000		0.083		0.048
2015						
No sex work	8	2 (25)	186	90 (48)	195	93 (48)
Sex work	2	1 (50)	7	3 (43)	9	4 (44)
p value		1.000		1.000		1.000

Table 6.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

South Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Non Indigenous	112	56 (50)	62	25 (40)	176	81 (46)
Indigenous	16	11 (69)	12	5 (42)	28	16 (57)
p value		0.189		1.000		0.312
2012						
Non Indigenous	112	47 (42)	62	26 (42)	175	73 (42)
Indigenous	9	4 (44)	7	1 (14)	16	5 (31)
p value		1.000		0.233		0.596
2013						
Non Indigenous	123	59 (48)	62	26 (42)	186	86 (46)
Indigenous	21	16 (76)	10	4 (40)	31	20 (65)
p value		0.017		1.000		0.059
2014						
Non Indigenous	111	55 (50)	66	33 (50)	178	89 (50)
Indigenous	14	11 (79)	13	7 (54)	27	18 (67)
p value		0.040		0.800		0.106
2015						
Non Indigenous	108	55 (51)	77	33 (43)	188	88 (47)
Indigenous	10	5 (50)	10	7 (70)	20	12 (60)
p value		0.955		0.105		0.262

Table 6.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

South Australia	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
English speaking	116	59 (51)	68	28 (41)	186	87 (47)
Non-English speaking	11	7 (64)	6	2 (33)	17	9 (53)
p value		0.534		1.000		0.801
2012						
English speaking	102	47 (46)	70	28 (40)	173	75 (43)
Non-English speaking	20	4 (20)	1	0 (0)	21	4 (19)
p value		0.046		1.000		0.036
2013						
English speaking	139	73 (53)	70	30 (43)	210	104 (50)
Non-English speaking	14	5 (36)	4	2 (50)	18	7 (39)
p value		0.271		1.000		0.386
2014						
English speaking	119	66 (55)	76	39 (51)	196	106 (54)
Non-English speaking	7	1 (14)	3	1 (33)	10	2 (20)
p value		0.050		0.615		0.050
2015						
English speaking	106	53 (50)	85	39 (46)	194	92 (47)
Non-English speaking	12	5 (42)	2	1 (50)	14	6 (43)
p value		0.584		1.000		0.741

Table 6.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

South Australia		Male		Female		Total	
Region/Country of birth	N^o tested	N^o with HCV (%)	N^o tested	N^o with HCV (%)	N^o tested	N^o with HCV (%)	
2011							
Australia	111	57 (51)	66	23 (35)	179	80 (45)	
Other Oceania	2	0 (0)	2	2 (100)	4	2 (50)	
Asia	4	4 (100)	0	0 (0)	4	4 (100)	
UK & Ireland	5	2 (40)	3	3 (100)	8	5 (63)	
Other	6	4 (67)	3	2 (67)	9	6 (67)	
p value		0.164		0.008		0.124	
2012							
Australia	102	38 (37)	68	26 (38)	171	64 (37)	
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	7	5 (71)	2	2 (100)	9	7 (78)	
Other	12	7 (58)	0	0 (0)	12	7 (58)	
p value		0.092		0.152		0.030	
2013							
Australia	127	68 (54)	68	30 (44)	196	99 (51)	
Other Oceania	2	1 (50)	1	0 (0)	3	1 (33)	
Asia	2	1 (50)	1	1 (100)	3	2 (67)	
UK & Ireland	15	6 (40)	2	1 (50)	17	7 (41)	
Other	7	2 (29)	2	0 (0)	9	2 (22)	
p value		0.641		0.655		0.445	
2014							
Australia	108	61 (56)	75	37 (49)	184	99 (54)	
Other Oceania	4	2 (50)	0	0 (0)	4	2 (50)	
Asia	2	0 (0)	0	0 (0)	2	0 (0)	
UK & Ireland	7	3 (43)	4	3 (75)	11	6 (55)	
Other	6	2 (33)	0	0 (0)	6	2 (33)	
p value		0.440		0.615		0.583	
2015							
Australia	103	50 (49)	82	36 (44)	188	86 (46)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	2	2 (100)	0	0 (0)	2	2 (100)	
UK & Ireland	5	0 (0)	4	3 (75)	9	3 (33)	
Other	6	4 (67)	1	1 (100)	7	5 (71)	
p value		0.046		0.214		0.207	

Tasmania

Table 7.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Tasmania	2011	2012	2013	2014	2015
Number of sites	4	4	3	4	4
N° surveyed	N=68	N=75	N=70	N=69	N=48
Response rate (%)	28%	28%	33%	36%	20%
Gender (%)					
Male	43 (63)	37 (49)	42 (60)	37 (54)	30 (62)
Female	25 (37)	38 (51)	28 (40)	31 (45)	18 (38)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Sexual identity (%)					
Heterosexual	61 (90)	62 (83)	61 (87)	52 (75)	39 (81)
Bisexual	2 (3)	7 (9)	3 (4)	3 (4)	2 (4)
Homosexual	3 (4)	4 (5)	2 (3)	2 (3)	3 (6)
Not reported	2 (3)	2 (3)	4 (6)	12 (17)	4 (8)
Aboriginal and Torres Strait Islander origin (%)					
No	59 (87)	64 (85)	60 (86)	56 (81)	39 (81)
Yes	8 (12)	10 (13)	9 (13)	11 (16)	8 (17)
Not reported	1 (1)	1 (1)	1 (1)	2 (3)	1 (2)
Region/country of birth (%)					
Australia	64 (94)	69 (92)	67 (96)	67 (97)	43 (90)
Other Oceania	0 (0)	0 (0)	1 (1)	0 (0)	1 (2)
Asia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
UK & Ireland	2 (3)	1 (1)	2 (3)	2 (3)	2 (4)
Other	2 (3)	3 (4)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	2 (3)	0 (0)	0 (0)	2 (4)
Main language spoken at home by parents (%)					
English	68 (100)	73 (97)	70 (100)	69 (100)	47 (98)
Non-English	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	1 (2)
Age and time since first injection (years)					
<i>Median age</i>	38	38	37	41	42
<i>Age range</i>	17-58	18-57	21-63	21-60	23-61
<i>Age group (%)</i>					
<25 years	4 (6)	3 (4)	3 (4)	1 (1)	1 (2)
25+ years	64 (94)	72 (96)	66 (94)	68 (99)	47 (98)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
<i>Median age first injection</i>					
	19	18	19	20	20
<i>Age range</i>					
	13-49	13-45	12-40	12-53	12-50
<i>N° not reported</i>					
	3	3	3	2	0
<i>Median yrs since first injection</i>					
	15	15	16	18	18
<i>Range</i>					
	<1-40	<1-38	1-41	1-43	<1-43
<i>Years since first injection</i>					
<3 years	7 (10)	5 (7)	3 (4)	1 (1)	2 (4)
3+ years	58 (85)	67 (89)	64 (91)	66 (96)	46 (96)
Not reported	3 (4)	3 (4)	3 (4)	2 (3)	0 (0)
Imprisonment last year (%)					
No	63 (93)	68 (91)	54 (77)	56 (81)	41 (85)
Yes	4 (6)	4 (5)	9 (13)	3 (4)	3 (6)
Not reported	1 (1)	3 (4)	7 (10)	10 (14)	4 (8)
N° in prison					
	N=4	N=4	N=9	N=3	N=3
Injected in prison	1 (25)	2 (50)	1 (11)	1 (33)	0 (100)

Table 7.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Tasmania N° surveyed	2011 N=68	2012 N=75	2013 N=70	2014 N=69	2015 N=48
Drug last injected (%)					
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Methamphetamine	18 (26)	24 (32)	17 (24)	23 (33)	20 (42)
Heroin	1 (1)	1 (1)	2 (3)	2 (3)	0 (0)
Pharm. opioids	23 (34)	30 (40)	23 (33)	25 (36)	15 (31)
Methadone	21 (31)	13 (17)	19 (27)	10 (14)	11 (23)
Buprenorphine	1 (1)	2 (3)	3 (4)	1 (1)	1 (2)
Buprenorphine/naloxone	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)
PIEDs	0 (0)	1 (1)	1 (1)	0 (0)	1 (2)
More than one	3 (4)	0 (0)	3 (4)	7 (10)	0 (0)
Other	1 (1)	3 (4)	1 (1)	1 (1)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Frequency of injection last month (%)					
Not last month	5 (7)	7 (9)	5 (7)	1 (1)	4 (8)
Less than weekly	10 (15)	14 (19)	13 (19)	7 (10)	9 (19)
Weekly not daily	27 (40)	19 (25)	26 (37)	24 (35)	15 (31)
Daily or more	26 (38)	35 (47)	24 (34)	36 (52)	19 (40)
Not reported	0 (0)	0 (0)	2 (3)	1 (1)	1 (2)
Present when someone injected for the first time in the last 12 months (%)					
Yes	--	9 (12)	6 (9)	7 (10)	6 (13)
No	--	57 (76)	57 (81)	61 (88)	41 (85)
Not reported	--	9 (12)	7 (10)	1 (1)	1 (2)
Overdosed in last 12 months					
Yes	--	--	6 (9)	4 (6)	2 (4)
No	--	--	62 (89)	63 (91)	45 (94)
Not reported	--	--	2 (3)	2 (3)	1 (2)

Table 7.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Tasmania	2011	2012	2013	2014	2015
N° injected last month	N=63	N=68	N=63	N=67	N=43
Places injected last month (%)					
Any public	23 (37)	17 (25)	16 (25)	15 (22)	15 (35)
All private	39 (62)	48 (71)	46 (73)	52 (78)	28 (65)
Not reported	1 (2)	3 (4)	1 (2)	0 (0)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	55 (87)	53 (78)	55 (87)	64 (96)	36 (84)
Most of the time	7 (11)	11 (16)	6 (10)	2 (3)	7 (16)
Half of the time	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
Some of the time	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	1 (1)	4 (6)	1 (2)	1 (1)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	51 (81)	54 (79)	61 (97)	61 (91)	40 (93)
Once	5 (8)	5 (7)	1 (2)	4 (6)	1 (2)
Twice	1 (1)	1 (1)	0 (0)	1 (1)	1 (2)
3-5 times	4 (6)	1 (1)	0 (0)	0 (0)	1 (2)
>5 times	0 (0)	3 (4)	1 (2)	0 (0)	0 (0)
Not reported	2 (3)	4 (6)	0 (0)	1 (1)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	51 (81)	54 (79)	61 (97)	61 (91)	40 (93)
One	3 (5)	2 (3)	0 (0)	0 (0)	1 (2)
Two	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Three to five	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
More than five	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Don't know	6 (10)	2 (3)	0 (0)	0 (0)	1 (2)
Not reported	3 (5)	8 (12)	2 (3)	6 (9)	1 (2)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	3 (5)	1 (1)	0 (0)	0 (0)	1 (2)
Casual sex partner	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Close friend	3 (5)	3 (4)	0 (0)	0 (0)	0 (0)
Acquaintance	3 (5)	1 (1)	0 (0)	0 (0)	0 (0)
Other	2 (3)	0 (0)	0 (0)	0 (0)	0 (0)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	9 (14)	9 (13)	6 (10)	7 (10)	2 (5)
Water	5 (8)	5 (7)	10 (16)	14 (21)	2 (5)
Filter	2 (3)	3 (4)	8 (13)	2 (3)	4 (9)
Drug mix	3 (5)	4 (6)	2 (3)	2 (3)	1 (2)
None	51 (81)	54 (79)	46 (73)	46 (69)	36 (84)
Injected by someone after that person injected themselves or others last month (%)					
No	54 (86)	53 (78)	50 (79)	60 (90)	38 (88)
Yes	7 (11)	10 (15)	9 (14)	5 (7)	5 (12)
Not reported	2 (3)	5 (7)	4 (6)	2 (3)	0 (0)
Source of needle acquisition					
Needle Syringe Program	58 (92)	61 (90)	63 (100)	66 (99)	39 (91)
Chemist/Pharmacy	10 (16)	18 (26)	6 (10)	7 (10)	8 (19)
Personal sources	2 (3)	4 (6)	2 (3)	3 (4)	4 (9)
Dispensing/Vending Machine	1 (2)	5 (7)	5 (8)	1 (1)	12 (28)
Other sources	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)

Table 7.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Tasmania N° surveyed	2011 N=68	2012 N=75	2013 N=70	2014 N=69	2015 N=48
Ever any treatment/therapy for drug use (%)					
No	13 (19)	19 (25)	13 (19)	17 (25)	14 (29)
Yes	53 (78)	55 (73)	56 (80)	52 (75)	34 (71)
Not reported	2 (3)	1 (1)	1 (1)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	20 (30)	22 (29)	27 (39)	21 (30)	14 (29)
Previously	18 (26)	21 (28)	14 (20)	16 (23)	8 (17)
Never	25 (37)	31 (41)	29 (41)	32 (46)	25 (52)
Not reported	5 (7)	1 (1)	0 (0)	0 (0)	1 (2)
History of buprenorphine (Subutex®) treatment (%)					
Currently	5 (7)	7 (9)	5 (7)	9 (13)	5 (10)
Previously	19 (28)	18 (24)	18 (26)	13 (19)	7 (15)
Never	42 (62)	47 (63)	46 (66)	45 (65)	35 (73)
Not reported	2 (3)	3 (4)	1 (1)	2 (3)	1 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	1 (1)	6 (8)	3 (4)	5 (7)	2 (4)
Previously	13 (19)	12 (16)	12 (17)	11 (16)	11 (23)
Never	53 (78)	54 (72)	51 (73)	50 (72)	35 (73)
Not reported	1 (1)	3 (4)	4 (6)	3 (4)	0 (0)

Table 7.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Tasmania N° surveyed	2011 N=68	2012 N=75	2013 N=70	2014 N=69	2015 N=48
Previous HIV test (%)					
Yes, ever	54 (79)	55 (73)	61 (87)	56 (81)	45 (94)
Yes, last year	24 (35)	29 (39)	33 (47)	25 (36)	21 (44)
>1 year ago	30 (44)	26 (35)	28 (40)	31 (45)	24 (50)
Never tested	12 (18)	15 (20)	5 (7)	12 (17)	3 (6)
Not reported	2 (3)	5 (7)	4 (6)	1 (1)	0 (0)
Previous HCV test (%)					
Yes, ever	57 (84)	63 (84)	56 (80)	63 (91)	44 (92)
Yes, last year	30 (44)	36 (48)	33 (47)	38 (55)	23 (48)
>1 year ago	27 (40)	27 (36)	23 (33)	25 (36)	21 (44)
Never tested	7 (10)	7 (9)	6 (9)	3 (4)	2 (4)
Not reported	4 (6)	5 (7)	8 (11)	3 (4)	2 (4)
Lifetime treatment for HCV (%)					
N° self-reported chronic HCV#*					
Antiviral treatment	0 (0)	4 (29)	1 (6)	3 (38)	1 (17)
No antiviral treatment	14 (93)	9 (64)	16 (94)	5 (63)	5 (83)
Not reported	1 (7)	1 (7)	0 (0)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)					
N° self-reported chronic HCV#					
Antiviral treatment	0 (0)	2 (18)	0 (0)	0 (0)	0 (0)
No antiviral treatment	15 (100)	9 (82)	16 (94)	6 (75)	6 (100)
Not reported	0 (0)	0 (0)	1 (6)	2 (25)	0 (0)

among people who tested HCV antibody positive

* includes people who reported treatment induced clearance

Table 7.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Tasmania N° surveyed	2011	2012	2013	2014	2015
Sex with a regular partner last month (%)					
No	28 (41)	34 (45)	23 (33)	28 (41)	16 (33)
Yes	37 (54)	37 (49)	41 (59)	36 (52)	29 (60)
Not reported	3 (4)	4 (5)	6 (9)	5 (7)	3 (6)
Condom used with regular partner last month (%)					
N° surveyed	N=37	N=37	N=41	N=36	N=29
Never	24 (65)	27 (73)	27 (66)	27 (75)	22 (76)
Sometimes	9 (24)	4 (11)	2 (5)	1 (3)	2 (7)
Every time	4 (11)	6 (16)	7 (17)	6 (17)	4 (14)
Not reported	0 (0)	0 (0)	5 (12)	2 (6)	1 (3)
Sex with other partner(s) last month (%)					
No	57 (84)	58 (77)	59 (84)	59 (86)	39 (81)
Yes	8 (12)	8 (11)	5 (7)	4 (6)	6 (13)
Not reported	3 (4)	9 (12)	6 (9)	6 (9)	3 (6)
Condom used with other partner(s) last month (%)					
N° surveyed	N=8	N=8	N=5	N=4	N=6
Never	3 (28)	3 (38)	3 (60)	2 (50)	0 (0)
Sometimes	2 (25)	2 (25)	1 (20)	0 (0)	3 (50)
Every time	3 (38)	2 (25)	1 (20)	1 (25)	3 (50)
Not reported	0 (0)	1 (13)	0 (0)	1 (25)	0 (0)
Sex work last month (%)					
No	64 (94)	68 (91)	58 (83)	56 (81)	45 (94)
Yes	1 (1)	2 (3)	1 (1)	1 (1)	0 (0)
Not reported	3 (4)	5 (7)	11 (16)	12 (17)	3 (6)
Condom used at last sex work (%)					
Yes	1 (100)	2 (100)	1 (100)	1 (100)	--

HIV antibody prevalence

Table 7.2.1 HIV antibody prevalence by gender and survey year

Tasmania Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011	43	0 (0.0)	25	0 (0.0)	68	0 (0.0)
2012	36	0 (0.0)	38	0 (0.0)	74	0 (0.0)
2013	41	0 (0.0)	28	0 (0.0)	69	0 (0.0)
2014	32	0 (0.0)	30	0 (0.0)	63	0 (0.0)
2015	29	0 (0.0)	18	0 (0.0)	47	0 (0.0)
X ² p trend p value		--		--		--

HCV antibody prevalence

Table 7.3.1 HCV antibody prevalence by gender and survey year

Tasmania Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011	42	17 (40)	25	14 (56)	67	31 (46)
2012	36	17 (47)	37	17 (46)	73	34 (47)
2013	41	19 (46)	28	18 (64)	69	37 (54)
2014	30	16 (53)	30	18 (60)	61	35 (57)
2015	26	16 (62)	18	10 (56)	44	26 (59)
X ² p trend value		0.320		0.741		0.319

Table 7.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Tasmania Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Heterosexual	38	15 (39)	22	11 (50)	60	26 (43)
Bisexual	0	0 (0)	2	2 (100)	2	2 (100)
Homosexual	3	2 (67)	0	0 (0)	3	2 (67)
p value		0.560		0.482		0.236
2012						
Heterosexual	30	15 (50)	30	16 (53)	60	31 (52)
Bisexual	2	1 (50)	5	1 (20)	7	2 (29)
Homosexual	3	0 (0)	1	0 (0)	4	0 (0)
p value		0.298		0.252		0.100
2013						
Heterosexual	36	17 (47)	24	15 (63)	60	32 (53)
Bisexual	1	1 (100)	2	2 (100)	3	3 (100)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.730		0.283		0.081
2014						
Heterosexual	24	14 (58)	24	15 (63)	48	29 (60)
Bisexual	0	0 (0)	3	2 (67)	3	2 (67)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.440		0.726		0.283
2015						
Heterosexual	23	14 (61)	13	7 (54)	36	21 (58)
Bisexual	0	0 (0)	2	1 (50)	2	1 (50)
Homosexual	2	1 (50)	1	1 (100)	3	2 (67)
p value		1.000		1.000		1.000

Table 7.3.3 HCV antibody prevalence by age group, gender and survey year

Tasmania Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
<25 years	2	0 (0)	2	1 (50)	4	1 (25)
25-34 years	12	3 (25)	10	6 (60)	22	9 (41)
35-44 years	19	9 (47)	8	5 (63)	27	14 (52)
45+ years	9	5 (56)	5	2 (40)	14	7 (50)
p value		0.330		0.871		0.772
2012						
<25 years	1	0 (0)	2	0 (0)	3	0 (0)
25-34 years	11	5 (45)	13	7 (54)	24	12 (50)
35-44 years	14	8 (57)	17	7 (41)	31	15 (48)
45+ years	10	4 (40)	5	3 (60)	15	7 (47)
p value		0.795		0.605		0.515
2013						
<25 years	2	0 (0)	1	1 (100)	3	1 (33)
25-34 years	11	3 (27)	9	4 (44)	20	7 (35)
35-44 years	17	9 (53)	12	9 (75)	29	18 (62)
45+ years	11	7 (64)	5	3 (60)	16	10 (63)
p value		0.191		0.423		0.188
2014						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	2	1 (50)	8	5 (63)	10	6 (60)
35-44 years	18	9 (50)	12	6 (50)	31	16 (52)
45+ years	10	6 (60)	10	7 (70)	20	13 (65)
p value		0.848		0.651		0.649
2015						
<25 years	1	1 (100)	0	0 (0)	1	1 (100)
25-34 years	4	3 (75)	6	4 (67)	10	7 (70)
35-44 years	12	4 (33)	7	1 (14)	19	5 (26)
45+ years	9	8 (89)	5	5 (100)	14	13 (93)
p value		0.030		0.013		<0.001

Table 7.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Tasmania Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
<3 years	3	1 (33)	4	1 (25)	7	2 (29)
3 to 10 years	5	0 (0)	7	5 (71)	12	5 (42)
11+years	32	15 (47)	13	8 (62)	45	23 (51)
p value		0.156		0.388		0.535
2012						
<3 years	1	0 (0)	4	1 (25)	5	1 (20)
3 to 10 years	5	2 (40)	5	2 (40)	10	4 (40)
11+years	29	15 (52)	26	14 (54)	55	29 (53)
p value		1.000		0.643		0.356
2013						
<3 years	1	0 (0)	2	0 (0)	3	0 (0)
3 to 10 years	5	2 (40)	8	3 (38)	13	5 (38)
11+years	34	16 (47)	16	13 (81)	50	29 (58)
p value		1.000		0.022		0.086
2014						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	4	1 (25)	6	4 (67)	10	5 (50)
11+years	25	15 (60)	23	14 (61)	49	30 (61)
p value		0.299		1.000		0.510
2015						
<3 years	1	0 (0)	1	0 (0)	2	0 (0)
3 to 10 years	6	2 (33)	2	1 (50)	8	3 (38)
11+years	19	14 (74)	15	9 (60)	34	23 (68)
p value		0.086		0.706		0.078

Table 7.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Tasmania Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No receptive sharing	1	0 (0)	47	26 (55)	50	27 (54)
Receptive sharing	5	2 (40)	4	1 (25)	10	3 (30)
p value		1.000		0.331		0.299
2012						
No receptive sharing	3	1 (33)	47	25 (53)	53	26 (49)
Receptive sharing	0	0 (0)	10	5 (50)	10	5 (50)
p value		--		1.000		1.000
2013						
No receptive sharing	2	0 (0)	56	30 (54)	60	32 (53)
Receptive sharing	0	0 (0)	1	0 (0)	2	1 (50)
p value		--		0.474		1.000
2014						
No receptive sharing	0	0 (0)	52	32 (61)	54	32 (59)
Receptive sharing	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		0.295		0.305
2015						
No receptive sharing	2	0 (0)	36	21 (58)	38	21 (55)
Receptive sharing	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.509		0.499

Table 7.3.6 HCV antibody prevalence by last drug injected, years since first injection, and survey year

Tasmania Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Methamphetamine	3	1 (33)	13	6 (46)	18	7 (39)
Pharmaceutical opioids	2	0 (0)	19	7 (37)	22	8 (36)
OST	0	0 (0)	22	13 (59)	22	13 (59)
Other drugs	2	1 (50)	3	2 (67)	5	3 (60)
p value		0.526		0.487		0.377
2012						
Methamphetamine	2	1 (50)	19	8 (42)	22	9 (41)
Pharmaceutical opioids	1	0 (0)	28	15 (54)	30	15 (50)
OST	0	0 (0)	15	9 (60)	16	9 (56)
Other drugs	2	0 (0)	3	1 (33)	5	1 (20)
p value		0.392		0.674		0.485
2013						
Methamphetamine	1	0 (0)	14	7 (50)	16	8 (50)
Pharmaceutical opioids	0	0 (0)	23	13 (57)	23	13 (57)
OST	0	0 (0)	21	11 (52)	23	13 (57)
Other drugs	2	0 (0)	5	3 (60)	7	7 (43)
p value		--		0.970		0.904
2014						
Methamphetamine	0	0 (0)	18	10 (56)	18	10 (56)
Pharmaceutical opioids	0	0 (0)	24	13 (54)	25	13 (52)
OST	0	0 (0)	11	9 (82)	11	9 (82)
Other drugs	0	0 (0)	6	3 (50)	7	3 (43)
p value		--		0.408		0.307
2015						
Methamphetamine	1	0 (0)	17	9 (53)	18	9 (50)
Pharmaceutical opioids	0	0 (0)	14	11 (79)	14	11 (79)
OST	0	0 (0)	11	6 (55)	11	6 (55)
Other drugs	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		0.286		0.226

Table 7.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Tasmania Frequency of injection last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Less than daily	4	1 (25)	31	14 (45)	37	15 (41)
Daily or more	2	1 (50)	22	13 (59)	25	15 (60)
Not last month	1	0 (0)	4	1 (25)	5	1 (20)
p value		1.000		0.345		0.162
2012						
Less than daily	2	1 (50)	31	14 (45)	33	15 (45)
Daily or more	2	0 (0)	29	16 (55)	34	16 (47)
Not last month	1	0 (0)	5	3 (60)	6	3 (50)
p value		1.000		0.693		1.000
2013						
Less than daily	1	0 (0)	35	19 (54)	38	21 (55)
Daily or more	1	0 (0)	22	11 (50)	24	12 (50)
Not last month	1	0 (0)	4	2 (50)	5	2 (40)
p value		--		0.919		0.804
2014						
Less than daily	0	0 (0)	27	15 (56)	28	15 (54)
Daily or more	0	0 (0)	30	19 (63)	31	19 (61)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.414		0.429
2015						
Less than daily	2	0 (0)	20	11 (55)	22	11 (50)
Daily or more	0	0 (0)	18	12 (67)	18	12 (67)
Not last month	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		0.649		0.531

Table 7.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Tasmania Imprisonment last year	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No imprisonment	7	2 (29)	54	26 (48)	62	28 (45)
Imprisonment	0	0 (0)	2	2 (100)	4	3 (75)
p value		--		0.491		0.335
2012						
No imprisonment	5	1 (20)	58	31 (53)	66	32 (48)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		1.000		1.000
2013						
No imprisonment	3	0 (0)	49	24 (49)	54	26 (48)
Imprisonment	0	0 (0)	9	8 (89)	9	8 (89)
p value		--		0.033		0.031
2014						
No imprisonment	0	0 (0)	51	27 (53)	53	27 (51)
Imprisonment	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		1.000		1.000
2015						
No imprisonment	2	0 (0)	36	21 (58)	38	21 (55)
Imprisonment	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000

Table 7.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year

Tasmania	<3 years		3+ years		Total	
Sex work last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
No sex work	7	2 (29)	54	27 (50)	63	30 (48)
Sex work	0	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		1.000
2012						
No sex work	5	1 (20)	59	31 (53)	66	32 (48)
Sex work	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000
2013						
No sex work	3	0 (0)	52	26 (50)	57	28 (49)
Sex work	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		1.000		1.000
2014						
No sex work	0	0 (0)	51	29 (57)	53	29 (55)
Sex work	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.442		0.463
2015						
No sex work	2	0 (0)	39	23 (59)	41	23 (56)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

Table 7.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Tasmania	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Non Indigenous	38	16 (42)	20	10 (50)	58	26 (45)
Indigenous	3	1 (33)	5	4 (80)	8	5 (63)
p value		1.000		0.341		0.459
2012						
Non Indigenous	33	17 (52)	29	12 (41)	62	29 (47)
Indigenous	2	0 (0)	8	5 (63)	10	5 (50)
p value		0.486		0.428		1.000
2013						
Non Indigenous	36	17 (47)	23	13 (57)	59	30 (51)
Indigenous	5	2 (40)	4	4 (100)	9	6 (67)
p value		1.000		0.264		0.484
2014						
Non Indigenous	26	15 (58)	23	12 (52)	50	28 (56)
Indigenous	3	1 (33)	6	5 (83)	9	6 (67)
p value		0.573		0.168		0.551
2015						
Non Indigenous	22	14 (64)	13	6 (46)	35	20 (57)
Indigenous	3	2 (67)	5	4 (80)	8	6 (75)
p value		1.000		0.314		0.351

Table 7.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Tasmania Main language spoken at home by parents	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
English speaking	42	17 (40)	25	14 (56)	67	31 (46)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2012						
English speaking	34	16 (47)	37	17 (46)	71	33 (46)
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.486		--		0.472
2013						
English speaking	41	19 (46)	28	18 (64)	69	37 (54)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2014						
English speaking	30	16 (53)	30	18 (60)	61	35 (57)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2015						
English speaking	25	15 (60)	18	10 (56)	43	25 (58)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

Table 7.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Tasmania		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2011							
Australia	39	14 (36)	24	13 (54)	63	27 (43)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)	
Other	2	2 (100)	0	0 (0)	2	2 (100)	
p value		0.059		1.000		0.041	
2012							
Australia	33	15 (45)	34	15 (44)	67	30 (45)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	1	1 (100)	1	1 (100)	
Other	1	1 (100)	2	1 (50)	3	2 (67)	
p value		0.471		0.723		0.403	
2013							
Australia	39	17 (44)	27	17 (63)	66	34 (52)	
Other Oceania	0	0 (0)	1	1 (100)	1	1 (100)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	2	2 (100)	0	0 (0)	2	2 (100)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.209		1.000		0.495	
2014							
Australia	29	15 (52)	29	17 (59)	59	33 (56)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		1.000		1.000		0.503	
2015							
Australia	22	13 (59)	17	9 (53)	39	22 (56)	
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.670		1.000		0.322	

Victoria

Table 8.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Victoria	2011	2012	2013	2014	2015
Number of sites	6	6	6	6	6
N° surveyed	N=506	N=463	N=448	N=436	N=459
Response rate (%)	55%	52%	61%	41%	62%
Gender (%)					
Male	341 (67)	322 (70)	302 (67)	288 (66)	303 (66)
Female	163 (32)	140 (30)	139 (31)	146 (33)	153 (33)
Transgender	1 (<1)	1 (<1)	4 (<1)	2 (<1)	3 (1)
Not reported	1 (<1)	0 (0)	3 (<1)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	415 (82)	367 (79)	338 (75)	349 (81)	381 (83)
Bisexual	45 (9)	46 (10)	31 (7)	36 (8)	36 (8)
Homosexual	14 (3)	17 (4)	25 (6)	11 (3)	17 (4)
Not reported	32 (6)	33 (7)	54 (12)	40 (9)	25 (5)
Aboriginal and Torres Strait Islander origin (%)					
No	442 (87)	389 (84)	380 (85)	378 (87)	401 (87)
Yes	55 (11)	67 (14)	52 (12)	53 (12)	53 (12)
Not reported	9 (2)	7 (2)	16 (4)	5 (1)	5 (1)
Region/country of birth (%)					
Australia	444 (88)	388 (84)	364 (81)	360 (83)	376 (82)
Other Oceania	11 (2)	14 (3)	10 (2)	10 (2)	18 (4)
Asia	6 (1)	14 (3)	20 (4)	20 (5)	16 (3)
UK & Ireland	20 (4)	21 (5)	22 (5)	20 (5)	27 (6)
Other	24 (5)	24 (5)	30 (7)	25 (6)	20 (4)
Not reported	1 (<1)	2 (<1)	2 (<1)	1 (<1)	2 (<1)
Main language spoken at home by parents (%)					
English	457 (90)	417 (90)	393 (88)	378 (87)	414 (90)
Non-English	45 (9)	45 (10)	54 (12)	57 (13)	42 (9)
Not reported	4 (1)	1 (<1)	1 (<1)	1 (<1)	3 (1)
Age and time since first injection (years)					
<i>Median age</i>	37	37	38	39	40
<i>Age range</i>	18-63	17-64	15-66	16-65	18-64
<i>Age group (%)</i>					
<25 years	38 (8)	21 (5)	18 (4)	12 (3)	8 (2)
25+ years	464 (92)	440 (95)	429 (96)	422 (97)	450 (98)
Not reported	4 (1)	2 (<1)	1 (<1)	2 (<1)	1 (<1)
<i>Median age first injection</i>					
	18	18	18	18	18
<i>Age range</i>					
	10-50	10-59	10-52	10-52	11-54
<i>N° not reported</i>					
	11	17	23	6	10
<i>Median yrs since first injection</i>					
	17	18	18	20	20
<i>Range</i>					
	<1-47	<1-43	<1-40	<1-41	<1-41
<i>Years since first injection</i>					
<3 years	13 (3)	14 (3)	13 (3)	17 (4)	19 (4)
3+ years	481 (95)	431 (93)	412 (92)	399 (92)	429 (93)
Not reported	12 (2)	18 (4)	23 (5)	20 (5)	11 (2)
Imprisonment last year (%)					
No	403 (80)	368 (80)	354 (79)	359 (82)	373 (81)
Yes	59 (12)	75 (16)	48 (11)	50 (11)	61 (13)
Not reported	44 (9)	20 (4)	46 (10)	27 (6)	25 (5)
N° in prison					
	N=59	N=75	N=48	N=50	N=61
Injected in prison	19 (32)	22 (29)	14 (29)	19 (38)	15 (25)

Table 8.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Victoria N° surveyed	2011 N=506	2012 N=463	2013 N=448	2014 N=436	2015 N=459
Drug last injected (%)					
Cocaine	2 (<1)	0 (0)	1 (<1)	6 (1)	5 (1)
Methamphetamine	91 (18)	82 (18)	96 (21)	98 (22)	142 (31)
Heroin	307 (61)	299 (65)	241 (54)	240 (55)	237 (52)
Pharm. opioids	26 (5)	15 (3)	19 (4)	18 (4)	16 (3)
Methadone	12 (2)	7 (2)	8 (2)	10 (2)	9 (2)
Buprenorphine	20 (4)	13 (3)	22 (5)	14 (3)	16 (3)
Buprenorphine/naloxone	16 (3)	10 (2)	10 (2)	14 (3)	7 (2)
PIEDs	1 (<1)	2 (<1)	3 (<1)	0 (0)	4 (1)
More than one	26 (5)	32 (7)	43 (10)	27 (6)	19 (4)
Other	2 (<1)	2 (<1)	4 (<1)	6 (1)	4 (1)
Not reported	3 (<1)	1 (<1)	1 (<1)	3 (<1)	0 (0)
Frequency of injection last month (%)					
Not last month	46 (9)	26 (6)	33 (7)	38 (9)	35 (8)
Less than weekly	68 (13)	93 (20)	84 (19)	68 (16)	74 (16)
Weekly not daily	109 (22)	99 (21)	102 (23)	122 (28)	129 (28)
Daily or more	278 (55)	236 (51)	210 (47)	204 (47)	216 (47)
Not reported	5 (1)	9 (2)	19 (4)	4 (1)	5 (1)
Present when someone injected for the first time in the last 12 months (%)					
Yes	--	70 (15)	49 (11)	71 (16)	66 (14)
No	--	356 (77)	318 (71)	349 (80)	379 (83)
Not reported	--	81 (18)	81 (18)	16 (4)	14 (3)
Overdosed in last 12 months					
Yes	--	--	78 (17)	82 (19)	97 (21)
No	--	--	358 (80)	339 (78)	353 (77)
Not reported	--	--	12 (3)	15 (3)	9 (2)

Table 8.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Victoria N° injected last month	2011 N=455	2012 N=428	2013 N=396	2014 N=394	2015 N=419
Places injected last month (%)					
Any public	292 (64)	259 (61)	224 (57)	215 (55)	233 (56)
All private	149 (33)	148 (35)	164 (41)	177 (45)	183 (44)
Not reported	14 (3)	21 (5)	8 (2)	2 (<1)	3 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	327 (72)	319 (75)	269 (68)	278 (71)	283 (68)
Most of the time	87 (19)	70 (16)	103 (26)	92 (23)	108 (26)
Half of the time	13 (3)	9 (2)	2 (<1)	10 (3)	15 (4)
Some of the time	5 (1)	4 (1)	8 (2)	3 (1)	9 (2)
Not last month	0 (0)	2 (<1)	2 (<1)	0 (0)	2 (<1)
Not reported	23 (5)	24 (6)	12 (3)	11 (3)	2 (<1)
Re-used someone else's used needle & syringe last month (%)					
None	330 (73)	316 (74)	313 (79)	318 (81)	333 (79)
Once	30 (7)	43 (10)	19 (5)	23 (6)	23 (5)
Twice	25 (5)	18 (4)	18 (5)	15 (4)	27 (6)
3-5 times	21 (5)	17 (4)	20 (5)	17 (4)	21 (5)
>5 times	16 (4)	16 (4)	16 (4)	12 (3)	12 (3)
Not reported	33 (7)	18 (4)	10 (3)	9 (2)	3 (1)
Number of people needle & syringe was re-used after last month (%)					
None	330 (73)	316 (74)	313 (79)	318 (81)	333 (79)
One	49 (11)	50 (12)	30 (8)	31 (8)	42 (10)
Two	9 (2)	5 (1)	8 (2)	6 (2)	9 (2)
Three to five	5 (1)	5 (1)	2 (<1)	1 (<1)	5 (1)
More than five	5 (1)	3 (1)	6 (2)	2 (<1)	2 (<1)
Don't know	20 (4)	16 (4)	18 (5)	11 (3)	15 (4)
Not reported	37 (8)	33 (8)	19 (5)	25 (6)	13 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	47 (10)	28 (7)	28 (7)	25 (6)	30 (7)
Casual sex partner	3 (1)	3 (1)	5 (1)	0 (0)	5 (1)
Close friend	50 (11)	29 (7)	18 (5)	17 (4)	28 (7)
Acquaintance	23 (5)	13 (3)	14 (4)	7 (2)	12 (3)
Other	13 (3)	10 (2)	6 (2)	5 (1)	5 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	163 (36)	143 (33)	128 (32)	131 (33)	145 (35)
Water	100 (22)	90 (21)	83 (21)	86 (22)	99 (24)
Filter	76 (17)	68 (16)	56 (14)	69 (18)	78 (19)
Drug mix	53 (12)	60 (14)	43 (11)	49 (12)	64 (15)
None	246 (54)	228 (53)	238 (60)	240 (61)	247 (59)
Injected by someone after that person injected themselves or others last month (%)					
No	359 (79)	336 (79)	315 (80)	326 (83)	345 (82)
Yes	72 (16)	65 (15)	58 (15)	53 (13)	67 (16)
Not reported	24 (5)	27 (6)	23 (6)	15 (4)	7 (2)
Source of needle acquisition					
Needle Syringe Program	425 (93)	394 (92)	374 (94)	368 (93)	384 (92)
Chemist/Pharmacy	92 (20)	88 (21)	90 (23)	87 (22)	93 (22)
Personal sources	46 (10)	65 (15)	29 (7)	55 (14)	80 (19)
Dispensing/Vending Machine	0 (0)	0 (0)	1 (<1)	1 (<1)	3 (1)
Other sources	4 (1)	7 (2)	7 (2)	4 (1)	16 (4)

Table 8.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Victoria N° surveyed	2011 N=506	2012 N=463	2013 N=448	2014 N=436	2015 N=459
Ever any treatment/therapy for drug use (%)					
No	58 (11)	38 (8)	39 (9)	36 (8)	67 (15)
Yes	441 (87)	423 (91)	406 (91)	396 (91)	388 (85)
Not reported	7 (1)	2 (<1)	3 (<1)	4 (1)	4 (1)
History of methadone maintenance treatment (%)					
Currently	169 (33)	162 (35)	171 (38)	152 (35)	137 (30)
Previously	157 (31)	176 (38)	142 (32)	153 (35)	151 (33)
Never	162 (32)	123 (27)	133 (30)	126 (30)	162 (35)
Not reported	18 (4)	2 (<1)	2 (<1)	5 (1)	9 (2)
History of buprenorphine (Subutex®) treatment (%)					
Currently	57 (11)	55 (12)	44 (10)	48 (11)	40 (9)
Previously	197 (39)	198 (43)	197 (44)	196 (45)	188 (41)
Never	234 (46)	203 (44)	200 (45)	183 (42)	221 (48)
Not reported	18 (4)	7 (2)	7 (2)	9 (2)	10 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	69 (14)	53 (11)	61 (14)	50 (11)	48 (10)
Previously	137 (27)	165 (36)	156 (35)	167 (38)	156 (34)
Never	281 (56)	238 (51)	225 (50)	208 (48)	246 (54)
Not reported	19 (4)	7 (2)	6 (1)	11 (3)	9 (2)

Table 8.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Victoria N° surveyed	2011 N=506	2012 N=463	2013 N=448	2014 N=436	2015 N=459
Previous HIV test (%)					
Yes, ever	430 (85)	404 (87)	381 (85)	386 (89)	397 (86)
Yes, last year	264 (52)	274 (59)	253 (56)	244 (56)	243 (53)
>1 year ago	166 (33)	130 (28)	128 (29)	142 (33)	154 (34)
Never tested	52 (10)	44 (10)	42 (9)	33 (8)	48 (10)
Not reported	24 (5)	15 (3)	25 (6)	17 (4)	14 (3)
Previous HCV test (%)					
Yes, ever	458 (91)	417 (90)	393 (88)	395 (91)	429 (93)
Yes, last year	305 (60)	295 (64)	268 (60)	263 (60)	278 (61)
>1 year ago	153 (30)	122 (26)	125 (28)	132 (30)	151 (33)
Never tested	18 (4)	22 (5)	13 (3)	19 (4)	17 (4)
Not reported	30 (6)	24 (5)	42 (9)	22 (5)	13 (3)
Lifetime treatment for HCV (%)					
N° self-reported chronic HCV#*					
Antiviral treatment	12 (7)	15 (9)	10 (7)	8 (6)	10 (8)
No antiviral treatment	161 (92)	139 (87)	128 (90)	134 (94)	107 (86)
Not reported	2 (1)	5 (3)	4 (3)	0 (0)	8 (6)
Treatment for HCV in past 12 months (%)					
N° self-reported chronic HCV#					
Antiviral treatment	4 (2)	2 (1)	2 (1)	0 (0)	3 (3)
No antiviral treatment	163 (98)	146 (97)	128 (95)	131 (98)	110 (94)
Not reported	0 (0)	3 (2)	5 (4)	3 (2)	4 (3)

among people who tested HCV antibody positive

* includes people who reported treatment induced clearance

Table 8.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Victoria	2011	2012	2013	2014	2015
N° surveyed	N=506	N=463	N=448	N=436	N=459
Sex with a regular partner last month (%)					
No	249 (49)	256 (55)	244 (54)	240 (55)	260 (57)
Yes	209 (41)	196 (42)	182 (41)	175 (40)	180 (39)
Not reported	48 (9)	11 (2)	22 (5)	21 (5)	19 (4)
Condom used with regular partner last month (%)					
N° surveyed	N=209	N=196	N=182	N=175	N=180
Never	146 (70)	124 (63)	117 (64)	129 (74)	134 (74)
Sometimes	29 (14)	28 (14)	30 (16)	24 (14)	22 (12)
Every time	25 (12)	25 (13)	20 (11)	12 (7)	20 (11)
Not reported	9 (4)	19 (10)	15 (8)	10 (6)	4 (2)
Sex with other partner(s) last month (%)					
No	406 (80)	359 (78)	351 (78)	350 (80)	377 (82)
Yes	81 (16)	86 (19)	70 (16)	60 (14)	64 (14)
Not reported	19 (4)	18 (4)	27 (6)	26 (6)	18 (4)
Condom used with other partner(s) last month (%)					
N° surveyed	N=81	N=86	N=70	N=60	N=64
Never	28 (35)	30 (35)	17 (24)	20 (33)	22 (34)
Sometimes	16 (20)	24 (28)	24 (34)	11 (18)	23 (36)
Every time	32 (40)	30 (35)	24 (34)	21 (35)	16 (25)
Not reported	5 (6)	2 (2)	5 (7)	8 (13)	3 (5)
Sex work last month (%)					
No	454 (90)	418 (90)	390 (87)	372 (85)	416 (91)
Yes	31 (6)	34 (7)	19 (4)	28 (6)	25 (5)
Not reported	21 (4)	11 (2)	39 (9)	36 (8)	18 (4)
Condom used at last sex work (%)					
Yes	25 (81)	29 (85)	12 (63)	16 (57)	18 (72)

HIV antibody prevalence

Table 8.2.1 HIV antibody prevalence by gender and survey year

Victoria Survey year	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011	335	4 (1.2)	162	0 (0.0)	499	4 (0.8)
2012	304	1 (0.3)	128	0 (0.0)	433	1 (0.2)
2013	300	5 (1.7)	139	1 (0.7)	446	6 (1.3)
2014	277	4 (1.4)	143	3 (2.1)	421	7 (1.7)
2015	300	10 (3.3)	152	0 (0.0)	455	10 (2.2)
X ² p trend p value		0.020		0.298		0.012

Table 8.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Victoria Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
Heterosexual	303	1 (0.3)	107	0 (0.0)	411	1 (0.2)
Bisexual	10	0 (0.0)	35	0 (0.0)	45	0 (0.0)
Homosexual	5	3 (37.5)	5	0 (0.0)	13	3 (23.1)
p value		<0.001		--		<0.001
2012						
Heterosexual	262	1 (0.4)	82	0 (0.0)	344	1 (0.3)
Bisexual	16	0 (0.0)	27	0 (0.0)	43	0 (0.0)
Homosexual	5	0 (0.0)	9	0 (0.0)	15	0 (0.0)
p value		1.000		--		1.000
2013						
Heterosexual	243	2 (0.8)	91	1 (1.1)	337	3 (0.9)
Bisexual	8	0 (0.0)	22	0 (0.0)	31	0 (0.0)
Homosexual	13	2 (15.4)	8	0 (0.0)	24	2 (8.3)
p value		<0.001		1.000		0.006
2014						
Heterosexual	230	4 (1.7)	106	3 (2.8)	337	7 (2.1)
Bisexual	12	0 (0.0)	23	0 (0.0)	35	0 (0.0)
Homosexual	9	0 (0.0)	2	0 (0.0)	11	0 (0.0)
p value		1.000		1.000		1.000
2015						
Heterosexual	259	4 (1.5)	118	0 (0.0)	377	4 (1.1)
Bisexual	17	1 (5.9)	18	0 (0.0)	36	1 (2.8)
Homosexual	9	4 (44.4)	6	0 (0.0)	17	4 (23.5)
p value		<0.001		--		<0.001

Table 8.2.3 HIV antibody prevalence by age group, gender and survey year

Victoria Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
<25 years	18	0 (0.0)	20	0 (0.0)	38	0 (0.0)
25-34 years	104	1 (1.0)	62	0 (0.0)	167	1 (0.6)
35-44 years	136	1 (0.7)	55	0 (0.0)	191	1 (1.5)
45+ years	75	2 (2.7)	24	0 (0.0)	99	2 (2.0)
p value		0.567		--		0.594
2012						
<25 years	13	0 (0.0)	7	0 (0.0)	20	0 (0.0)
25-34 years	93	0 (0.0)	50	0 (0.0)	144	0 (0.0)
35-44 years	133	1 (0.8)	52	0 (0.0)	185	1 (0.5)
45+ years	64	0 (0.0)	19	0 (0.0)	83	0 (0.0)
p value		1.000		--		1.000
2013						
<25 years	8	0 (0.0)	10	0 (0.0)	18	0 (0.0)
25-34 years	80	2 (2.5)	48	0 (0.0)	132	2 (1.5)
35-44 years	135	0 (0.0)	48	0 (0.0)	185	0 (0.0)
45+ years	76	3 (4.0)	33	1 (3.0)	110	4 (3.6)
p value		0.086		0.309		0.054
2014						
<25 years	5	0 (0.0)	5	0 (0.0)	11	0 (0.0)
25-34 years	70	3 (4.3)	51	0 (0.0)	121	3 (2.5)
35-44 years	124	0 (0.0)	51	2 (3.9)	175	2 (1.1)
45+ years	76	1 (1.3)	36	1 (2.8)	112	2 (1.8)
p value		0.098		0.531		0.703
2015						
<25 years	4	0 (0.0)	4	0 (0.0)	8	0 (0.0)
25-34 years	60	6 (10.0)	47	0 (0.0)	108	6 (5.6)
35-44 years	125	2 (1.6)	55	0 (0.0)	181	2 (1.1)
45+ years	110	2 (1.8)	46	0 (0.0)	157	2 (1.3)
p value		0.036		--		0.059

Table 8.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Victoria						
Last drug injected	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
Heroin	209	2 (1.0)	93	0 (0.0)	302	2 (0.7)
Methamphetamine	50	2 (4.0)	39	0 (0.0)	90	2 (2.2)
Other opioids	53	0 (0.0)	21	0 (0.0)	74	0 (0.0)
Other drugs	21	0 (0.0)	8	0 (0.0)	30	0 (0.0)
p value		0.303		--		0.443
2012						
Heroin	199	1 (0.5)	89	0 (0.0)	288	1 (0.4)
Methamphetamine	48	0 (0.0)	19	0 (0.0)	68	0 (0.0)
Other opioids	30	0 (0.0)	12	0 (0.0)	42	0 (0.0)
Other drugs	26	0 (0.0)	8	0 (0.0)	34	0 (0.0)
p value		1.000		--		1.000
2013						
Heroin	160	2 (1.3)	76	1 (1.3)	239	3 (1.3)
Methamphetamine	61	3 (4.9)	34	0 (0.0)	96	3 (3.1)
Other opioids	45	0 (0.0)	14	0 (0.0)	59	0 (0.0)
Other drugs	33	0 (0.0)	15	0 (0.0)	51	0 (0.0)
p value		0.258		1.000		0.434
2014						
Heroin	157	4 (2.6)	73	1 (1.4)	230	5 (2.1)
Methamphetamine	55	0 (0.0)	39	1 (2.6)	95	1 (1.1)
Other opioids	40	0 (0.0)	16	0 (0.0)	56	0 (0.0)
Other drugs	23	0 (0.0)	14	1 (7.1)	37	1 (2.7)
p value		0.627		0.344		0.628
2015						
Heroin	155	5 (3.2)	79	0 (0.0)	236	5 (2.1)
Methamphetamine	95	5 (5.3)	44	0 (0.0)	140	5 (3.6)
Other opioids	31	0 (0.0)	17	0 (0.0)	48	0 (0.0)
Other drugs	19	0 (0.0)	12	0 (0.0)	31	0 (0.0)
p value		0.554		--		0.544

Table 8.2.5 HIV antibody prevalence by years of injection, gender and survey year

Victoria Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
<3 years	5	0 (0.0)	8	0 (0.0)	13	0 (0.0)
3 to 10 years	50	0 (0.0)	37	0 (0.0)	87	0 (0.0)
11 + years	276	4 (1.5)	110	0 (0.0)	387	4 (1.0)
p value		1.000		--		1.000
2012						
<3 years	9	0 (0.0)	4	0 (0.0)	13	0 (0.0)
3 to 10 years	46	0 (0.0)	18	0 (0.0)	64	0 (0.0)
11 + years	239	1 (0.4)	99	0 (0.0)	339	1 (0.3)
p value		1.000		--		1.000
2013						
<3 years	5	0 (0.0)	6	0 (0.0)	13	0 (0.0)
3 to 10 years	39	2 (5.1)	26	0 (0.0)	66	2 (3.0)
11 + years	239	3 (1.3)	102	1 (1.0)	344	4 (1.2)
p value		0.219		1.000		0.378
2014						
<3 years	8	0 (0.0)	9	0 (0.0)	17	0 (0.0)
3 to 10 years	24	2 (8.3)	22	0 (0.0)	47	2 (4.3)
11 + years	231	2 (0.9)	106	3 (2.8)	337	5 (1.5)
p value		0.074		1.000		0.416
2015						
<3 years	12	0 (0.0)	7	0 (0.0)	19	0 (0.0)
3 to 10 years	32	4 (12.5)	23	0 (0.0)	57	4 (7.0)
11 + years	248	6 (2.4)	119	0 (0.0)	368	6 (1.6)
p value		0.033		--		0.051

Table 8.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Victoria Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No receptive sharing	223	3 (1.4)	104	0 (0.0)	327	3 (0.9)
Receptive sharing	59	0 (0.0)	30	0 (0.0)	90	0 (0.0)
p value		1.000		--		1.000
2012						
No receptive sharing	212	1 (0.5)	87	0 (0.0)	300	1 (0.3)
Receptive sharing	61	0 (0.0)	25	0 (0.0)	86	0 (0.0)
p value		1.000		--		1.000
2013						
No receptive sharing	207	4 (1.9)	99	1 (1.0)	311	5 (1.6)
Receptive sharing	55	0 (0.0)	18	0 (0.0)	73	0 (0.0)
p value		0.582		1.000		0.588
2014						
No receptive sharing	206	2 (1.0)	98	2 (2.0)	305	4 (1.3)
Receptive sharing	37	2 (5.4)	28	1 (3.6)	65	3 (4.6)
p value		0.111		0.533		0.107
2015						
No receptive sharing	212	10 (4.7)	114	0 (0.0)	329	10 (3.0)
Receptive sharing	59	0 (0.0)	24	0 (0.0)	83	0 (0.0)
p value		0.125		--		0.223

Table 8.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Victoria	Male		Female		Total	
Frequency of injection	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
Less than daily	114	3 (2.6)	61	0 (0.0)	175	3 (1.7)
Daily or more	184	0 (0.0)	89	0 (0.0)	274	0 (0.0)
Not last month	33	1 (3.0)	11	0 (0.0)	45	1 (2.2)
p value		0.040		--		0.055
2012						
Less than daily	125	1 (0.8)	56	0 (0.0)	182	1 (0.6)
Daily or more	158	0 (0.0)	61	0 (0.0)	219	0 (0.0)
Not last month	14	0 (0.0)	11	0 (0.0)	25	0 (0.0)
p value		0.468		--		0.486
2013						
Less than daily	119	1 (0.8)	65	1 (1.5)	185	2 (1.1)
Daily or more	147	3 (2.0)	58	0 (0.0)	209	3 (1.5)
Not last month	24	1 (4.2)	9	0 (0.0)	33	1 (3.0)
p value		0.357		1.000		0.520
2014						
Less than daily	119	0 (0.0)	63	0 (0.0)	183	0 (0.0)
Daily or more	129	4 (3.1)	67	3 (4.5)	196	7 (3.6)
Not last month	26	0 (0.0)	12	0 (0.0)	38	0 (0.0)
p value		0.199		0.313		0.031
2015						
Less than daily	126	6 (4.8)	72	0 (0.0)	200	6 (3.0)
Daily or more	146	4 (2.7)	68	0 (0.0)	215	4 (1.9)
Not last month	25	0 (0.0)	10	0 (0.0)	35	0 (0.0)
p value		0.536		--		0.605

Table 8.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Victoria	Male		Female		Total	
Imprisonment last year	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No imprisonment	252	4 (1.6)	143	0 (0.0)	397	4 (1.0)
Imprisonment	44	0 (0.0)	14	0 (0.0)	58	0 (0.0)
p value		1.000		--		1.000
2012						
No imprisonment	230	1 (0.4)	114	0 (0.0)	345	1 (0.3)
Imprisonment	61	0 (0.0)	8	0 (0.0)	69	0 (0.0)
p value		1.000		--		1.000
2013						
No imprisonment	228	4 (1.8)	118	1 (0.9)	352	5 (1.4)
Imprisonment	38	1 (2.6)	10	0 (0.0)	48	1 (2.1)
p value		0.540		1.000		0.538
2014						
No imprisonment	220	4 (1.8)	129	3 (2.3)	350	7 (2.0)
Imprisonment	38	0 (0.0)	8	0 (0.0)	46	0 (0.0)
p value		1.000		1.000		1.000
2015						
No imprisonment	233	9 (3.9)	135	0 (0.0)	371	9 (2.4)
Imprisonment	48	0 (0.0)	11	0 (0.0)	59	0 (0.0)
p value		0.366		--		0.618

Table 8.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Victoria Condom use at last sex	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No condom use	81	1 (1.2)	64	0 (0.0)	145	1 (0.7)
Condom use	42	0 (0.0)	9	0 (0.0)	51	0 (0.0)
p value		1.000		--		1.000
2012						
No condom use	72	0 (0.0)	38	0 (0.0)	111	0 (0.0)
Condom use	33	0 (0.0)	18	0 (0.0)	51	0 (0.0)
p value		--		--		--
2013						
No condom use	65	1 (1.6)	51	0 (0.0)	117	1 (0.9)
Condom use	32	2 (6.3)	16	0 (0.0)	50	2 (4.0)
p value		0.252		--		0.214
2014						
No condom use	67	1 (1.5)	57	1 (1.8)	124	2 (1.6)
Condom use	22	0 (0.0)	13	0 (0.0)	35	0 (0.0)
p value		1.000		1.000		1.000
2015						
No condom use	75	1 (1.3)	57	0 (0.0)	133	1 (0.8)
Condom use	25	1 (4.0)	15	0 (0.0)	41	1 (2.4)
p value		0.439		--		0.417

Table 8.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Victoria Sex work last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No sex work	310	4 (1.3)	136	0 (0.0)	447	4 (0.9)
Sex work	10	0 (0.0)	21	0 (0.0)	31	0 (0.0)
p value		1.000		--		1.000
2012						
No sex work	282	1 (0.4)	105	0 (0.0)	388	1 (0.3)
Sex work	13	0 (0.0)	21	0 (0.0)	34	0 (0.0)
p value		1.000		--		1.000
2013						
No sex work	268	5 (1.9)	115	1 (0.9)	388	6 (1.6)
Sex work	7	0 (0.0)	11	0 (0.0)	19	0 (0.0)
p value		1.000		1.000		1.000
2014						
No sex work	241	3 (1.2)	119	3 (2.2)	360	6 (1.7)
Sex work	12	0 (0.0)	15	0 (0.0)	28	0 (0.0)
p value		1.000		1.000		1.000
2015						
No sex work	278	8 (2.9)	133	0 (0.0)	412	8 (1.9)
Sex work	6	2 (33.3)	17	0 (0.0)	25	2 (8.0)
p value		0.016		--		0.107

Table 8.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Victoria	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Non Indigenous	295	4 (1.4)	139	0 (0.0)	435	4 (0.9)
Indigenous	33	0 (0.0)	21	0 (0.0)	55	0 (0.0)
p value		1.000		--		1.000
2012						
Non Indigenous	252	1 (0.4)	110	0 (0.0)	363	1 (0.3)
Indigenous	48	0 (0.0)	16	0 (0.0)	64	0 (0.0)
p value		1.000		--		1.000
2013						
Non Indigenous	256	4 (1.6)	119	1 (0.8)	379	5 (1.3)
Indigenous	32	1 (3.1)	17	0 (0.0)	51	1 (2.0)
p value		0.448		1.000		0.533
2014						
Non Indigenous	245	2 (0.8)	120	2 (1.7)	366	4 (1.1)
Indigenous	30	2 (6.7)	20	1 (5.0)	50	3 (6.0)
p value		0.060		0.373		0.040
2015						
Non Indigenous	261	6 (2.3)	134	0 (0.0)	398	6 (1.5)
Indigenous	34	4 (11.8)	18	0 (0.0)	52	4 (7.7)
p value		0.019		--		0.020

Table 8.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Victoria	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
English speaking	296	3 (1.0)	154	0 (0.0)	451	3 (0.7)
Non-English speaking	36	1 (2.8)	7	0 (0.0)	44	1 (2.3)
p value		0.370		--		0.312
2012						
English speaking	269	1 (0.4)	118	0 (0.0)	388	1 (0.3)
Non-English speaking	35	0 (0.0)	9	0 (0.0)	44	0 (0.0)
p value		1.000		--		1.000
2013						
English speaking	254	4 (1.6)	130	1 (0.8)	391	5 (1.3)
Non-English speaking	45	1 (2.2)	9	0 (0.0)	54	1 (1.9)
p value		0.560		1.000		0.542
2014						
English speaking	235	3 (1.3)	129	2 (1.6)	364	5 (1.4)
Non-English speaking	42	1 (2.4)	13	1 (7.7)	56	2 (3.6)
p value		0.484		0.252		0.237
2015						
English speaking	266	9 (3.4)	141	0 (0.0)	410	9 (2.2)
Non-English speaking	31	1 (3.2)	11	0 (0.0)	42	1 (2.4)
p value		1.000		--		1.000

Table 8.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Victoria Region/country of birth	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Australia	285	3 (1.1)	152	0 (0.0)	439	3 (0.7)
Other Oceania	10	0 (0.0)	0	0 (0.0)	11	0 (0.0)
Asia	6	1 (16.7)	1	0 (0.0)	6	1 (16.7)
UK & Ireland	15	0 (0.0)	4	0 (0.0)	19	0 (0.0)
Other	18	0 (0.0)	5	0 (0.0)	23	0 (0.0)
p value		0.149		--		0.104
2012						
Australia	248	1 (0.4)	111	0 (0.0)	360	1 (0.3)
Other Oceania	9	0 (0.0)	4	0 (0.0)	13	0 (0.0)
Asia	13	0 (0.0)	1	0 (0.0)	14	0 (0.0)
UK & Ireland	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)
Other	17	0 (0.0)	7	0 (0.0)	24	0 (0.0)
p value		1.000		--		1.000
2013						
Australia	235	3 (1.3)	121	1 (0.8)	363	4 (1.1)
Other Oceania	10	0 (0.0)	0	0 (0.0)	10	0 (0.0)
Asia	17	1 (5.9)	3	0 (0.0)	20	1 (5.0)
UK & Ireland	14	0 (0.0)	7	0 (0.0)	21	0 (0.0)
Other	22	1 (4.6)	8	0 (0.0)	30	1 (3.3)
p value		0.486		1.000		0.258
2014						
Australia	220	3 (1.4)	127	2 (1.6)	348	5 (1.4)
Other Oceania	9	0 (0.0)	1	0 (0.0)	10	0 (0.0)
Asia	17	1 (5.9)	2	1 (50.0)	19	2 (10.5)
UK & Ireland	14	0 (0.0)	6	0 (0.0)	20	0 (0.0)
Other	16	0 (0.0)	7	0 (0.0)	26	0 (0.0)
p value		0.599		0.083		0.121
2015						
Australia	243	9 (3.7)	128	0 (0.0)	373	9 (2.4)
Other Oceania	14	0 (0.0)	3	0 (0.0)	17	0 (0.0)
Asia	13	1 (7.7)	3	0 (0.0)	16	1 (6.3)
UK & Ireland	13	0 (0.0)	13	0 (0.0)	27	0 (0.0)
Other	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)
p value		0.719		--		0.613

HCV ANTIBODY PREVALENCE

Table 8.3.1 HCV antibody prevalence by gender and survey year

Victoria Survey year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011	332	229 (69)	158	93 (59)	492	324 (66)
2012	301	214 (71)	127	83 (65)	429	297 (69)
2013	299	199 (67)	138	94 (68)	444	296 (67)
2014	267	183 (69)	138	90 (65)	406	273 (67)
2015	278	207 (74)	143	98 (69)	424	306 (72)
X ² p trend value		0.686		0.458		0.501

Table 8.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Victoria Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Heterosexual	300	212 (71)	102	60 (59)	403	273 (68)
Bisexual	10	5 (50)	35	18 (51)	45	23 (51)
Homosexual	9	5 (56)	5	2 (40)	14	7 (50)
p value		0.893		0.409		0.442
2012						
Heterosexual	259	182 (70)	80	50 (63)	339	232 (68)
Bisexual	16	12 (75)	28	19 (68)	44	31 (70)
Homosexual	5	2 (40)	9	7 (78)	15	9 (60)
p value		0.308		0.665		0.717
2013						
Heterosexual	242	166 (69)	90	63 (70)	335	231 (69)
Bisexual	8	6 (75)	22	12 (55)	31	18 (58)
Homosexual	13	4 (31)	8	6 (75)	24	11 (46)
p value		0.019		0.350		0.040
2014						
Heterosexual	221	149 (67)	102	64 (63)	324	213 (66)
Bisexual	12	9 (75)	22	14 (64)	34	23 (68)
Homosexual	9	6 (67)	2	2 (100)	11	8 (73)
p value		0.859		0.750		0.873
2015						
Heterosexual	245	182 (74)	110	75 (68)	355	257 (72)
Bisexual	12	8 (67)	17	11 (65)	30	19 (63)
Homosexual	7	7 (100)	6	5 (83)	15	13 (87)
p value		0.247		0.695		0.281

Table 8.3.3 HCV antibody prevalence by age group, gender and survey year

Victoria Age group	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
<25 years	18	8 (44)	20	5 (25)	38	13 (34)
25-34 years	102	68 (67)	60	40 (67)	163	109 (67)
35-44 years	135	93 (69)	53	33 (62)	188	126 (67)
45+ years	75	59 (79)	24	15 (63)	99	47 (75)
p value		0.037		0.011		<0.001
2012						
<25 years	14	3 (21)	7	2 (29)	21	5 (24)
25-34 years	91	63 (69)	50	32 (64)	142	95 (67)
35-44 years	132	101 (77)	50	35 (70)	182	136 (75)
45+ years	63	46 (73)	20	14 (70)	83	60 (72)
p value		0.001		0.214		<0.001
2013						
<25 years	8	1 (13)	10	4 (40)	18	5 (28)
25-34 years	79	37 (47)	48	28 (58)	131	67 (51)
35-44 years	135	101 (75)	47	36 (77)	184	137 (74)
45+ years	76	59 (78)	33	26 (79)	110	86 (78)
p value		<0.001		0.030		<0.001
2014						
<25 years	5	2 (40)	5	3 (60)	11	5 (45)
25-34 years	69	42 (61)	48	26 (54)	117	68 (58)
35-44 years	120	80 (67)	49	38 (78)	169	118 (70)
45+ years	71	58 (82)	36	23 (64)	107	81 (76)
p value		0.015		0.093		0.013
2015						
<25 years	4	0 (0)	4	0 (0)	8	0 (0)
25-34 years	54	28 (52)	44	30 (68)	99	58 (59)
35-44 years	117	93 (79)	50	34 (68)	168	127 (76)
45+ years	102	85 (83)	45	34 (76)	148	120 (81)
p value		<0.001		0.030		<0.001

Table 8.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Victoria Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
<3 years	5	0 (0)	8	3 (38)	13	3 (23)
3 to 10 years	49	29 (59)	37	15 (41)	86	44 (51)
11+years	274	198 (72)	107	71 (66)	382	270 (71)
p value		0.001		0.008		<0.001
2012						
<3 years	9	2 (22)	4	1 (25)	13	3 (23)
3 to 10 years	46	27 (59)	18	7 (39)	64	34 (53)
11+years	236	175 (74)	99	70 (71)	336	245 (73)
p value		0.001		0.008		<0.001
2013						
<3 years	5	2 (40)	6	1 (17)	13	4 (31)
3 to 10 years	38	13 (34)	26	18 (69)	65	31 (48)
11+years	239	170 (71)	101	74 (73)	343	245 (71)
p value		<0.001		<0.001		<0.001
2014						
<3 years	8	1 (13)	9	3 (33)	17	4 (24)
3 to 10 years	24	16 (67)	22	11 (50)	47	27 (57)
11+years	221	159 (72)	101	71 (70)	322	230 (71)
p value		0.002		0.024		<0.001
2015						
<3 years	11	2 (18)	6	1 (17)	17	3 (18)
3 to 10 years	31	16 (52)	21	11 (52)	54	27 (50)
11+years	230	183 (80)	113	84 (74)	344	268 (78)
p value		<0.001		0.003		<0.001

Table 8.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Victoria Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No receptive sharing	10	2 (20)	306	197 (64)	323	203 (63)
Receptive sharing	1	0 (0)	84	64 (76)	87	66 (76)
p value		1.000		0.049		0.030
2012						
No receptive sharing	10	2 (20)	282	195 (69)	299	203 (68)
Receptive sharing	2	1 (50)	76	57 (75)	84	64 (76)
p value		0.455		0.321		0.179
2013						
No receptive sharing	9	3 (33)	288	192 (67)	309	203 (66)
Receptive sharing	1	0 (0)	65	45 (69)	73	50 (68)
p value		1.000		0.771		0.682
2014						
No receptive sharing	13	3 (23)	273	182 (67)	296	192 (65)
Receptive sharing	3	0 (0)	56	49 (88)	63	52 (83)
p value		1.000		0.002		0.006
2015						
No receptive sharing	9	1 (11)	291	210 (72)	305	216 (71)
Receptive sharing	5	2 (40)	75	61 (81)	81	64 (79)
p value		0.505		0.106		0.142

Table 8.3.6 HCV antibody prevalence by last drug injected, years since first injection, and survey year

Victoria Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Heroin	8	1 (13)	283	202 (71)	297	208 (70)
Methamphetamine	1	1 (100)	87	49 (56)	89	50 (56)
Other opioids	4	1 (25)	68	45 (66)	74	46 (62)
Other drugs	0	0 (0)	27	16 (59)	29	18 (62)
p value		0.146		0.053		0.084
2012						
Heroin	9	2 (22)	268	188 (70)	287	199 (69)
Methamphetamine	1	0 (0)	68	45 (66)	69	45 (65)
Other opioids	2	1 (50)	34	28 (82)	39	32 (82)
Other drugs	1	1 (0)	30	18 (60)	33	20 (61)
p value		0.701		0.227		0.197
2013						
Heroin	4	1 (25)	225	161 (72)	237	170 (72)
Methamphetamine	4	1 (25)	86	53 (62)	96	58 (60)
Other opioids	1	0 (0)	54	36 (67)	59	38 (64)
Other drugs	4	2 (50)	43	26 (60)	51	29 (57)
p value		0.738		0.258		0.080
2014						
Heroin	9	2 (22)	204	150 (74)	223	159 (71)
Methamphetamine	4	1 (25)	84	47 (56)	91	50 (55)
Other opioids	1	0 (0)	48	35 (73)	51	37 (73)
Other drugs	3	1 (33)	33	25 (76)	38	27 (71)
p value		0.923		0.021		0.031
2015						
Heroin	4	1 (25)	220	171 (78)	227	175 (77)
Methamphetamine	9	2 (22)	109	73 (67)	122	79 (65)
Other opioids	0	0 (0)	42	29 (69)	42	29 (69)
Other drugs	4	0 (0)	23	18 (78)	28	18 (64)
p value		0.567		0.163		0.070

Table 8.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Victoria Frequency of injection last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Less than daily	3	0 (0)	168	106 (63)	173	106 (61)
Daily or more	10	3 (30)	251	176 (70)	269	186 (69)
Not last month	0	0 (0)	44	28 (64)	45	28 (62)
p value		0.528		0.276		0.206
2012						
Less than daily	6	1 (17)	167	116 (69)	179	123 (69)
Daily or more	6	2 (33)	206	146 (71)	219	154 (70)
Not last month	1	0 (0)	21	14 (67)	24	16 (67)
p value		1.000		0.901		0.900
2013						
Less than daily	6	1 (17)	168	117 (70)	185	122 (66)
Daily or more	4	2 (50)	193	126 (65)	207	138 (67)
Not last month	2	1 (50)	30	20 (67)	33	22 (67)
p value		0.414		0.688		0.987
2014						
Less than daily	5	0 (0)	166	112 (67)	178	116 (65)
Daily or more	11	3 (27)	171	125 (73)	189	134 (71)
Not last month	1	1 (100)	30	19 (63)	35	21 (60)
p value		0.168		0.386		0.312
2015						
Less than daily	7	0 (0)	178	125 (70)	188	128 (68)
Daily or more	8	3 (38)	190	148 (78)	201	154 (77)
Not last month	2	0 (0)	26	18 (69)	30	19 (63)
p value		0.300		0.211		0.098

Table 8.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Victoria Imprisonment last year	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No imprisonment	12	3 (25)	372	238 (64)	392	248 (63)
Imprisonment	1	0 (0)	53	42 (79)	56	42 (75)
p value		1.000		0.030		0.100
2012						
No imprisonment	12	3 (25)	315	210 (67)	341	226 (66)
Imprisonment	1	0 (0)	66	52 (79)	69	54 (78)
p value		1.000		0.058		0.065
2013						
No imprisonment	10	4 (40)	325	212 (65)	351	227 (65)
Imprisonment	1	0 (0)	44	34 (77)	47	35 (74)
p value		1.000		0.127		0.184
2014						
No imprisonment	13	2 (15)	307	206 (67)	336	218 (65)
Imprisonment	2	1 (50)	42	33 (79)	45	34 (76)
p value		0.371		0.133		0.155
2015						
No imprisonment	17	3 (18)	324	233 (72)	348	242 (70)
Imprisonment	0	0 (0)	50	42 (84)	52	44 (85)
p value		--		0.071		0.031

Table 8.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year

Victoria	<3 years		3+ years		Total	
Sex work last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
No sex work	12	3 (23)	421	274 (65)	442	283 (64)
Sex work	0	0 (0)	28	23 (82)	29	23 (79)
p value		--		0.097		0.110
2012						
No sex work	11	3 (27)	359	249 (69)	384	265 (69)
Sex work	2	0 (0)	31	24 (77)	34	25 (74)
p value		1.000		0.418		0.584
2013						
No sex work	11	3 (27)	358	237 (66)	386	251 (65)
Sex work	2	1 (50)	16	10 (63)	19	12 (63)
p value		1.000		0.790		1.000
2014						
No sex work	12	1 (8)	317	216 (68)	346	228 (66)
Sex work	3	2 (67)	24	21 (88)	28	23 (82)
p value		0.081		0.047		0.078
2015						
No sex work	15	3 (20)	365	270 (74)	386	278 (72)
Sex work	1	0 (0)	14	14 (74)	21	15 (71)
p value		1.000		0.978		0.953

Table 8.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Victoria	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Non Indigenous	292	201 (69)	136	82 (60)	429	284 (66)
Indigenous	33	25 (76)	20	9 (45)	54	35 (65)
p value		0.550		0.229		0.879
2012						
Non Indigenous	251	173 (69)	109	75 (69)	361	248 (69)
Indigenous	46	39 (85)	16	6 (38)	62	45 (73)
p value		0.029		0.014		0.540
2013						
Non Indigenous	255	167 (65)	118	79 (67)	377	247 (66)
Indigenous	32	21 (66)	17	13 (76)	51	35 (69)
p value		0.988		0.431		0.660
2014						
Non Indigenous	236	165 (70)	115	70 (61)	352	235 (67)
Indigenous	29	16 (55)	20	17 (85)	49	33 (67)
p value		0.107		0.037		0.935
2015						
Non Indigenous	242	176 (73)	127	87 (70)	369	264 (72)
Indigenous	31	29 (94)	19	11 (58)	50	40 (80)
p value		0.012		0.284		0.209

Table 8.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Victoria	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
English speaking	293	200 (68)	150	88 (59)	444	289 (65)
Non-English speaking	36	27 (75)	7	4 (57)	44	32 (73)
p value		0.452		1.000		0.405
2012						
English speaking	266	186 (70)	117	75 (64)	384	261 (68)
Non-English speaking	35	28 (80)	9	7 (78)	44	35 (80)
p value		0.216		0.493		0.115
2013						
English speaking	253	163 (64)	129	87 (67)	389	253 (65)
Non-English speaking	45	35 (78)	9	7 (78)	54	42 (78)
p value		0.081		0.719		0.063
2014						
English speaking	228	153 (67)	124	80 (65)	352	233 (66)
Non-English speaking	39	30 (77)	13	9 (69)	53	39 (74)
p value		0.222		0.735		0.285
2015						
English speaking	245	181 (74)	132	88 (67)	380	270 (71)
Non-English speaking	31	25 (81)	11	10 (91)	42	35 (83)
p value		0.415		0.096		0.092

Table 8.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Victoria	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Australia	283	198 (70)	148	87 (59)	413	287 (66)
Other Oceania	10	6 (60)	1	1 (100)	11	7 (64)
Asia	6	4 (67)	0	0 (0)	6	4 (67)
UK & Ireland	15	9 (60)	4	2 (50)	19	11 (58)
Other	17	11 (65)	5	3 (60)	22	14 (64)
p value		0.808		1.000		0.939
2012						
Australia	245	169 (69)	110	71 (65)	356	240 (67)
Other Oceania	9	6 (67)	4	2 (50)	13	8 (62)
Asia	13	13 (100)	1	1 (100)	14	14 (100)
UK & Ireland	15	11 (73)	5	4 (80)	20	15 (75)
Other	17	14 (82)	7	5 (71)	24	19 (79)
p value		0.090		0.881		0.042
2013						
Australia	235	154 (66)	120	82 (68)	362	239 (66)
Other Oceania	10	4 (40)	0	0 (0)	10	4 (40)
Asia	16	15 (94)	3	3 (100)	19	18 (95)
UK & Ireland	14	9 (64)	7	4 (57)	21	13 (62)
Other	22	15 (68)	8	5 (63)	30	20 (67)
p value		0.055		0.673		0.022
2014						
Australia	211	142 (67)	122	78 (64)	334	220 (66)
Other Oceania	8	5 (63)	1	1 (100)	9	6 (67)
Asia	17	16 (94)	2	2 (100)	19	18 (95)
UK & Ireland	14	8 (57)	6	4 (67)	20	12 (60)
Other	16	12 (75)	7	5 (71)	23	17 (74)
p value		0.157		0.969		0.101
2015						
Australia	224	167 (75)	119	86 (72)	345	254 (74)
Other Oceania	13	10 (77)	3	3 (100)	16	13 (81)
Asia	13	10 (77)	3	1 (33)	16	11 (69)
UK & Ireland	12	9 (75)	13	5 (38)	26	14 (54)
Other	15	10 (67)	5	3 (60)	20	13 (65)
p value		0.967		0.038		0.202

Western Australia

Table 9.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Western Australia	2011	2012	2013	2014	2015
Number of sites	3	3	3	3	2
N° surveyed	N=192	N=186	N=220	N=225	N=218
Response rate (%)	77%	79%	77%	82%	70%
Gender (%)					
Male	114 (59)	121 (65)	135 (61)	142 (63)	125 (57)
Female	77 (40)	64 (34)	83 (38)	81 (36)	89 (41)
Transgender	1 (<1)	1 (<1)	1 (<1)	2 (1)	3 (1)
Not reported	0 (0)	0 (0)	1 (<1)	0 (0)	1 (<1)
Sexual identity (%)					
Heterosexual	159 (83)	150 (81)	177 (80)	184 (82)	173 (79)
Bisexual	17 (9)	17 (9)	19 (9)	25 (11)	16 (7)
Homosexual	9 (5)	4 (2)	7 (3)	6 (3)	8 (4)
Not reported	7 (4)	15 (8)	17 (8)	10 (4)	21 (10)
Aboriginal and Torres Strait Islander origin (%)					
No	177 (92)	166 (89)	191 (87)	200 (89)	184 (84)
Yes	13 (7)	16 (9)	15 (7)	19 (8)	23 (11)
Not reported	2 (1)	4 (2)	14 (6)	6 (3)	11 (5)
Region/country of birth (%)					
Australia	150 (78)	150 (95)	172 (78)	176 (78)	165 (76)
Other Oceania	11 (6)	12 (6)	10 (5)	10 (4)	11 (5)
Asia	3 (2)	1 (<1)	1 (<1)	2 (1)	4 (2)
UK & Ireland	19 (10)	14 (8)	19 (9)	18 (8)	18 (8)
Other	9 (5)	8 (4)	14 (6)	16 (7)	14 (6)
Not reported	0 (0)	1 (<1)	4 (2)	3 (1)	6 (3)
Main language spoken at home by parents (%)					
English	186 (97)	176 (95)	205 (93)	211 (94)	201 (92)
Non-English	6 (3)	9 (5)	11 (5)	12 (5)	10 (5)
Not reported	0 (0)	1 (<1)	4 (2)	2 (1)	7 (3)
Age and time since first injection (years)					
<i>Median age</i>	40	40	39	41	41
<i>Age range</i>	16-64	20-65	15-66	18-67	15-70
Age group (%)					
<25 years	8 (4)	4 (2)	13 (6)	6 (3)	18 (8)
25+ years	183 (95)	181 (97)	204 (93)	217 (96)	198 (91)
Not reported	1 (<1)	1 (<1)	3 (1)	2 (1)	2 (1)
Median age first injection					
<i>Median age first injection</i>	19	19	19	18	18
<i>Age range</i>	11-47	10-53	12-50	11-45	12-57
<i>N° not reported</i>	5	6	9	5	12
Median yrs since first injection					
<i>Median yrs since first injection</i>	18	19	17	20	20
<i>Range</i>	<1-45	<1-47	<1-49	<1-49	2-50
Years since first injection					
<3 years	6 (3)	4 (2)	18 (8)	9 (4)	6 (3)
3+ years	180 (94)	176 (95)	193 (88)	210 (93)	200 (92)
Not reported	6 (3)	6 (3)	9 (4)	6 (3)	12 (6)
Imprisonment last year (%)					
No	162 (84)	159 (85)	178 (81)	175 (78)	178 (82)
Yes	16 (8)	20 (11)	17 (8)	24 (11)	23 (11)
Not reported	14 (7)	7 (4)	25 (11)	26 (12)	17 (8)
N° in prison					
Injected in prison	4 (25)	4 (20)	2 (12)	11 (46)	8 (35)

Table 9.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Western Australia N° surveyed	2011 N=192	2012 N=186	2013 N=220	2014 N=225	2015 N=218
Drug last injected (%)					
Cocaine	1 (<1)	1 (<1)	3 (1)	0 (0)	0 (0)
Methamphetamine	65 (34)	59 (32)	79 (36)	78 (35)	98 (45)
Heroin	48 (25)	48 (26)	51 (23)	79 (35)	63 (29)
Pharm. opioids	34 (18)	28 (15)	28 (13)	20 (9)	17 (8)
Methadone	12 (6)	6 (3)	10 (5)	6 (3)	6 (3)
Buprenorphine	8 (4)	11 (6)	9 (4)	4 (2)	6 (3)
Buprenorphine/naloxone	11 (6)	9 (5)	13 (6)	7 (3)	4 (2)
PIEDs	0 (0)	1 (<1)	5 (2)	6 (3)	1 (<1)
More than one	12 (6)	19 (10)	18 (8)	23 (10)	17 (8)
Other	0 (0)	1 (<1)	1 (<1)	1 (<1)	6 (3)
Not reported	1 (<1)	3 (2)	3 (1)	1 (<1)	0 (0)
Frequency of injection last month (%)					
Not last month	11 (6)	8 (4)	19 (9)	16 (7)	12 (6)
Less than weekly	27 (14)	27 (15)	28 (13)	23 (10)	25 (11)
Weekly not daily	46 (24)	36 (19)	38 (17)	36 (16)	51 (23)
Daily or more	106 (55)	112 (60)	124 (56)	146 (65)	121 (56)
Not reported	2 (1)	3 (2)	11 (5)	4 (2)	9 (4)
Present when someone injected for the first time in the last 12 months (%)					
Yes	--	24 (13)	22 (10)	52 (23)	43 (20)
No	--	145 (78)	150 (68)	161 (72)	163 (75)
Not reported	--	17 (9)	48 (22)	12 (5)	12 (6)
Overdosed in last 12 months					
Yes	--	--	25 (11)	49 (22)	40 (18)
No	--	--	183 (83)	164 (73)	166 (76)
Not reported	--	--	12 (5)	12 (5)	12 (6)

Table 9.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Western Australia N° injected last month	2011 N=179	2012 N=175	2013 N=190	2014 N=205	2015 N=197
Places injected last month (%)					
Any public	75 (42)	61 (35)	95 (50)	89 (43)	88 (45)
All private	91 (51)	105 (60)	92 (48)	112 (55)	109 (55)
Not reported	13 (7)	9 (5)	3 (2)	4 (2)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	126 (70)	118 (67)	128 (67)	141 (69)	136 (69)
Most of the time	33 (18)	34 (19)	50 (26)	47 (23)	47 (24)
Half of the time	2 (1)	5 (3)	3 (2)	4 (2)	8 (4)
Some of the time	6 (3)	6 (3)	4 (2)	5 (2)	4 (2)
Not last month	0 (0)	1 (<1)	2 (1)	2 (1)	1 (1)
Not reported	12 (7)	11 (6)	3 (2)	6 (3)	1 (1)
Re-used someone else's used needle & syringe last month (%)					
None	131 (73)	128 (73)	148 (78)	157 (77)	144 (73)
Once	7 (4)	15 (9)	11 (6)	15 (7)	15 (8)
Twice	9 (5)	7 (4)	7 (4)	7 (3)	12 (6)
3-5 times	9 (5)	9 (5)	10 (5)	11 (5)	17 (9)
>5 times	9 (5)	6 (3)	8 (4)	9 (4)	7 (4)
Not reported	14 (8)	10 (6)	6 (3)	6 (3)	2 (1)
Number of people needle & syringe was re-used after last month (%)					
None	131 (73)	128 (73)	148 (78)	157 (77)	144 (73)
One	20 (11)	14 (8)	18 (9)	16 (8)	24 (12)
Two	1 (<1)	3 (2)	4 (2)	1 (<1)	8 (4)
Three to five	2 (1)	1 (<1)	2 (1)	3 (1)	3 (2)
More than five	3 (2)	5 (3)	2 (1)	6 (3)	1 (1)
Don't know	4 (2)	5 (3)	6 (3)	6 (3)	7 (4)
Not reported	18 (10)	19 (11)	10 (5)	16 (8)	10 (5)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	19 (11)	10 (6)	17 (9)	15 (7)	13 (7)
Casual sex partner	2 (1)	1 (<1)	3 (2)	2 (1)	1 (1)
Close friend	8 (4)	13 (7)	11 (6)	9 (4)	24 (12)
Acquaintance	5 (3)	7 (4)	9 (5)	3 (1)	4 (2)
Other	5 (3)	3 (2)	7 (4)	5 (2)	7 (4)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	42 (23)	39 (22)	49 (26)	44 (21)	53 (27)
Water	15 (8)	30 (17)	43 (23)	41 (20)	39 (20)
Filter	17 (10)	27 (15)	24 (13)	23 (11)	23 (12)
Drug mix	11 (6)	18 (10)	16 (8)	17 (8)	19 (10)
None	107 (60)	107 (61)	116 (61)	139 (68)	122 (62)
Injected by someone after that person injected themselves or others last month (%)					
No	140 (78)	135 (77)	143 (75)	157 (77)	159 (81)
Yes	140 (78)	26 (15)	35 (18)	36 (18)	36 (18)
Not reported	12 (7)	14 (8)	12 (6)	12 (6)	2 (1)
Source of needle acquisition					
Needle Syringe Program	154 (86)	134 (77)	160 (84)	167 (81)	161 (82)
Chemist/Pharmacy	44 (25)	60 (34)	58 (31)	53 (26)	58 (29)
Personal sources	24 (13)	24 (14)	24 (13)	26 (13)	26 (13)
Dispensing/Vending Machine	4 (2)	3 (2)	2 (1)	3 (1)	5 (3)
Other sources	3 (2)	0 (0)	9 (5)	5 (2)	5 (3)

Table 9.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Western Australia N° surveyed	2011 N=192	2012 N=186	2013 N=220	2014 N=225	2015 N=218
Ever any treatment/therapy for drug use (%)					
No	43 (22)	49 (26)	67 (30)	56 (25)	63 (29)
Yes	147 (77)	133 (72)	148 (67)	163 (72)	145 (67)
Not reported	2 (1)	4 (2)	5 (2)	6 (3)	10 (5)
History of methadone maintenance treatment (%)					
Currently	41 (21)	35 (19)	39 (18)	41 (18)	41 (19)
Previously	59 (31)	49 (26)	53 (24)	54 (24)	47 (22)
Never	84 (44)	101 (54)	125 (57)	124 (55)	119 (55)
Not reported	8 (4)	1 (<1)	3 (1)	6 (3)	11 (5)
History of buprenorphine (Subutex®) treatment (%)					
Currently	19 (10)	21 (11)	19 (9)	16 (7)	15 (7)
Previously	39 (20)	39 (21)	51 (23)	59 (26)	53 (24)
Never	124 (65)	125 (67)	144 (65)	144 (64)	140 (64)
Not reported	10 (5)	1 (<1)	6 (3)	6 (3)	10 (5)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	32 (17)	23 (12)	23 (10)	23 (10)	14 (6)
Previously	25 (13)	23 (12)	37 (17)	41 (18)	47 (22)
Never	129 (67)	136 (73)	150 (68)	156 (69)	146 (67)
Not reported	6 (3)	4 (2)	10 (5)	5 (2)	11 (5)

Table 9.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Western Australia N° surveyed	2011 N=192	2012 N=186	2013 N=220	2014 N=225	2015 N=218
Previous HIV test (%)					
Yes, ever	167 (87)	148 (80)	167 (76)	173 (77)	172 (79)
Yes, last year	104 (54)	81 (44)	95 (43)	98 (44)	109 (50)
>1 year ago	63 (33)	67 (36)	72 (33)	75 (33)	63 (29)
Never tested	19 (10)	28 (15)	39 (18)	36 (16)	37 (17)
Not reported	6 (3)	10 (5)	14 (6)	16 (7)	9 (4)
Previous HCV test (%)					
Yes, ever	173 (90)	165 (89)	167 (76)	190 (84)	184 (84)
Yes, last year	115 (60)	96 (52)	106 (48)	113 (50)	115 (54)
>1 year ago	58 (30)	69 (37)	61 (28)	77 (34)	69 (32)
Never tested	8 (4)	10 (5)	25 (11)	14 (6)	20 (9)
Not reported	11 (6)	11 (6)	28 (13)	21 (9)	14 (6)
Lifetime treatment for HCV (%)					
N° self-reported chronic HCV#*					
Antiviral treatment	11 (19)	4 (10)	5 (12)	7 (13)	5 (15)
No antiviral treatment	47 (80)	37 (90)	34 (79)	43 (83)	24 (73)
Not reported	1 (2)	0 (0)	4 (9)	2 (4)	4 (12)
Treatment for HCV in past 12 months (%)					
N° self-reported chronic HCV#					
Antiviral treatment	5 (9)	2 (5)	3 (7)	0 (0)	1 (3)
No antiviral treatment	50 (91)	37 (95)	35 (85)	46 (92)	27 (93)
Not reported	0 (0)	0 (0)	3 (7)	4 (8)	1 (3)

among people who tested HCV antibody positive

* includes people who reported treatment induced clearance

Table 9.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Western Australia	2011	2012	2013	2014	2015
N° surveyed	N=192	N=186	N=220	N=225	N=218
Sex with a regular partner last month (%)					
No	86 (45)	105 (56)	108 (49)	113 (50)	100 (46)
Yes	93 (48)	74 (40)	96 (44)	93 (41)	104 (48)
Not reported	13 (7)	7 (4)	16 (7)	19 (8)	14 (6)
Condom used with regular partner last month (%)					
N° surveyed	N=93	N=74	N=96	N=93	N=104
Never	70 (75)	56 (76)	70 (73)	73 (78)	76 (73)
Sometimes	10 (11)	8 (11)	13 (14)	8 (9)	9 (9)
Every time	10 (11)	6 (8)	8 (8)	7 (8)	13 (13)
Not reported	3 (3)	4 (5)	5 (5)	5 (5)	6 (6)
Sex with other partner(s) last month (%)					
No	163 (85)	147 (79)	159 (72)	169 (75)	169 (78)
Yes	24 (13)	28 (15)	39 (18)	34 (15)	34 (16)
Not reported	5 (3)	11 (6)	22 (10)	22 (10)	15 (7)
Condom used with other partner(s) last month (%)					
N° surveyed	N=24	N=28	N=39	N=34	N=34
Never	11 (46)	14 (50)	12 (31)	14 (41)	11 (32)
Sometimes	5 (21)	8 (29)	12 (31)	9 (26)	11 (32)
Every time	7 (29)	5 (18)	14 (36)	7 (21)	10 (30)
Not reported	1 (4)	1 (4)	1 (3)	4 (12)	2 (6)
Sex work last month (%)					
No	173 (90)	169 (91)	188 (85)	181 (80)	190 (87)
Yes	10 (5)	11 (6)	11 (5)	14 (6)	14 (6)
Not reported	9 (5)	6 (3)	21 (10)	30 (13)	14 (6)
Condom used at last sex work (%)					
Yes	8 (80)	8 (73)	9 (80)	6 (43)	10 (71)

HIV antibody prevalence

Table 9.2.1 HIV antibody prevalence by gender and survey year

Western Australia Survey year	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011	112	1 (0.9)	77	3 (3.9)	190	4 (2.1)
2012	120	0 (0.0)	63	3 (4.8)	184	3 (1.6)
2013	126	3 (2.4)	71	2 (2.8)	199	5 (2.5)
2014	131	1 (0.8)	75	0 (0.0)	208	1 (0.0)
2015	112	1 (0.9)	83	1 (1.2)	198	2 (1.0)
X ² p trend p value		0.793		0.085		0.229

Table 9.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Western Australia Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
Heterosexual	99	0 (0.0)	58	3 (5.2)	157	3 (1.9)
Bisexual	4	1 (25.0)	12	0 (0.0)	17	1 (5.9)
Homosexual	3	0 (0.0)	6	0 (0.0)	9	0 (0.0)
p value		0.066		1.000		0.461
2012						
Heterosexual	106	0 (0.0)	42	2 (4.8)	148	2 (1.4)
Bisexual	6	0 (0.0)	10	0 (0.0)	17	0 (0.0)
Homosexual	0	0 (0.0)	4	0 (0.0)	4	0 (0.0)
p value		--		1.000		1.000
2013						
Heterosexual	110	2 (1.8)	49	2 (4.1)	159	4 (2.5)
Bisexual	4	1 (25.0)	15	0 (0.0)	19	1 (5.3)
Homosexual	4	0 (0.0)	2	0 (0.0)	6	0 (0.0)
p value		0.191		1.000		0.522
2014						
Heterosexual	118	0 (0.0)	52	0 (0.0)	170	0 (0.0)
Bisexual	6	1 (16.7)	15	0 (0.0)	23	1 (4.4)
Homosexual	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
p value		0.071		--		0.146
2015						
Heterosexual	99	0 (0.0)	57	1 (1.8)	158	1 (0.6)
Bisexual	1	0 (0.0)	15	0 (0.0)	16	0 (0.0)
Homosexual	2	1 (50.0)	3	0 (0.0)	5	1 (20.0)
p value		0.029		1.000		0.063

Table 9.2.3 HIV antibody prevalence by age group, gender and survey year

Western Australia Age group	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
<25 years	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
25-34 years	26	0 (0.0)	27	0 (0.0)	53	0 (0.0)
35-44 years	41	0 (0.0)	23	0 (0.0)	65	0 (0.0)
45+ years	38	1 (2.6)	25	3 (12.0)	63	4 (6.4)
p value		0.631		0.133		0.043
2012						
<25 years	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)
25-34 years	29	0 (0.0)	18	1 (5.6)	47	1 (2.1)
35-44 years	45	0 (0.0)	21	0 (0.0)	67	0 (0.0)
45+ years	43	0 (0.0)	22	2 (9.1)	65	2 (3.1)
p value		--		0.530		0.411
2013						
<25 years	8	1 (12.5)	5	0 (0.0)	13	1 (7.7)
25-34 years	41	1 (2.4)	22	0 (0.0)	63	1 (1.6)
35-44 years	36	1 (2.8)	22	0 (0.0)	58	1 (1.7)
45+ years	39	0 (0.0)	22	2 (9.1)	62	2 (3.2)
p value		0.228		0.416		0.518
2014						
<25 years	6	0 (0.0)	0	0 (0.0)	6	0 (0.0)
25-34 years	33	0 (0.0)	14	0 (0.0)	47	0 (0.0)
35-44 years	46	0 (0.0)	26	0 (0.0)	73	0 (0.0)
45+ years	45	1 (2.2)	35	0 (0.0)	81	1 (1.2)
p value		0.646		--		1.000
2015						
<25 years	6	0 (0.0)	6	0 (0.0)	14	0 (0.0)
25-34 years	21	0 (0.0)	14	0 (0.0)	35	0 (0.0)
35-44 years	40	0 (0.0)	34	0 (0.0)	74	0 (0.0)
45+ years	44	1 (2.3)	29	1 (3.5)	74	2 (2.7)
p value		1.000		0.590		0.716

Table 9.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Western Australia		Male		Female		Total	
Last drug injected	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	
2011							
Heroin	25	0 (0.0)	22	3 (13.6)	48	3 (6.3)	
Methamphetamine	36	1 (2.8)	27	0 (0.0)	63	1 (1.6)	
Other opioids	41	0 (0.0)	24	0 (0.0)	65	0 (0.0)	
Other drugs	10	0 (0.0)	3	0 (0.0)	13	0 (0.0)	
p value		0.634		0.062		0.136	
2012							
Heroin	31	0 (0.0)	17	3 (17.7)	48	3 (6.3)	
Methamphetamine	31	0 (0.0)	25	0 (0.0)	57	0 (0.0)	
Other opioids	37	0 (0.0)	17	0 (0.0)	54	0 (0.0)	
Other drugs	18	0 (0.0)	4	0 (0.0)	22	0 (0.0)	
p value		--		0.071		0.057	
2013							
Heroin	35	1 (2.9)	14	2 (14.3)	49	3 (6.1)	
Methamphetamine	35	2 (5.7)	34	0 (0.0)	70	2 (2.9)	
Other opioids	36	0 (0.0)	15	0 (0.0)	51	0 (0.0)	
Other drugs	19	0 (0.0)	7	0 (0.0)	26	0 (0.0)	
p value		0.364		0.046		0.265	
2014							
Heroin	47	0 (0.0)	27	0 (0.0)	75	0 (0.0)	
Methamphetamine	39	1 (2.6)	30	0 (0.0)	70	1 (1.4)	
Other opioids	21	0 (0.0)	15	0 (0.0)	36	0 (0.0)	
Other drugs	23	0 (0.0)	3	0 (0.0)	25	0 (0.0)	
p value		0.638		--		0.638	
2015							
Heroin	38	0 (0.0)	21	1 (4.8)	59	1 (1.7)	
Methamphetamine	42	1 (2.4)	42	0 (0.0)	87	1 (1.2)	
Other opioids	17	0 (0.0)	15	0 (0.0)	32	0 (0.0)	
Other drugs	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)	
p value		1.000		0.494		1.000	

Table 9.2.5 HIV antibody prevalence by years of injection, gender and survey year

Western Australia Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
<3 years	2	0 (0.0)	4	0 (0.0)	6	0 (0.0)
3 to 10 years	19	0 (0.0)	15	0 (0.0)	34	0 (0.0)
11 + years	85	1 (1.2)	58	3 (5.2)	144	4 (2.8)
p value		1.000		1.000		1.000
2012						
<3 years	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)
3 to 10 years	16	0 (0.0)	10	1 (10.0)	26	1 (3.9)
11 + years	98	0 (0.0)	49	2 (4.1)	148	2 (1.4)
p value		--		0.488		0.427
2013						
<3 years	7	0 (0.0)	7	0 (0.0)	14	0 (0.0)
3 to 10 years	16	1 (6.3)	11	0 (0.0)	27	1 (3.7)
11 + years	97	2 (2.1)	51	2 (3.9)	149	4 (2.7)
p value		0.475		1.000		0.708
2014						
<3 years	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)
3 to 10 years	9	0 (0.0)	9	0 (0.0)	18	0 (0.0)
11 + years	112	1 (0.9)	63	0 (0.0)	177	1 (0.6)
p value		1.000		--		1.000
2015						
<3 years	4	1 (25.0)	1	0 (0.0)	5	1 (20.0)
3 to 10 years	9	0 (0.0)	21	0 (0.0)	32	0 (0.0)
11 + years	93	0 (0.0)	57	1 (1.8)	151	1 (0.7)
p value		0.038		1.000		0.081

Table 9.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Western Australia Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No receptive sharing	71	1 (1.4)	57	3 (5.3)	129	4 (3.1)
Receptive sharing	24	0 (0.0)	10	0 (0.0)	34	0 (0.0)
p value		1.000		1.000		0.581
2012						
No receptive sharing	81	0 (0.0)	44	3 (6.8)	126	3 (2.4)
Receptive sharing	26	0 (0.0)	11	0 (0.0)	37	0 (0.0)
p value		--		1.000		1.000
2013						
No receptive sharing	89	3 (3.4)	45	2 (4.4)	314	5 (3.7)
Receptive sharing	18	0 (0.0)	16	0 (0.0)	34	0 (0.0)
p value		1.000		1.000		0.584
2014						
No receptive sharing	90	1 (1.1)	56	0 (0.0)	147	1 (0.7)
Receptive sharing	25	0 (0.0)	11	0 (0.0)	36	0 (0.0)
p value		1.000		--		1.000
2015						
No receptive sharing	72	1 (1.4)	63	1 (1.6)	136	2 (1.5)
Receptive sharing	28	0 (0.0)	14	0 (0.0)	42	0 (0.0)
p value		1.000		1.000		1.000

Table 9.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Western Australia		Male		Female		Total	
Frequency of injection	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	
2011							
Less than daily	37	1 (2.7)	34	1 (2.9)	72	2 (2.8)	
Daily or more	66	0 (0.0)	39	2 (5.1)	105	2 (1.9)	
Not last month	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)	
p value		0.400		1.000		1.000	
2012							
Less than daily	41	0 (0.0)	20	2 (10.0)	62	2 (3.2)	
Daily or more	71	0 (0.0)	40	1 (2.5)	111	1 (0.9)	
Not last month	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)	
p value		--		0.326		0.382	
2013							
Less than daily	33	1 (3.0)	25	1 (4.0)	58	2 (3.5)	
Daily or more	78	2 (2.6)	37	1 (2.7)	115	3 (2.6)	
Not last month	10	0 (0.0)	5	0 (0.0)	16	0 (0.0)	
p value		1.000		1.000		1.000	
2014							
Less than daily	33	1 (3.0)	23	0 (0.0)	56	1 (1.8)	
Daily or more	84	0 (0.0)	47	0 (0.0)	132	0 (0.0)	
Not last month	10	0 (0.0)	5	0 (0.0)	16	0 (0.0)	
p value		0.339		--		0.353	
2015							
Less than daily	44	1 (2.3)	23	1 (4.4)	68	2 (2.9)	
Daily or more	57	0 (0.0)	54	0 (0.0)	111	0 (0.0)	
Not last month	4	0 (0.0)	4	0 (0.0)	10	0 (0.0)	
p value		0.457		0.333		0.232	

Table 9.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Western Australia		Male		Female		Total	
Imprisonment last year	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	
2011							
No imprisonment	88	1 (1.1)	71	3 (4.2)	160	4 (2.5)	
Imprisonment	16	0 (0.0)	0	0 (0.0)	16	0 (0.0)	
p value		1.000		--		1.000	
2012							
No imprisonment	102	0 (0.0)	54	3 (5.6)	157	3 (1.9)	
Imprisonment	17	0 (0.0)	3	0 (0.0)	20	0 (0.0)	
p value		--		1.000		1.000	
2013							
No imprisonment	100	3 (3.0)	63	2 (3.2)	163	5 (3.1)	
Imprisonment	13	0 (0.0)	3	0 (0.0)	16	0 (0.0)	
p value		1.000		1.000		1.000	
2014							
No imprisonment	99	1 (1.0)	64	0 (0.0)	163	1 (0.6)	
Imprisonment	17	0 (0.0)	3	0 (0.0)	21	0 (0.0)	
p value		1.000		--		1.000	
2015							
No imprisonment	91	1 (1.1)	72	0 (0.0)	165	1 (0.6)	
Imprisonment	13	0 (0.0)	6	0 (0.0)	20	0 (0.0)	
p value		1.000		--		1.000	

Table 9.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Western Australia	Male		Female		Total	
Condom use at last sex	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No condom use	37	0 (0.0)	32	2 (6.3)	69	2 (2.9)
Condom use	10	1 (10.0)	10	0 (0.0)	20	1 (5.0)
p value		0.213		1.000		0.539
2012						
No condom use	36	0 (0.0)	20	0 (0.0)	56	0 (0.0)
Condom use	8	0 (0.0)	6	0 (0.0)	14	0 (0.0)
p value		--		--		--
2013						
No condom use	29	0 (0.0)	33	0 (0.0)	62	0 (0.0)
Condom use	13	1 (7.7)	7	0 (0.0)	20	1 (5.0)
p value		0.310		---		0.244
2014						
No condom use	36	0 (0.0)	32	0 (0.0)	68	0 (0.0)
Condom use	12	1 (8.3)	2	0 (0.0)	14	1 (7.1)
p value		0.250		--		0.171
2015						
No condom use	33	0 (0.0)	34	0 (0.0)	68	0 (0.0)
Condom use	11	0 (0.0)	8	0 (0.0)	19	0 (0.0)
p value		--		--		--

Table 9.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Western Australia	Male		Female		Total	
Sex work last month	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2011						
No sex work	102	1 (1.0)	69	3 (4.4)	171	4 (2.3)
Sex work	4	0 (0.0)	5	0 (0.0)	10	0 (0.0)
p value		1.000		1.000		1.000
2012						
No sex work	109	0 (0.0)	58	3 (5.2)	167	3 (1.8)
Sex work	7	0 (0.0)	3	0 (0.0)	11	0 (0.0)
p value		--		1.000		1.000
2013						
No sex work	110	3 (2.7)	60	2 (3.3)	171	5 (2.9)
Sex work	4	0 (0.0)	6	0 (0.0)	10	0 (0.0)
p value		1.000		1.000		1.000
2014						
No sex work	100	1 (1.0)	66	0 (0.0)	167	1 (0.6)
Sex work	10	0 (0.0)	3	0 (0.0)	13	0 (0.0)
p value		1.000		--		1.000
2015						
No sex work	99	1 (1.0)	72	1 (1.4)	174	2 (1.2)
Sex work	6	0 (0.0)	7	0 (0.0)	13	0 (0.0)
p value		1.000		1.000		1.000

Table 9.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Western Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Non Indigenous	103	0 (0.0)	71	3 (4.2)	175	3 (1.7)
Indigenous	7	1 (14.3)	6	0 (0.0)	13	1 (7.7)
p value		0.064		1.000		0.251
2012						
Non Indigenous	109	0 (0.0)	55	3 (5.5)	165	3 (1.8)
Indigenous	8	0 (0.0)	7	0 (0.0)	15	0 (0.0)
p value		--		1.000		1.000
2013						
Non Indigenous	109	3 (2.8)	63	2 (3.2)	173	5 (2.9)
Indigenous	7	0 (0.0)	8	0 (0.0)	15	0 (0.0)
p value		1.000		1.000		1.000
2014						
Non Indigenous	119	0 (0.0)	65	0 (0.0)	186	0 (0.0)
Indigenous	6	1 (16.7)	10	0 (0.0)	16	1 (6.3)
p value		0.048		--		0.079
2015						
Non Indigenous	99	1 (1.0)	69	1 (1.5)	171	2 (1.2)
Indigenous	10	0 (0.0)	10	0 (0.0)	20	0 (0.0)
p value		1.000		1.000		1.000

Table 9.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Western Australia	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
English speaking	107	1 (0.9)	76	3 (4.0)	184	4 (2.2)
Non-English speaking	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)
p value		1.000		1.000		1.000
2012						
English speaking	113	0 (0.0)	60	3 (5.0)	174	3 (1.7)
Non-English speaking	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)
p value		--		1.000		1.000
2013						
English speaking	117	2 (1.7)	66	2 (3.0)	184	4 (2.2)
Non-English speaking	6	1 (16.7)	5	0 (0.0)	11	1 (9.1)
p value		0.140		1.000		0.254
2014						
English speaking	122	1 (0.8)	71	0 (0.0)	195	1 (0.5)
Non-English speaking	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)
p value		1.000		--		1.000
2015						
English speaking	102	1 (1.0)	78	1 (1.3)	183	2 (1.1)
Non-English speaking	7	0 (0.0)	3	0 (0.0)	10	0 (0.0)
p value		1.000		1.000		1.000

Table 9.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Western Australia		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2011							
Australia	92	1 (1.1)	55	3 (5.5)	148	4 (2.7)	
Other Oceania	4	0 (0.0)	7	0 (0.0)	11	0 (0.0)	
Asia	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)	
UK & Ireland	11	0 (0.0)	8	0 (0.0)	19	0 (0.0)	
Other	3	0 (0.0)	6	0 (0.0)	9	0 (0.0)	
p value		1.000		1.000		1.000	
2012							
Australia	99	0 (0.0)	49	3 (6.1)	149	3 (2.0)	
Other Oceania	5	0 (0.0)	7	0 (0.0)	12	0 (0.0)	
Asia	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)	
UK & Ireland	10	0 (0.0)	3	0 (0.0)	13	0 (0.0)	
Other	5	0 (0.0)	3	0 (0.0)	8	0 (0.0)	
p value		--		1.000		1.000	
2013							
Australia	98	2 (2.0)	55	2 (3.6)	154	4 (2.6)	
Other Oceania	4	0 (0.0)	5	0 (0.0)	9	0 (0.0)	
Asia	1	1 (100.0)	0	0 (0.0)	1	1 (100.0)	
UK & Ireland	12	0 (0.0)	6	0 (0.0)	18	0 (0.0)	
Other	8	0 (0.0)	5	0 (0.0)	13	0 (0.0)	
p value		0.068		1.000		0.072	
2014							
Australia	106	1 (0.9)	57	0 (0.0)	165	1 (0.6)	
Other Oceania	4	0 (0.0)	5	0 (0.0)	9	0 (0.0)	
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)	
UK & Ireland	13	0 (0.0)	4	0 (0.0)	17	0 (0.0)	
Other	6	0 (0.0)	8	0 (0.0)	14	0 (0.0)	
p value		1.000		--		1.000	
2015							
Australia	82	1 (1.2)	66	1 (1.5)	150	2 (1.3)	
Other Oceania	8	0 (0.0)	2	0 (0.0)	10	0 (0.0)	
Asia	2	0 (0.0)	1	0 (0.0)	4	0 (0.0)	
UK & Ireland	10	0 (0.0)	7	0 (0.0)	17	0 (0.0)	
Other	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)	
p value		1.000		1.000		1.000	

HCV ANTIBODY PREVALENCE

Table 9.3.1 HCV antibody prevalence by gender and survey year

Western Australia Survey year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011	110	69 (63)	73	34 (47)	184	104 (57)
2012	120	71 (59)	64	31 (48)	185	103 (56)
2013	123	66 (54)	71	23 (32)	196	90 (46)
2014	128	72 (56)	75	40 (53)	205	113 (55)
2015	107	58 (54)	82	39 (48)	192	98 (51)
X ² p trend value		0.486		0.800		0.592

Table 9.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Western Australia Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
Heterosexual	98	64 (65)	55	27 (49)	153	91 (59)
Bisexual	4	0 (0)	11	5 (45)	16	6 (38)
Homosexual	3	1 (33)	6	2 (33)	9	3 (33)
p value		0.006		0.845		0.090
2012						
Heterosexual	106	64 (60)	43	24 (56)	149	88 (59)
Bisexual	6	2 (33)	10	3 (30)	17	6 (35)
Homosexual	0	0 (0)	4	2 (50)	4	2 (50)
p value		0.226		0.329		0.151
2013						
Heterosexual	107	56 (52)	49	17 (35)	156	73 (47)
Bisexual	4	3 (75)	15	5 (33)	19	8 (42)
Homosexual	4	2 (50)	2	0 (0)	6	2 (33)
p value		0.857		0.890		0.832
2014						
Heterosexual	116	64 (55)	52	30 (58)	168	94 (56)
Bisexual	6	4 (67)	15	8 (53)	23	13 (57)
Homosexual	3	1 (33)	3	0 (0)	6	1 (17)
p value		0.652		0.171		0.181
2015						
Heterosexual	94	51 (54)	57	25 (44)	153	77 (50)
Bisexual	1	0 (0)	14	9 (64)	15	9 (60)
Homosexual	2	0 (0)	3	1 (33)	5	1 (20)
p value		0.103		0.418		0.306

Table 9.3.3 HCV antibody prevalence by age group, gender and survey year

Western Australia Age group	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
<25 years	6	1 (17)	2	1 (50)	8	2 (25)
25-34 years	25	13 (52)	24	8 (33)	49	21 (43)
35-44 years	41	28 (68)	22	13 (59)	64	42 (66)
45+ years	37	26 (70)	12	12 (48)	62	38 (61)
p value		0.046		0.320		0.021
2012						
<25 years	3	1 (33)	1	0 (0)	4	1 (25)
25-34 years	29	18 (62)	19	7 (37)	48	25 (52)
35-44 years	45	27 (60)	21	8 (38)	67	36 (54)
45+ years	43	25 (58)	22	15 (68)	65	40 (62)
p value		0.853		0.079		0.448
2013						
<25 years	7	1 (14)	5	0 (0)	12	1 (8)
25-34 years	40	17 (43)	22	7 (32)	62	24 (39)
35-44 years	35	22 (63)	22	6 (27)	57	28 (49)
45+ years	39	25 (64)	22	10 (45)	62	36 (58)
p value		0.027		0.281		0.006
2014						
<25 years	6	1 (17)	0	0 (0)	6	1 (17)
25-34 years	32	13 (41)	14	9 (64)	46	22 (48)
35-44 years	45	26 (58)	26	10 (38)	72	36 (50)
45+ years	44	31 (70)	35	21 (60)	80	53 (67)
p value		0.013		0.174		0.023
2015						
<25 years	5	1 (20)	6	1 (17)	13	2 (15)
25-34 years	21	10 (48)	13	8 (62)	34	18 (53)
35-44 years	37	16 (43)	34	14 (41)	71	30 (42)
45+ years	43	30 (70)	29	16 (55)	73	47 (64)
p value		0.030		0.218		0.002

Table 9.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Western Australia Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
<3 years	2	0 (0)	4	3 (75)	6	3 (50)
3 to 10 years	19	6 (32)	15	7 (47)	34	13 (38)
11+years	83	57 (69)	54	24 (44)	138	82 (59)
p value		0.002		0.588		0.073
2012						
<3 years	2	2 (100)	2	1 (50)	4	3 (75)
3 to 10 years	16	9 (56)	10	4 (40)	26	13 (50)
11+years	98	59 (60)	50	24 (48)	149	84 (56)
p value		0.640		0.867		0.674
2013						
<3 years	7	0 (0)	7	1 (14)	14	1 (7)
3 to 10 years	14	6 (43)	11	1 (9)	25	7 (28)
11+years	96	57 (59)	51	21 (41)	148	79 (53)
p value		0.004		0.072		<0.001
2014						
<3 years	8	0 (0)	1	0 (0)	9	0 (0)
3 to 10 years	9	4 (44)	9	4 (44)	18	8 (44)
11+years	109	66 (61)	63	35 (56)	174	102 (59)
p value		0.002		0.596		0.001
2015						
<3 years	4	1 (25)	1	0 (0)	5	1 (20)
3 to 10 years	8	5 (63)	21	7 (33)	31	12 (39)
11+years	89	51 (57)	56	31 (55)	146	83 (57)
p value		0.509		0.099		0.064

Table 9.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Western Australia Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2011						
No receptive sharing	5	2 (40)	118	68 (58)	125	72 (58)
Receptive sharing	1	1 (100)	30	13 (43)	33	16 (48)
p value		1.000		0.218		0.431
2012						
No receptive sharing	4	3 (75)	121	64 (53)	127	69 (54)
Receptive sharing	0	0 (0)	36	24 (67)	37	24 (65)
p value		--		0.144		0.255
2013						
No receptive sharing	9	0 (0)	121	67 (55)	132	69 (52)
Receptive sharing	1	0 (0)	31	11 (35)	34	12 (35)
p value		--		0.048		0.077
2014						
No receptive sharing	6	0 (0)	138	82 (59)	146	83 (57)
Receptive sharing	1	0 (0)	34	17 (50)	35	17 (49)
p value		--		0.320		0.376
2015						
No receptive sharing	2	0 (0)	131	71 (54)	134	71 (53)
Receptive sharing	1	0 (0)	38	22 (58)	41	24 (59)
p value		--		0.687		0.532

Table 9.3.6 HCV antibody prevalence by last drug injected, years since first injection, and survey year

Western Australia Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Heroin	2	2 (100)	42	26 (62)	46	30 (65)
Methamphetamine	2	0 (0)	57	23 (40)	61	25 (41)
Other opioids	2	1 (50)	59	37 (63)	63	40 (63)
Other drugs	0	0 (0)	13	9 (69)	13	9 (69)
p value		0.135		0.041		0.023
2012						
Heroin	0	0 (0)	48	32 (67)	48	32 (67)
Methamphetamine	3	2 (67)	54	16 (30)	58	18 (31)
Other opioids	0	0 (0)	51	34 (67)	54	36 (67)
Other drugs	1	1 (100)	19	13 (65)	22	15 (68)
p value		0.505		<0.001		<0.001
2013						
Heroin	0	0 (0)	49	29 (59)	49	29 (59)
Methamphetamine	10	1 (10)	56	14 (25)	68	17 (25)
Other opioids	0	0 (0)	48	32 (67)	50	32 (64)
Other drugs	4	0 (0)	19	10 (53)	26	11 (42)
p value		0.512		<0.001		<0.001
2014						
Heroin	1	0 (0)	73	43 (59)	74	43 (58)
Methamphetamine	3	0 (0)	66	31 (47)	70	31 (44)
Other opioids	0	0 (0)	36	24 (67)	36	24 (67)
Other drugs	5	0 (0)	16	11 (69)	24	14 (58)
p value		--		0.165		0.132
2015						
Heroin	0	0 (0)	56	37 (66)	56	37 (66)
Methamphetamine	4	0 (0)	76	28 (37)	82	29 (35)
Other opioids	0	0 (0)	30	23 (77)	31	24 (77)
Other drugs	0	0 (0)	12	6 (50)	15	6 (40)
p value		--		<0.001		<0.001

Table 9.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Western Australia	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Less than daily	2	1 (50)	68	36 (53)	70	37 (53)
Daily or more	4	2 (50)	94	55 (59)	102	61 (60)
Not last month	0	0 (0)	8	3 (38)	10	5 (50)
p value		1.000		0.453		0.639
2012						
Less than daily	2	1 (50)	60	30 (50)	63	32 (51)
Daily or more	2	2 (100)	106	64 (60)	111	68 (61)
Not last month	0	0 (0)	6	1 (17)	8	1 (13)
p value		1.000		0.074		0.018
2013						
Less than daily	8	0 (0)	48	23 (48)	56	23 (41)
Daily or more	3	0 (0)	107	56 (52)	114	59 (52)
Not last month	3	1 (33)	12	4 (33)	16	5 (31)
p value		0.429		0.461		0.181
2014						
Less than daily	5	0 (0)	49	31 (63)	56	32 (57)
Daily or more	2	0 (0)	128	70 (55)	130	70 (54)
Not last month	2	0 (0)	12	7 (58)	15	8 (53)
p value		--		0.585		0.912
2015						
Less than daily	1	0 (0)	65	36 (55)	68	37 (54)
Daily or more	2	0 (0)	105	57 (54)	108	58 (54)
Not last month	1	0 (0)	4	1 (25)	8	1 (13)
p value		--		0.560		0.082

Table 9.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Western Australia	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
No imprisonment	3	2 (67)	146	79 (54)	154	86 (56)
Imprisonment	2	0 (0)	13	10 (77)	16	11 (69)
p value		0.400		0.148		0.429
2012						
No imprisonment	4	3 (75)	150	78 (52)	158	83 (53)
Imprisonment	0	0 (0)	19	16 (84)	20	16 (80)
p value		--		0.012		0.020
2013						
No imprisonment	12	1 (8)	143	69 (48)	161	71 (44)
Imprisonment	1	0 (0)	14	10 (71)	16	11 (69)
p value		1.000		0.160		0.059
2014						
No imprisonment	9	0 (0)	148	85 (57)	160	87 (54)
Imprisonment	0	0 (0)	20	11 (55)	20	11 (55)
p value		--		0.837		0.958
2015						
No imprisonment	4	1 (25)	148	80 (54)	160	82 (51)
Imprisonment	1	0 (0)	16	7 (44)	19	8 (42)
p value		1.000		0.433		0.451

Table 9.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year

Western Australia	<3 years		3+ years		Total	
Sex work last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
No sex work	6	3 (50)	156	84 (54)	166	91 (55)
Sex work	0	0 (0)	8	4 (50)	9	5 (56)
p value		--		1.000		1.000
2012						
No sex work	4	3 (75)	159	89 (56)	168	95 (57)
Sex work	0	0 (0)	10	7 (70)	11	7 (64)
p value		--		0.517		0.760
2013						
No sex work	10	0 (0)	152	77 (51)	169	79 (47)
Sex work	3	1 (33)	6	4 (67)	10	6 (60)
p value		0.231		0.682		0.521
2014						
No sex work	8	0 (0)	152	86 (57)	164	89 (54)
Sex work	0	0 (0)	13	9 (69)	13	9 (69)
p value		--		0.376		0.296
2015						
No sex work	5	0 (0)	154	81 (53)	168	83 (49)
Sex work	0	0 (0)	12	10 (83)	13	11 (85)
p value		--		0.039		0.014

Table 9.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Western Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
Non Indigenous	101	64 (63)	68	33 (49)	170	98 (58)
Indigenous	7	4 (57)	5	1 (20)	12	5 (42)
p value		0.708		0.363		0.369
2012						
Non Indigenous	109	63 (58)	55	27 (49)	165	91 (55)
Indigenous	8	5 (63)	8	3 (38)	16	8 (50)
p value		1.000		0.710		0.795
2013						
Non Indigenous	106	59 (56)	63	22 (35)	170	82 (48)
Indigenous	7	2 (29)	8	1 (13)	15	3 (20)
p value		0.245		0.261		0.056
2014						
Non Indigenous	117	64 (55)	65	36 (55)	184	101 (55)
Indigenous	6	4 (67)	10	4 (40)	16	8 (50)
p value		0.691		0.500		0.706
2015						
Non Indigenous	95	49 (52)	69	35 (51)	167	85 (51)
Indigenous	10	9 (90)	9	2 (22)	19	11 (58)
p value		0.020		0.159		0.563

Table 9.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Western Australia	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2011						
English speaking	105	65 (62)	72	34 (47)	178	100 (56)
Non-English speaking	5	4 (80)	1	0 (0)	6	4 (67)
p value		0.649		1.000		0.699
2012						
English speaking	113	69 (61)	61	28 (46)	175	98 (56)
Non-English speaking	7	2 (29)	2	2 (100)	9	4 (44)
p value		0.120		0.223		0.515
2013						
English speaking	114	62 (54)	66	22 (33)	181	85 (47)
Non-English speaking	6	2 (33)	5	1 (20)	11	3 (27)
p value		0.416		1.000		0.231
2014						
English speaking	119	65 (55)	71	37 (52)	192	103 (54)
Non-English speaking	8	6 (75)	3	2 (67)	11	8 (73)
p value		0.261		1.000		0.216
2015						
English speaking	97	53 (55)	77	37 (48)	177	91 (51)
Non-English speaking	7	4 (57)	3	1 (33)	10	5 (50)
p value		1.000		1.000		1.000

Table 9.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Western Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2011							
Australia	90	55 (61)	51	23 (45)	142	79 (56)	
Other Oceania	4	3 (75)	7	5 (71)	11	8 (73)	
Asia	2	2 (100)	1	1 (100)	3	3 (100)	
UK & Ireland	11	7 (64)	8	4 (50)	19	11 (58)	
Other	3	2 (67)	6	1 (17)	9	3 (33)	
p value		0.945		0.274		0.287	
2012							
Australia	99	60 (61)	50	22 (44)	150	83 (55)	
Other Oceania	5	4 (80)	7	5 (71)	12	9 (75)	
Asia	0	0 (0)	1	1 (100)	1	1 (100)	
UK & Ireland	10	5 (50)	3	2 (67)	13	7 (54)	
Other	5	2 (40)	3	1 (33)	8	3 (38)	
p value		0.543		0.516		0.453	
2013							
Australia	95	51 (54)	55	16 (29)	151	68 (45)	
Other Oceania	4	2 (50)	5	3 (60)	9	5 (56)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	12	6 (50)	6	3 (50)	18	9 (50)	
Other	8	5 (63)	5	1 (20)	13	6 (46)	
p value		0.929		0.395		0.956	
2014							
Australia	103	57 (55)	56	27 (48)	161	85 (53)	
Other Oceania	4	1 (25)	5	3 (60)	9	4 (44)	
Asia	1	0 (0)	1	1 (100)	2	1 (50)	
UK & Ireland	13	11 (85)	5	4 (80)	18	15 (83)	
Other	6	2 (33)	8	5 (63)	14	7 (50)	
p value		0.044		0.590		0.097	
2015							
Australia	77	41 (53)	66	32 (48)	145	74 (51)	
Other Oceania	8	3 (38)	2	1 (50)	10	4 (40)	
Asia	2	1 (50)	4	0 (0)	4	1 (25)	
UK & Ireland	10	7 (70)	6	3 (50)	16	10 (63)	
Other	7	5 (71)	5	2 (40)	12	7 (58)	
p value		0.624		1.000		0.644	

Appendix A: Participating NSP Services

Year		'11	'12	'13	'14	'15
Number of NSP sites		52	52	50	50	47
Australian Capital Territory		1	1	1	1	1
Canberra	Directions ACT	✓	✓	✓	✓	✓
New South Wales		20	20	19	19	16
Albury	Albury Community Health Centre	✓	✓	✓	✓	
Ballina/Byron	Harm Reduction Services	✓	✓	✓	✓	✓
Blacktown	HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	✓
Coffs Harbour/Grafton	Harm Reduction Services	✓	✓	✓	✓	✓
Canterbury	Harm Minimisation Program					✓
Central Coast	Gosford, Long Jetty and Woy Woy Harm Reduction	✓	✓	✓	✓	
Liverpool	Health ConneXions	✓	✓	✓		
Kings Cross	Clinic 180	✓	✓	✓	✓	✓
Kings Cross	Kirketon Road Centre	✓	✓	✓	✓	✓
Kogarah/Sutherland	Central Access Service	✓	✓	✓	✓	
Mt Druitt	Kelly Close Needle Syringe Program	✓	✓	✓	✓	✓
Murwillumbah/Tweed	Harm Reduction Services	✓	✓	✓	✓	✓
Kingswood	South Court Primary Care NSP	✓	✓		✓	✓
Newcastle	Hunter Harm Reduction Services	✓	✓	✓	✓	✓
Newcastle	AIDS Council of NSW Hunter	✓	✓	✓	✓	✓
Nimbin/Lismore	Harm Reduction Services	✓	✓	✓	✓	✓
Parramatta	HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	✓
Port Kembla	First Step Program	✓	✓	✓	✓	✓
Redfern	Harm Minimisation Program	✓	✓	✓	✓	✓
Surry Hills	NSW Users and AIDS Association	✓	✓	✓	✓	✓
Wagga Wagga	Wagga Wagga Community Health Centre	✓	✓	✓	✓	
Northern Territory		3	3	3	3	3
Alice Springs	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Darwin	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Palmerston	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Queensland		8	8	8	7	8
Brisbane	Biala Community Alcohol and Drug Services	✓	✓	✓	✓	✓
Brisbane	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Cairns	Cairns ATODS NSP	✓	✓	✓	✓	✓
Gold Coast	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Ipswich	West Moreton Sexual Health Service	✓	✓	✓		✓
Sunshine Coast	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Toowoomba	Kobi House	✓	✓	✓	✓	✓
Townsville	Townsville ATODS NSP	✓	✓	✓	✓	✓

Australian NSP Survey: National Data Report 2011-2015

<i>Year</i>		'11	'12	'13	'14	'15
Number of NSP sites		52	52	52	51	47
South Australia		7	7	7	7	7
Adelaide	Nunkuarrin Yunti Community Health Centre	✓	✓	✓	✓	✓
Adelaide	Streetlink Youth Services			✓	✓	✓
Angle Park	SAVIVE - Central Northern Adelaide Health Service	✓	✓	✓	✓	
Hindmarsh	Hindmarsh Centre	✓	✓	✓	✓	✓
Norwood	SAVIVE, Clean Needle Program	✓	✓			
Noarlunga	Noarlunga Primary Health	✓	✓	✓	✓	✓
Port Adelaide	SAVIVE, Central Northern Adelaide Health Service	✓	✓	✓	✓	✓
Salisbury	Anglicare SA Salisbury	✓	✓	✓	✓	✓
Warradale	Drug Arm Australasia					✓
Tasmania		4	4	3	4	4
Clarence	Clarence Community Health Centre	✓	✓	✓	✓	✓
Glenorchy	Glenorchy NSP Service	✓	✓	✓	✓	✓
Hobart	Hobart NSP Service	✓	✓		✓	✓
Launceston	Salvation Army Launceston	✓	✓	✓	✓	✓
Victoria		6	6	6	6	6
Barwon	Barwon Health Drug and Alcohol Services	✓	✓	✓	✓	✓
Collingwood	Inner Space	✓	✓	✓	✓	✓
Footscray	Health Works	✓	✓	✓	✓	✓
Frankston	Southern Hepatitis/HIV/AIDS Resource & Prevention Service	✓	✓	✓	✓	✓
North Richmond	North Richmond NSP Services	✓	✓	✓	✓	✓
St Kilda	Health Information Exchange	✓	✓	✓	✓	✓
Western Australia		3	3	3	3	2
Bunbury	Western Australia Substance Users Association (WASUA)	✓	✓	✓	✓	
Northbridge	Western Australia Substance Users Association (WASUA)	✓	✓	✓	✓	✓
Perth	WA AIDS Council Mobile Exchange	✓	✓	✓	✓	✓

Appendix B: Methodological notes

Capillary blood was obtained by finger-prick using disposable lancets and cotton-fibre blotting paper. Dried blood samples were kept at room temperature at the survey sites and couriered to a central laboratory every second or third day. HIV antibody was detected using the Murex 1.2.0 ELISA (Diasorin). Repeatedly reactive specimens were subjected to Western blot confirmatory testing (Bio-Rad New LAV blot 1, France). A modified third generation enzyme immunoassay (Monalisa anti-HCV Plus Version 2 EIA, Biorad, France) was used to test for HCV antibody. A modified cut off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cut off ratio was greater than or equal to one on initial and subsequent testing.

Data presented in this report were analysed using Stata, Version 14 (Stata Corporation, College Station TX). Changes in HIV and HCV antibody prevalence overtime were assessed using the X^2 test for linear trend. Associations between demographic and behavioural variables and HIV and HCV antibody prevalence were assessed using the X^2 test or Fisher's exact test where expected frequencies were less than five.

Percentage values in tables may not add to 100 due to rounding. Totals in HIV and HCV antibody prevalence tables stratified by gender include people whose gender was not reported or reported as transgender. Time since first injection was calculated by subtracting age at first injection from age at survey completion. Totals in HIV and HCV antibody prevalence tables stratified by time since first injection include people who did not report age at survey completion or age at first injection.

Tables reporting HIV antibody prevalence stratified by demographic and drug use characteristics are not included in this report for states and territories or survey years where the number of HIV antibody positive participants was less than 5 in all years. Where data were collected but no participants endorsed a particular response, results are presented as "0 (0)". The symbol "--" shown in some tables denotes missing data; and is used to identify circumstances where data were not collected in the reported format. The vast majority of survey questions were consistent over all survey years.

NSP staff recorded sex, age group and survey participation for all clients at the NSP during the survey period and this data was used to assess response rates. Some clients visited the site more than once during the survey week, and only one attendance per person was included in the response rate denominator. Ethical approvals for the study were obtained from Human Research Ethics Committees associated with the investigators and participating sites. Verbal rather than written informed consent was obtained to assure the anonymity of participants.

Appendix C: List of Tables

1. Demographic characteristics and drug use

Table 1.1.1	Number (percentage) of respondents by demographic characteristics and survey year
Table 1.1.2	Number (percentage) of respondents by last drug injected, frequency of injecting and survey year
Table 1.1.3	Number (percentage) of respondents by injecting behaviour in the last month and survey year
Table 1.1.4	Number (percentage) of respondents by treatment for drug use and survey year
Table 1.1.5	Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year
Table 1.1.6	Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

2. HIV antibody prevalence

Table 1.2.1	HIV antibody prevalence by gender and survey year
Table 1.2.2	HIV antibody prevalence by sexual identity, gender and survey year
Table 1.2.3	HIV antibody prevalence by age group, gender and survey year
Table 1.2.4	HIV antibody prevalence by last drug injected, gender and survey year
Table 1.2.5	HIV antibody prevalence by years of injection, gender and survey year
Table 1.2.6	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year
Table 1.2.7	HIV antibody prevalence by frequency of drug injection last month, gender and survey year
Table 1.2.8	HIV antibody prevalence by imprisonment last year, gender and survey year
Table 1.2.9	HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year
Table 1.2.10	HIV antibody prevalence by sex work last month, gender and survey year
Table 1.2.11	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.2.12	HIV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.2.13	HIV antibody prevalence by region/country of birth, gender and survey year

3. HCV antibody prevalence

Table 1.3.1	HCV antibody prevalence by gender and survey year
Table 1.3.2	HCV antibody prevalence by sexual identity, gender and survey year
Table 1.3.3	HCV antibody prevalence by age group, gender and survey year
Table 1.3.4	HCV antibody prevalence by years since first injection, gender and survey year
Table 1.3.5	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year
Table 1.3.6	HCV antibody prevalence by last drug injected, years since first injection and survey year
Table 1.3.7	HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year
Table 1.3.8	HCV antibody prevalence by imprisonment last year, years since first injection and survey year
Table 1.3.9	HCV antibody prevalence by sex work last month, years since first injection and survey year
Table 1.3.10	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.3.11	HCV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.3.12	HCV antibody prevalence by region/country of birth, gender and survey year

